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Abstract
Aim: To analyse the epidemiological, clinical and immunological aspects 
of a recent epidemic of acute HCV in HIV co-infected individuals.
Methods: The epidemiology was characterised using combined molecular 
and clinical studies. A phylogenetic analysis of the E1/E2 region of the 
HCV genome was performed to determine HCV transmission. 
Transmission risk factors were then explored in a multicentre case- 
control study. Data was collected on the early clinical course of HCV in 
HIV. Longitudinal cell-mediated responses to HCV and HCV evolution 
were studied with PBMCs and serum collected during the acute phase. 
Results: The studies revealed significant differences in the epidemiology, 
natural history, cell-mediated responses and HCV evolution between 
acute HCV with and without HIV. The seven clusters demonstrated in the 
molecular study is strong evidence for common source transmission. The 
case-control study identified permucosal factors, including high-risk 
mucosally traumatic sexual and drug practices, were significantly 
associated with the recent transmission of HCV. HCV persistence was the 
outcome in the vast majority of HIV co-infected individuals and these 
rates are significantly higher than those for HCV mono-infection. The CD4 
T-cell responses lacked the magnitude and breadth of response for 
control of HCV. The virological data supported this, revealing 
quasispecies evolution that appeared not to be driven by immune 
pressure.
Conclusions: The phylogenetic clusters cross both HCV genotype and 
subtype implying that the HCV transmission is not due to a specific viral 
change, but that patient and/or environmental factors are responsible for 
the recent infections. Permucosal rather than parenteral behavioural risk 
factors are associated with this transmission. The immuno-deficient state 
associated with HIV results in very low spontaneous clearance of HCV 
and the vast majority of these patients become persistently infected. In 
order to mitigate this important and ongoing epidemic, these factors 
need to be the focus of a concerted effort on the part of public health 
specialist, clinicians and HIV-positive individuals themselves.
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Chapter 1: General Introduction
Hepatitis C virus (HCV) and Human Immunodeficiency virus (HIV) are 
two of the most prevalent persistent viral infections worldwide. Given 
the ir shared routes of transmission it is not surprising that HCV/HIV co- 
infection is relatively common. While the impact of HCV on the natural 
history of HIV infection is still controversial, HIV increases the 
pathogenicity of HCV, and leads to an increased morbidity and m ortality. 
The introduction of highly active antiretrovira l treatm ent (HAART) for HIV 
infection has led to dramatic reductions in morbidity and mortality due to 
AIDS (Palella et al., 1998). However, hepatocellular failure and 
hepatocellular carcinoma (HCC), complicating HCV-related cirrhosis, have 
become increasingly significant causes of morbidity and m ortality in HIV 
infected individuals when expressed as a percentage of all deaths. The 
increase in the HCV-related burden of illness in HIV is the result of the 
combination of relatively high prevalence rates of HCV/HIV co-infection 
and the accelerated HCV-related hepatic injury. I t  is not yet clear 
whether there has been an absolute or proportional increase in morbidity 
following the introduction of HAART. In the developed world, end-stage 
liver disease has been reported as the leading cause of deaths in H IV- 
infected patients (Puoti et al., 2000; Bica et al., 2001). While there has 
been an overall decline in HIV-related hospital admissions, HCV/HIV co- 
infected patients are at increased risk of hospitalisation compared to HIV 
mono-infected patients (Mocroft et al., 2004).
The epidemiology, natural history, pathogenesis and optimal 
management of HCV/HIV co-infection are not yet fully elucidated. 
Consequently, research is needed into these aspects of HIV/HCV co- 
infection. Hence studies of the acute phase of HCV in HIV would improve 
our understanding of the epidemiology of co-infection and viral 
interactions in the short-, medium- and long-term. However, very little is 
known about the early stage of co-infection.
15
1.1 The problem
Acute HCV is an unusual diagnosis because only 20% of HCV mono­
infections are clinically apparent (Hoofnagle, 1997). However, since the 
early 2000s, there has been a marked rise in the diagnosis of acute HCV 
in the HIV-positive population of London. This was first described at the 
Chelsea and Westminster Hospitals in London (Browne et al., 2004). In a 
review of case notes between 1997 and 2002, 25 cases were identified. 
While there was no increase in the amount of anti-HCV testing over this 
period there was a significant rise in the proportion of positive tests rising 
from 0.6% in 1997 to 9.3% (p<0.001) in 2002. While in part this may 
represent more appropriate testing and case ascertainment, it probably 
also represents the tip of the iceberg of as yet undiagnosed patients. 
Interestingly, whereas the m ajority of these cases might have been 
expected to have a percutaneous transmission risk, unsafe and high-risk 
sexual practices were in fact the main risk factor in 21 of these cases. 
Indeed, supporting the hypothesis of sexual transmission of HCV, nine 
cases were also diagnosed with syphilis around the time of the HCV 
diagnosis. Since this initial report from the Chelsea and Westminster 
Hospitals, more than 200 cases of acute HCV have been identified over 
the last three years in the South-Eastern UK (personal communication 
from Royal Free Hospital, Chelsea and Westminster, University College 
Hospital and Brighton HIV units). This epidemic is not limited to the UK; 
acute HCV in HIV infected individuals has been described by other groups 
in Europe and USA (Gambotti et al., 2005; Gotz et al., 2005; 
Luetkemeyer et al., 2006). In France, a cohort of 29 patients has been 
described from three centres (Gambotti et al., 2005). In the Netherlands, 
a cluster of seven acute HCV cases were described in association with a 
surveillance study of rectal lymphogranuloma, a recognised sexually 
transmitted disease (Gotz et al., 2005). All these groups report sexual 
rather than parenteral risk factors.
"Epidemics are a function of the people who transm it infectious agents, 
the infectious agent itself and the environment in which the infectious 
agent is operating. And when an epidemic tips, when it is jolted out of
16
equilibrium, it tips because something has happened, some change has 
occurred in one (or two or three) of those areas." (Gladwell, 2001). To 
understand why there has been a dramatic increase in the diagnosis of 
acute HCV in the HIV-positive population of the UK, the epidemiological 
signature of the virus, it's potential modes of transmission within the 
population and the current environment of this epidemic needs to be 
examined in detail. Identifying the factors responsible for this new 
epidemic of acute HCV, would allow specific strategies to be developed to 
mitigate and control the spread of this infection in the HIV infected 
population.
1.2 HCV mono-infection
A background understanding of the virology, immunology, epidemiology, 
natural history and treatment of HCV mono-infection and HCV/HIV co- 
infection is essential.
1.2 .1  Virology:
In 1989 Choo and colleagues discovered hepatitis C virus (HCV) via 
recombinant DNA cloning. HCV has subsequently been shown to cause 
the vast m ajority of non-A non-B (NANB) hepatitis (Choo et al., 1989). 
HCV is an enveloped single stranded positive sense RNA virus belonging 
to the Flaviviridae family with a genome of 9.4kb length. The genome has 
a single open reading frame encoding a 3011 amino acid polyprotein, 
which is cleaved into three structural proteins located towards the amino 
terminus and several non-structural proteins towards the carboxy 
terminus. The structural proteins are the nucleocapsid and two 
glycosylated envelope proteins E l and E2. The non-structural proteins 
consist of four major units, NS2, NS3, NS4, and NS5. The function of NS2 
is unclear but is thought to be a zinc-dependent metalloproteinase. The 
NS3 protein carries out a number of biochemical functions including 
serine protease, NTPase, and RNA helicase activities. The NS4 domain 
consists of two sub-units NS4A, a co-factor for NS3, and NS4B, the exact 
function remains to be elucidated. NS5 also consists of two sub-units 
NS5A and B. NS5A is a phosphorylated protein and although the exact
17
function of this protein is unknown it appears essential for activity of the 
RNA dependent RNA polymerase, NS5B. The viral genome is flanked by 
un-translated regions at both 5' and 3' ends which play an essential part 
in viral replication (Figure 1.1). HCV leads to persistent infection in the 
majority of cases (Lauer & Walker, 2001).
Figure 1.1: HCV genome.
1____  192 364 747 810 1027 1658 1712 1973 2421 3011■ 61
• t ♦
Core Envelope Pmtoase Seme Hehcase Senne Mombr. 7 RNA-dependent
glycoproteins protease protease web RNA polymerase
col actor
HCV has significant molecular diversity which can be elucidated at three 
different levels; genotype, subtype, and quasispecies (Simmonds, 2004). 
The major variation is between HCV genotypes, which differ by more 
than 30% of the nucleotide sequence. Six different genotypes, classified 
as clades by analysis of the NS5B region, exist in specific geographic or 
risk group populations (Simmonds et al., 1993). Genotype 1 is 
distributed in the USA and northern Europe, especially in the IVDU 
population. Genotype 2 is predominantly Mediterranean and Asian. 
Genotype 3 is widely distributed in the intravenous drug users (IVDU) 
population of Europe. Genotype 4 is distributed in the Middle East and 
regions of Africa. In Egypt this genotype has been particularly associated 
with previous medical treatment and instrumentation for schistosomiasis; 
genotype 5 is more common in South Africa; and Genotype 6 is most 
prevalent in South East Asia. Each of these genotypes contains subtypes 
which vary by between 20-25% in nucleotide sequence. Subtypes are an 
epidemiological phenomenon associated with relatively recent spread of 
the virus. Finally, quasispecies represent the variation in sequence 
diversity within a replicating population, usually an individual, at a given 
time point. A simple model that initially described viral diversity of HIV 
can be applied to HCV (McMichael & Rowland-Jones, 2001; Stumpf & 
Pybus, 2002). This model describes quasispecies viral diversity as a 
function of the selective pressure of the immune system and the effective 
viral population. This model is supported by Farci et al. who studied HCV 
quasispecies diversity and clinical outcome (Farci et al., 2000).
NS4B NS5A
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Molecular phylogenetic analysis uses nucleotide sequences to reconstruct 
the evolutionary relationships between the sequences. The evolutionary 
relationship is then described using a computer generated tree topology. 
Molecular techniques can be used to facilitate epidemiological studies, 
including disease surveillance, outbreak investigations, the identification 
of transmission patterns and risk factors in populations, and to 
characterise the host-virus interaction providing a better understanding 
of disease pathogenesis at a molecular level (Foxman & Riley, 2001). 
These techniques are particularly relevant to the study of viruses, such as 
HCV.
Phylogenetic patterns are the result of natural selection of genetic 
mutations favouring the survival of the virus. Viruses have exceedingly 
high replication rates. However, RNA encoded viral polymerases including 
HCV, lack a proofreading activity, resulting in high mutation rates and 
genetic variability. In viral genomes the same sequence often codes for 
more than one protein or regulatory function. Consequently, a large 
proportion of the mutations are harmful to the virus and reduce its 
fitness to survive. Two external processes modulate this variability; the 
host's immune response to the virus and the bottleneck at transmission. 
Intra-host viral diversity (quasispecies) is driven by humoral or cell- 
mediated immune responses (discussed below). In contrast, inter-host 
variation occurs as a result of the arbitrariness by which viral particles 
find a receptive cell in the passage of infection from one host to another 
(the bottleneck). There is little  evidence for different intrinsic 
transmissibility among strains of HCV. As a result, the inter-host 
phylogenetic structure is not determined by immune selection but instead 
reflects the demographic or spatial history of transmission (Grenfell et 
al., 2004). Therefore, the viral diversity and phylogenetic lineages 
depend on the prevailing epidemiological and immunological forces. 
Recently, population dynamic analysis has allowed the rate and 
magnitude of an evolutionary process through time to be inferred from 
current DNA or protein sequence in a representative population 
(Drummond et al., 2003). The most commonly used regions in the HCV
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genome for epidemiological study have been the hypervariable region 1 
(HVR1) and non-structural protein 5 (NS5B).
1 .2 .2  Im m unology:
Study of the acute phase of HCV has been difficult because it is usually 
not recognised clinically. While there is no specific serological marker of 
acute hepatitis C, it is conventionally defined as HCV infection diagnosed 
in the first six months of infection. This is characterised by documented 
seroconversion to anti-HCV and detection of HCV RNA in blood. Chronic 
HCV is usually defined as the persistence of HCV RNA for longer than six 
months. Up to 85% of individuals exposed to HCV will develop chronic 
infection (NIH, 1997; Communicable Disease Network of Australia and 
New Zealand, 1999; Lauer & Walker, 2001). However, in contrast to the 
conventional clinical definition, virological studies have suggested the 
change from acute to persistent HCV infection may occur between 3-4 
months of infection (Gordon, 2003). HCV RNA is detectable in the blood 
two days after infection but usually peaks after several weeks, when a 
steady state of viraemia is then reached of between 104-107 IU /m l 
(Thimme et al., 2002). Three patterns of HCV infection have been 
recognised in the early phase of infection. First, HCV viraemia falls 
precipitously within the first six months and then remains undetectable. 
This is consistent with viral eradication. Second, the viraemia reaches a 
steady state and persists beyond six months, consistent with chronic 
infection. Third, there may be early virological control within the firs t six 
months, however, viraemia rebounds and infection persists (Gerlach et 
al., 1999). The chronic state of the virus is the result of a balance 
between an individual's immune response and the level of viral 
replication in that individual.
A humoral response with antibodies (anti-HCV) develops a mean of 6 
(range 4-9) weeks after infection (Netski et al., 2005). In chimpanzee 
studies, antibodies have been shown to neutralise HCV infectivity in vivo 
(Farci et al., 1994). However, while there is a humoral response with 
neutralising antibodies, these antibodies are not protective in humans 
(Lai et al., 1994). Studies of the HCV quasispecies evolution in the acute
20
phase have demonstrated that antibodies to the E1/E2 region of the 
genome select for viral mutations and maybe associated with clinical 
outcome (Farci et al., 2000). However, humoral responses have been 
difficult to study because functional ex vivo studies have only been 
possible since the development of pseudovirus models.
I t  is clear that a broad, strong and persistent cell-mediated immune 
response is essential for control and eradication of the HCV infection in 
the acute phase. There are a number of observations that suggest CD4 
T-cells are important for control of HCV. Antigen-driven CD4 T-cell 
proliferation, particularly to the NS3 protein, was observed in all patients 
with acute HCV infection who resolved but only in some of those who 
developed persistent infection (Diepolder et al., 1995; Gerlach et al.,
1999). Gerlach et al. showed that persistence of these responses was 
im portant for eradication of the infection, describing a group of patients 
who initially controlled the infection and then relapsed with loss of CD4 T- 
cell responses (Gerlach e ta l.,  1999). HCV viral load has been associated 
with MHC class II alleles suggesting indirectly the importance of T-cell 
responses (Fanning et al., 2001). The appearance of CD8 T-cells is 
kinetically associated with elevated serum aminotransferases and control 
of viraemia (Cooper et al., 1999; Thimme e t al., 2002). Depletion of CD4 
T-cells by monoclonal antibodies in chimpanzees led to increased 
susceptibility to re-infection compared with controls (Grakoui et al.,
2003). Persistent broad CD4 T-cell responses have been demonstrated 
up to two decades after infection in individuals who successfully 
spontaneously eradicated HCV infection (Takaki e ta l., 2000).
Persistent HCV infection is thought to be the result of a failure of cell- 
mediated control. The most consistent feature of a successful 
immunological response is that it is sustained; in chronic HCV infection T- 
cell responses are diminished (Shoukry e t al., 2004). Multiple studies 
including functional lymphocyte assays, such as quantitative ELISpots, 
indicated that CD4 T-cell activity is of low frequency and, if present, 
proliferates against a limited number of epitopes in patients with 
persistent infection. (Gerlach et al., 1999; Takaki et al., 2000; Day et
21
al., 2003). Failure of CD4 T-cells is pivotal to viral persistence, and the 
inability of CD8 T-cells to control infection is the result of antigen specific 
CD4 T-cell failure. The mechanisms responsible for this failure remain 
unclear. An absence of response may represent an early defect in priming 
or expansion of naive CD4 T-cells, while a transient response may 
represent contraction of CD4 population before memory T-cells have 
developed (Shoukry et al., 2004).
1 .2 .3  Epidemiology:
HCV is a global disease, with an estimated worldwide prevalence of 
2.2% ; perhaps as many as 170 million people infected worldwide (WHO, 
2004). There is wide geographic variation in the prevalence of HCV, 
which ranges from approximately 1% in the developed world to more 
than 10% in parts of the developing world (Purcell, 1994). The World 
Health Organisation (WHO) has recently attempted to address the issue 
of the global burden of HCV by estimating its prevalence and incidence 
(WHO, 2004). The WHO estimates the prevalence of HCV in Europe is 
1.7%, while the prevalence in the USA is 1.8% (Alter et al., 1999; WHO,
2004). The WHO has suggested that 6.4 million new HCV infections occur 
worldwide each year, based on an estimate of a 10-fold increase in the 
HCV incidence since 1950 (WHO, 2004). This number is highest in the 
African and Eastern Mediterranean regions. While the introduction of viral 
sterilization of blood products in the mid-1980s reduced transfusion 
linked transmission, this did not significantly impact the incidence of 
transmission by IVDU. (Alter e ta /., 1990). However, there was a marked 
but unexplained reduction in the incidence of IVDU-related HCV from 
1989 on, which led to an 80% reduction in the overall incidence, w ith the 
number of estimated cases in the USA falling from 180 000 in the mid- 
1980's to 28 000 in 1995 (Alter et al., 1997). Currently, the WHO 
estimates of the morbidity and m orta lity are difficult to interpret as the 
common outcomes of cirrhosis and HCC are shared by other aetiologies 
such as hepatitis B and excessive alcohol. However, an estimated 8-10 
000 people die each year in the USA related to complications of HCV
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(Alter et at., 1999). Chronic HCV now is the m ajor indication for liver 
transplantation in the West.
The UK epidemiology of HCV is sim ilar to tha t of Western Europe and the 
USA. A large seroprevalence study (n=8297) analysing pooled stored 
serum samples from pathology laboratories in England and Wales found 
an overall prevalence of 0.46% (Balogun et al., 2002). The highest 
prevalence (1.07%) was found in the samples obtained before 1986. 
Males were twice as likely to be positive than females and London had a 
significantly higher prevalence than the rest of England or Wales. Of 
note, samples collected before 1991 excluded immunocompromised 
patients as well as those samples tested for HBV and HIV. The Trent HCV 
study group prospectively followed a cohort (n = 1128) of anti-HCV 
positive patients (Mohsen et al., 2005). The prevalence in this study, 
estimated from the regional population, was 0.05%, of which 81% were 
HCV RNA positive, with a sex ratio of 2:1 of males to females. IVDU was 
the commonest risk factor (65% ). Liver-related m ortality accounted for 
47% of deaths, significantly higher than the expected rates for this 
population.
1 .2 .4  Transmission o f HCV:
The m ajority of HCV transmissions are a consequence of parenteral 
exposure. In itia lly termed Non-A Non-B (NANB) hepatitis, HCV 
transmission was first described after transfusion of blood products 
(Prince et al., 1974; Alter et al., 1978). Following the discovery of HCV in 
1989, and the expression of recombinant HCV antigens, specific 
antibodies became available to diagnose exposure. In a seminal paper, 
A lter et al. used an anti-HCV antibody to a recently cloned viral protein 
(C100-3) to characterise both acute and chronic HCV in blood transfusion 
recipients previously diagnosed with NANB hepatitis (Alter et al., 1989a). 
In this cohort of 20 patients, NANB hepatitis had been diagnosed 
clinically and histologically. Serum from four patients transmitted NANB 
to chimpanzees. Of 15 patients diagnosed with chronic NANB, all 
seroconverted to anti-HCV while 3 of 5 acute cases seroconverted. The 
authors concluded that HCV was the m ajor cause of NANB hepatitis.
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Following this, results from a large case-control study of blood 
transfusion recipients and donors suggested that HCV accounted for 91% 
of all the NANB hepatitis seen in samples tested retrospectively between 
1976-1979 (Aach et al., 1991). As a result of lifelong factor concentrate 
transfusion, most haemophiliacs treated before 1985 are infected with 
HCV (Watson et al., 1992). Analysis of Factor V III, found that 83% of 
samples tested by PCR were positive for HCV RNA. (Makris et al., 1993). 
Pereira et al. explored HCV transmission from solid organ transplantation 
(Pereira et al., 1992). They demonstrated that HCV RNA negative 
recipients of solid organ transplants from HCV RNA positive donors 
developed infection in 100% of cases. Transfusion as a risk factor for 
transmission has been confirmed in a number of large epidemiological 
studies (Alter e ta !., 1990; Osmond et al., 1993; A lter e ta /., 1997). With 
the introduction of screening of blood and tissue products, transfusion, 
which pre-1990 accounted for 10% of transmission, is now an extremely 
rare route for transmission (Alter, 2002). I t  has been estimated that with 
blood product screening the current risk of infection is 0.001% /unit 
transfused (Schreiber et al., 1996).
Determining the mode of transmission of disease from one person to 
another is essential to understanding an epidemic. The mode of 
transmission must be biologically plausible and temporally related to 
infection. Prospective cohort studies and retrospective case-control 
studies of acute disease are the most reliable method of determining risk 
factors for transmission (Gordis, 2004). Other methods include cross- 
sectional or prevalence studies which examine both potential exposure 
and disease outcome simultaneously. However, these studies often have 
problems as the temporal relationship between the risk and disease is 
unclear. Furthermore, these methods often will not detect low frequency 
associations unless the studies are large.
While HCV transmission has been described via both parenteral and 
permucosal routes, the efficiency of transmission varies significantly 
between these routes. The burden of infection due to a transmission 
factor is a function of the efficiency of transmission and the size of the
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population exposed to that factor. A measure of the efficiency of HCV 
transmission by different routes can be made by comparison with HIV 
and HBV, which share sim ilar epidemiological characteristics. HCV is 
approximately ten times more efficiently transmitted than HIV by 
percutaneous exposure. The estimated transmission rate for HCV after a 
needle stick exposure is 1.5-3%, compared with 0.3% for HIV (CDC, 
2001b). This is supported by the higher prevalence of HCV than HIV in 
the IVDU population. In contrast, vertical and sexual transmission of HCV 
appear to be significantly less efficient than for HIV. In a cross-sectional 
study of the heterosexual transmission of HCV, HBV and HIV 
transmission in inner city women in Brooklyn (n = 599), Feldman et al. 
reported prevalences of HCV, HBV and HIV of 1.6%, 2% and 18.8% 
respectively (Feldman et al., 2000). The estimated transmission risk of 
HIV infection through a single heterosexual or homosexual intercourse is 
1-5%, in comparison with a risk of 0.1-0.3%  for transmission of HCV 
(Verucchi et al., 2004). In seroprevalence studies of anti-HCV in highly 
sexually active groups (female sex workers, homosexual males, STI clinic 
attendees) prevalence rates were lower fo r HCV than for HBV and HIV 
(Terrault, 2002). The vertical transmission of HIV is estimated at 
between 20-30% in those infants whose mothers were not on antiviral 
therapy (Zanetti et al., 1995). In contrast, HCV was transmitted to 2-5% 
of children born to HCV RNA-positive mothers (Gibb et al., 2000). The 
different efficiency of transmission of HCV in part explains the 
epidemiology.
IVDU is currently the major route of HCV transmission. HCV infection 
occurs through the transfer of HCV by sharing syringes and needles 
either directly or through contamination of the injecting equipment 
(Heimer et al., 1996). In the USA, 68% of new HCV infections occur 
among IVDUs, 18% among people with only sexual exposure to an 
infected person or multiple partners, 4% among health care workers 
whereas nosocomial, iatrogenic and perinatal exposure account for only 
1% of cases (Alter, 2002). In 9% of patients, no source could be 
identified. In large case-control studies, IVDU stands out as the major 
transmission factor (Alter et al., 1990; Osmond et al., 1993; Alter et al.,
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1997). The prevalence of HCV in IVDUs is between 30-98% (Roy et al., 
2002). Transmission occurs early in injecting drug use and after 5 years 
90% of individuals are infected (CDC, 1998). The high prevalence of HCV 
in the IVDU population contributes to this rate of transmission (CDC,
1998). A large case-control study of HCV-seropositive (n=758) blood 
donors and matched seronegative (n = 1039) blood donors, found that 
IVDU was the strongest risk factor for HCV seropositivity (Murphy et al.,
2000). I t  revealed a final multivariable model where IVDUs had an odds 
ratio of 50 for HCV infection compared with controls. Interestingly, while 
drug inhalation and high number of sexual partners were associated with 
HCV, this effect disappeared when adjusted for IVDU. This strong 
association has been confirmed in other studies (Alter et al., 1990; 
Osmond et al., 1993; Conry-Cantilena et al., 1996). Interestingly, a 
population dynamic analysis based on a phylogenetic study of the HCV 
subtypes la  and 3a in IVDU patients in the UK demonstrated exponential 
growth in HCV transmission in the second half of the 20th century (Pybus 
e ta !., 2005). This mirrored the growth of the IVDU population, explaining 
the increased transmission. With such a strong association, IVDU may 
cause residual confounding if it is unmeasured when assessing other 
factors such as inhaled drug use and sexual transmission.
Drug inhalation has been described as a source of HCV transmission. A 
USA-based study among blood donors found an independent association 
between intranasal cocaine use and HCV infection (Conry-Cantilena et al., 
1996). I t  is likely that this is through sharing of intranasal implements, 
such as straws. A significant proportion of the population of the USA (up 
to 14%) have used intranasal cocaine (CDC, 1998). However, intranasal 
drug use is identified only uncommonly as a risk factor in acute cases of 
HCV. I t  has been difficult to separate inhaled from parenteral drug use as 
the two routes are so strongly associated (Rail & Dienstag, 1995).
Renal dialysis is the most common nosocomial route of HCV transmission 
(Niu et al., 1993). The prevalence of HCV in the dialysis population has 
been reported to be between 10% and 60% (Tokars et al., 1994). A 
number of outbreaks of HCV have been described in the dialysis
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population (CDC, 2001a). Transmission was associated with the use of 
contaminated equipment and unsafe nosocomial injection practices. The 
prevalence of HCV increases with length of dialysis (Hardy et al., 1992; 
Niu et al., 1993). The most common occupational exposure route is 
needle stick injury with an average incidence of anti-HCV seroconversion 
of 1.8% of those exposed (CDC, 2001b). I t  has also been documented to 
occur through conjunctival blood splashes (Ippolito et al., 1998). Other 
percutaneous routes such as body piercing, tattoos, commercial 
barbering have been described in case reports. However, case-control 
studies of acute disease have not found an association between HCV and 
recent medical or dental procedures, tattooing, acupuncture or piercing 
(Alter et al., 1982; Alter et al., 1989b; Alter, 2002). Transmission by 
these routes seems rare, with recent exposure by these routes reported 
by fewer than 1% of both cases and controls.
Mother-to-infant HCV transmission is defined on the basis of persistence 
of anti-HCV beyond at least 12 months of age or the detection of HCV 
RNA on at least one occasion in the infant. Transmission can occur either 
by intrauterine, intrapartum or postnatal routes. Yeung et al., in a review 
of all published studies between 1990 and 2000, calculated a rate of 
m other-to-infant transmission from anti-HCV positive women was 1.7% 
(Yeung et al., 2001). In the same review, the estimated rate among HCV 
RNA positive women was 4.3%. A higher HCV viral load (levels >105 
IU /m l) appears to increase this transmission risk (Ohto et al., 1994; 
Thomas et al., 1998). Other factors associated with higher transmission 
rates include HIV co-infection and mode of delivery. The transmission 
rate among those co-infected with HIV is 19.4% compared to 3.5% for 
women infected only with HIV (Yeung et al., 2001). The transmission rate 
appears to be slightly higher among women having vaginal deliveries 
when compared with women having caesarean sections. While HCV RNA 
has been found in breast milk, no definitive case of transmission from 
breast-feeding has been described.
The importance of sexual transmission of HCV remains controversial. 
While there is convincing evidence that sexual transmission does occur,
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the magnitude of risk has been difficult to quantify (Terrault, 2005). The 
first study to suggest sexual transmission of HCV was an interview-based 
case-control study of acute NANB hepatitis in two county hospitals in the 
USA (Alter et al., 1989b). This study did not use virological testing to 
confirm the diagnosis of HCV. Of 140 patients with acute NANB hepatitis 
enrolled in the study, 53% had no identifiable risk factor. Comparison of 
this subgroup with controls selected from the community revealed 
significantly higher rates of multiple sexual partners (>2) and a history of 
hepatitis in the household/sexual contact, although this could have 
represented confounding with other unmeasured factors. Certainly, 
sexual transmission is biologically plausible because HCV RNA has been 
isolated from saliva, semen and vaginal fluids (Numata et al., 1993; 
Young et al., 1993; Leruez-Ville et al., 2000). Of 21 HCV RNA positive 
patients, 38% were demonstrated to have HCV RNA in the semen 
(Leruez-Ville et al., 2000). The median concentration of HCV in semen 
(1.78 log IU /m l) was significantly lower than in serum (5.63 log IU /m l). 
Sexual transmission has been demonstrated in a number of case studies 
by confirming viral homology between sexual partners following the 
exclusion of other possible transmission factors (Healey et al., 1995b; 
Sanchez-Beiza et al., 1996; Capelli et al., 1997; Halfon et al., 2001; Quer 
et al., 2003). Interestingly, these cases all described transmission from 
men to women. Mucosal trauma was implicated in these cases, related to 
anal intercourse or after vaginal instrumentation. Higher rates of 
transmission from men to women have also been suggested by other 
studies (Thomas et al., 1995). In partners of attendees at an STD clinic 
(n=309), the prevalence of anti-HCV was higher in female but not male 
partners of anti-HCV positive individuals. Currently, 20% of acute HCV 
cases in the USA have sexual contact as the only identifiable risk factor 
(CDC, 1998). This was either sexual intercourse with >2 partners, or with 
an HCV positive person in the preceding six months. I t  is often 
complicated by the coexistence of high-risk sexual practices, such as lack 
of condom use, anal and mucosally traumatic sexual practice, and 
multiple partners with drug use (in particular IVDU). In a review of anti- 
HCV studies, prevalence rates in partners of individuals with high-risk 
behaviours such as IVDU and sexual promiscuity were between 11 and
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27% compared with partners of low-risk individuals where the prevalence 
rates were between 0 and 7%, suggesting that partners of high risk 
individuals may also participate in these high-risk behaviours themselves 
(Rail & Dienstag, 1995).
The magnitude of the risk of sexual transmission is not known. A number 
of studies have tried to assess this and early studies suggested high rates 
of sexual transmission. A Japanese cross-sectional study (n = 154) found 
an anti-HCV prevalence of 18% in the spouses of patients with chronic 
hepatitis, cirrhosis and hepatocellular carcinoma (Akahane et al., 1994). 
This prevalence increased with the length of marriage, which was 
attributed to increased sexual exposure. However, on review some 
believe that this actually represented a cohort effect, with an increased 
prevalence in older individuals (Dienstag, 1997). In a review of early 
studies, Rail and Dienstag reported the prevalence of anti-HCV in 
partners of HCV patients to be between 0 and 27% (Rail & Dienstag, 
1995). Unfortunately, these studies assessed risk w ithout performing 
adequate assessment of viral homology to confirm viral transmission. 
This is important because simply testing anti-HCV may overestimate the 
rate of sexual transmission. Zylberberg et al. highlighted the importance 
of HCV sequencing in epidemiological studies (Zylberberg et al., 1999). 
They performed a detailed epidemiological and molecular analysis of 24 
anti-HCV couples, in whom, concordant genotypes were found in 12. 
Seven of these couples had sequencing of the NS5B region of the HCV 
genome. Only three couples had identical isolates. However, all three 
couples had a parenteral risk factor which could also have explained the 
transmission. They concluded that the risk of sexual transmission had 
been overestimated. Large prospective cohort studies using virological 
analysis have now been performed and suggest that sexual transmission 
rates are very low in monogamous heterosexual couples. Vandelli and 
collegues followed an Italian cohort of 895 monogamous heterosexual 
couples for over 8060 person-years (Vandelli et al., 2004). Over this 
period three spouses acquired HCV; however viral sequencing revealed 
all the isolates differed from the ir respective partners, ruling out 
transmission from these individuals. Tahan and collegues found none of
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the 216 HCV-negative partners became infected over a three-year follow- 
up (Tahan et al., 2005). In conclusion, sexual transmission in low-risk 
heterosexual relationships may occur but at an extremely low rate. 
Current clinical guidelines do not recommend barrier contraception to 
prevent HCV transmission in monogamous heterosexual couples (NIH, 
2002; Terrault, 2005).
Certain individuals appear to be at increased risk for sexual transmission. 
These groups include: sex workers, individuals with multiple sexual 
partners, men who have sex with men (MSM), HIV-positive individuals 
and sexually transmitted infection (STI) clinic attendees. Osmond et al. 
found that a high number of lifetime sexual partners was associated with 
HCV infection (OR 2.1, 95% Cl 0.9-4.8) (Osmond et al., 1993). Higher 
HCV prevalence has been found in studies of this group (Nakashima et 
al., 1992; Wu et al., 1993). In a study of Taiwanese prostitutes (n = 622), 
12% were anti-HCV positive. On multivariable analysis, a history of paid 
sex for more than six months and transfusion were associated with anti- 
HCV positivity (p<0.001) (Wu et al., 1993). HIV infected patients have 
been reported to have higher rates of anti-HCV positivity (Terrault,
2002). Other studies have reported higher rates of anti-HCV positivity in 
STI clinic attendees, individuals infected with STIs, MSM and individuals 
taking part in traumatic sexual practices (Thomas et al., 1995; Ndimbie 
et al., 1996; Hershow et al., 1998; Filippini et al., 2001). In comparison 
to the general population anti-HCV prevalence of 1.8%, Terrault 
estimated median prevalence rates of anti-HCV of 6% among female sex 
workers, 4% among MSM and 4% among those attending STI clinics and 
HIV surveillance studies (Terrault, 2002).
Although sexual transmission of HCV in MSM has been documented, 
recent evidence suggests that the risk of sexual transmission of HCV in 
MSM is low. Alary and collegues prospectively followed a cohort of 
Canadian HIV-negative MSM (n = 1085) to assess seroconversion rates 
(Alary et al., 2005). The entry prevalence of HCV was 2.9%; if IVDUs 
were excluded it was 0.3%, less than the Canadian population prevalence 
of 0.8%. Over 2653 person-years of follow-up there was only one
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seroconversion and this was attributed to IVDU on interview. They 
calculated an HCV incidence rate of 0.038 per 100 person-years. 
However, some studies have reported higher rates of HCV in MSM 
(Melbye e ta l. ,  1990; Thomas et al., 1995). In a Danish study, an 8-year 
culmulative incidence of 4.1% was found. (Melbye et al., 1990). I t  has 
also been suggested that HIV co-infection increases the risk of sexual 
transmission of HCV (Tor et al., 1990; Eyster et al., 1991; Osmond et al., 
1993). Filippini et al. performed a case-control study examining anti-HCV 
in hetrosexual and homosexual contacts of HIV-positive patients 
(n=318). The study demonstrated tha t subjects with only sexual 
exposure as a risk factor had a higher prevalence of HCV if co-infected 
with HIV (18.7% versus 1.6%, p=0.008) (Filippini et al., 2001). They 
suggested this was evidence for enhanced sexual transmission of HCV 
with HIV.
Case-control studies have identified non-sexual HCV transmission within 
families (Donahue et al., 1992; Napoli et al., 1993; Hou et al., 1995; 
Nakashima et al., 1995). The actual transmission route is difficult to 
identify, but is likely to be the result of inadvertent percutaneous or 
permucosal exposure to HCV infected blood or body fluids. In a review of 
these studies, Alter estimated the overall prevalence of anti-HCV in non- 
sexual contacts to be 4% (Alter, 1995). In a review of intrafamilial 
transmission, Akerman et al. calculated the prevalence of anti-HCV in 
non-sexual contacts to range from 1.14% in siblings and household 
contacts of children with paediatric liver disease to 10.96% in parents of 
the same population (Ackerman et al., 2000). Of note, the prevalence of 
all non-sexual contacts in Japanese studies was higher which was 
attributed to the endemicity of HCV in Japan and the increased frequency 
of different cultural practices, such as acupuncture. However, intrafamilial 
clustering in countries of high endemicity may represent another 
exposure and not intrafamilial transmission.
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1 .2 .5  N atural h istory o f HCV m ono-infection:
Unfortunately, there are a number of serious difficulties encountered 
when defining the natural history of an illness such as hepatitis C. Seeff 
outlined five criteria that are critical to studies of natural history (Seeff,
1997). The onset of disease must be accurately established, which 
requires the identification of the acute illness. I t  is important to identify 
the full spectrum of acute illness to avoid bias in focusing on more 
serious illness, which may have a different natural history. Third, the 
illness must be tracked to its resolution or end-points. This includes the 
determination of illness outcomes w ithout any therapeutic intervention. 
Finally, matched controls that could be followed with the same vigour 
would need to be available. There are many reasons why these studies 
are impossible in hepatitis C. The acute illness is symptomatic in only 25- 
35% of cases and estimates of the tim ing of the illness are often 
inaccurate (Hoofnagle, 1997). This makes the identification of controls 
difficult. HCV-related liver disease progresses very slowly and often 
asymptomatically, requiring decades of follow-up. Furthermore, effective 
treatm ent is now available with combination interferon and ribavirin, 
making such studies unethical. Consequently, we have to interpret the 
natural history of the illness through the retrospective and cross-sectional 
data that we have available. I t  is also im portant to realise that much of 
the available data are based on liver clinic series or selected populations 
(eg. haemophiliacs), which may have inherent referral and selection 
biases. Freeman and colleagues compared hepatitis C data from different 
referral sources and found significant differences in the rates of cirrhosis 
development (Freeman et al., 2001). The estimated prevalence of 
cirrhosis in a liver clinic population after 20 years infection was 23%, 
28% in post-transfusion cohorts, 4% in blood donor cohorts and 7% in 
community-based cohort studies.
I t  is estimated that 21% of community-acquired acute hepatitis is caused 
by hepatitis C (Alter, 1995). However, as stated, only 25% of patients 
become icteric. There have been reports of fulm inant hepatic failure 
associated with hepatitis C, although this is extremely rare (Villamil et 
al., 1995). A German study has provided important data on the early
32
natural history of HCV (Gerlach et al., 2003). Patients with acute HCV 
(n=60) were prospectively enrolled over seven years, and were either 
offered immediate or delayed treatm ent. Six patients opted for 
immediate treatm ent while 54 delayed treatment. Of those delaying 
therapy, 37 initially cleared HCV but 13 relapsed. This resulted in an 
overall spontaneous clearance rate of 44%. Those who cleared HCV were 
more likely to have been symptomatic as none of the asymptomatic 
patients cleared the infection. This contrasts with the overall rate of 15- 
20% spontaneous clearance that has been suggested based on 
seroprevalence data (Lauer & Walker, 2001; Seeff, 2002).
Although there is a large degree of variability with respect to disease 
progression, the development of fibrosis and cirrhosis is the major 
underlying cause of morbidity and m ortality. This can follow a relatively 
linear course from chronic infection to cirrhosis to hepatocellular 
carcinoma. On the other hand, the m ajority of people with hepatitis C will 
probably not progress to advanced liver disease and overall progression 
is highly variable. Most long-term follow-up data has been obtained from 
patients with post-transfusion hepatitis, because of the availability of 
accurate data on duration of infection. Seeff et al. found that, in a 
comparison of individuals with post-transfusion hepatitis and age- 
matched controls over a mean of 18 years, there was no difference in 
overall m ortality and only a small, but statistically significant increase in 
liver-related mortality (Seeff et al., 1992). Other studies with longer 
follow-ups have found significant m orbidity and m ortality in a 10 to 30- 
year period. In these studies the incidence of cirrhosis has ranged from 
8-32%, HCC was identified in 0.7-1.3%  of subjects and overall liver- 
related mortality ranged from 1.6-6%  (Di Bisceglie et al., 1991; 
Tremolada et al., 1992; Koretz et al., 1993; Mattsson et al., 1993). I t  
has been estimated that serious liver disease develops in one third of 
patients within 20 years and does not progress in another third for 30 
years or more (Lauer & Walker, 2001). In a Japanese cohort, of the 
approximately 75% of patients who developed chronic HCV infection, the 
estimated times for progression to chronic hepatitis was 10 years, to
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cirrhosis was 21 years, and hepatocellular carcinoma was 29 years 
(Kiyosawa e ta l. ,  1990; Tong et al., 1995).
Hepatic fibrosis is the final response of the liver to an insult, and is 
usually diagnosed histologically by liver biopsy. Hepatic fibrosis 
represents an increase of collagen fibre deposition in the liver, which can 
impede intrahepatic blood flow, and subsequently cause persistent and 
progressive hepatic dysfunction. Fibrosis was previously thought to have 
been irreversible, although there is mounting evidence that some 
fibrogenesis may be reversible (Benyon & Iredale, 2000). Many studies 
have shown that disease progression mainly depends upon the severity 
of fibrotic or cirrhotic change (Poynard et al., 1997; Niederau et al., 
1998). Fibrosis progression per year can be defined as the ratio between 
fibrosis stage, using the Metavir or Ishak histological scoring units, and 
the estimated duration of infection (Poynard et al., 1997; Wright et al.,
2003). This yields a score in fibrosis units per year. The fibrosis rate is 
probably modulated by a number of potential cofactors, which can be 
classified into host factors, viral factors and external factors. Viral factors 
include viral dose, viral genotype and quasispecies. Host-related factors 
include age, ethnicity and gender. Extraneous factors include alcohol, 
environmental factors, and geographical location. Unfortunately, fibrotic 
liver disease often presents late as a result of complications related to 
cirrhosis, and most studies are lim ited by lack of routine biopsy data. I t  is 
therefore important to identify risk factors associated with causation and 
progression of fibrosis.
Im portant host factors such as age, sex and ethnicity also need to be 
considered. Age seems to be an im portant predictor of progression of 
hepatitis C. In a study of patients who underwent repeat liver biopsy, 
Kage et al. found that liver fibrosis increased dramatically after the age of 
fifty  (Kage et al., 1997). In addition, there was an accelerated 
development of cirrhosis in those aged over fifty  years. This has been 
supported by evidence older age of acquisition of HCV, is associated with 
more rapid progression of fibrosis (Verbaan et al., 1998; Bonis et al., 
1999; Danta et al., 2002). There may also be slower progression in those
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infected in childhood. The evidence that gender has a significant effect is 
less clear. Poynard, in a large French study, identified men as having a 
higher risk of more advanced fibrosis (Poynard et al., 1997). However, 
another Swedish study did not confirm this relationship (Verbaan et al.,
1998). Geographically, there appear to be wide variations in the 
progression of HCV and its complications. A large proportion of patients 
with hepatocellular carcinoma in high prevalence countries are positive 
for HCV. In Japan, for example, relative risks of progression of up to 52 
fold for hepatocellular carcinoma have been described compared with 
estimates of 10.5 fold in the USA (Communicable Disease Network of 
Australia and New Zealand, 1999). This may reflect racial differences in 
progression of the disease or other confounding factors. Verbaan did 
identify immigrant status in Sweden as a risk factor for cirrhosis but did 
not specify the ethnic differences. (Verbaan et al., 1998). This may have 
been confounded by alcohol intake. Studies have also suggested a 
difference in response to combination therapy between African-American 
and white Americans, with poorer responses in African-Americans (Reddy 
e t al., 1999).
Viral factors are more important as predictors of treatm ent response. 
Early studies suggested an association between genotype lb  and more 
progressive disease (Hatzakis et al., 1996). This association was based 
on an increased prevalence of genotype lb  among people with cirrhosis 
and hepatocellular carcinoma. However, other studies found no 
association with genotype (Bonis et al., 1999). This probably reflected a 
cohort effect confounding genotype with duration of infection, as those 
with genotype lb  had been infected for longer. The size of the inoculum 
appears not to be significant, with little evidence of difference between 
the natural history of HCV in those infected from blood transfusion (a 
large inoculum) compared with IVDU (a small inoculum), when adjusted 
for other cofactors such as age at infection (Alter et al., 1992). As 
discussed, Farci has shown that quasispecies diversity is associated with 
clinical outcome representing the interaction of the immune system and 
virus (Farci et al., 2000).
35
Alcohol is an independent risk factor fo r liver disease. There is an 
association between HCV and alcohol, with a higher HCV prevalence 
found in populations with high alcohol intake. This is thought to be 
explained through a correlation between injecting drug use and high 
alcohol intake (McHutchison et al., 1992). There is strong evidence that 
alcohol causes progression of hepatic disease in HCV, even at relatively 
low intake levels. There are two forms of possible interaction. First, is the 
interaction with the virus, with the recognition that alcohol may increase 
the serum viral load. Pessione et al. showed a dose-response relationship 
between moderate alcohol intake and increased plasma HCV RNA levels 
(Pessione et al., 1998). The second interaction occurs directly, affecting 
histological progression of liver disease. An epidemiological review gave 
summary odds ratios, from a number of studies, of the increased risk 
with high alcohol intake for chronic hepatitis (OR 5.8, 95% Cl 2.1-5.5), 
cirrhosis (OR 3.4, 95% Cl 2.1-5.5), and hepatocellular carcinoma (OR 
2.5, 95% Cl 1.5-4.2) (Communicable Disease Network of Australia and 
New Zealand, 1999). Furthermore, abstinence from alcohol has led to 
improvements in liver histology (Yoshida et al., 1991). The mechanism of 
injury, which may relate to iron storage or immune modulation, still 
remains to be elucidated (Pessione et al., 1998; Wiley et al., 1998). 
Current recommendations based on our understanding of an interaction 
between alcohol and HCV are for reduced intake or abstinence, in 
particular for people who have significant liver fibrosis.
The relationship between progressive fibrosis and raised serum 
aminotransferases in HCV infection is unclear. Alanine aminotransferase 
(ALT) is a cytosolic enzyme while aspartate aminotransferase (AST) is a 
mitochondrial enzyme. Both rise with damage to hepatocytes. In 
addition, there is marked fluctuation of transaminase levels over the 
course of the illness (Alter et al., 1992). Healey et al. found significant 
histological abnormalities in patients with normal AST although the 
changes were more marked in those with a raised AST (Healey et al., 
1995a). Patients with elevated AST had higher alcohol intakes. 
Furthermore, Luo et al. showed no significant correlation between ALT 
levels and scores for portal, periportal and total inflammation, although
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ALT levels were generally higher in those with severe intralobular 
necroinflammatory activity (Luo et al., 1998). In a large French study of 
liver clinic patients the activity and fibrosis scores were significantly 
higher in the group with elevated ALT, even when corrected for viral load 
and alcohol intake (Mathurin et al., 1998). The calculated fibrosis 
progression rate for the normal ALT group was less than half that of the 
group with raised ALT, with an estimated progression time to cirrhosis of 
over 80 years. Severe fibrosis in the normal group was associated with 
heavy alcohol intake. I t  is clear from these and other studies that 
significant inflammation and fibrosis can occur in the absence of 
abnormal transaminases. Although not reflecting the severity of the 
histological abnormalities, there does appear to be a weak association 
between ALT and intralobular inflammation.
1 .2 .6  Treatm ent:
The primary aim of HCV treatm ent is the eradication of the infection. 
Successful eradication of HCV abolishes the inflammatory activity, 
preventing progression to fibrosis, cirrhosis and HCC. It  has also been 
associated with regression of fibrosis (Shiratori et al., 2000). There may 
be a benefit to treatment even if HCV is not eradicated (Shiratori & 
Omata, 2000), although these data require confirmation. Early studies 
demonstrated that interferon was effective against HCV (Zeuzem et al., 
1996; Hoofnagle & Di Bisceglie, 1997). Interferon inhibits the replication 
of HCV by unknown mechanisms. The pharmacokinetics and efficacy of 
interferon have been significantly improved by the combination of a 
polyethylene glycol molecule (pegylation) to the interferon molecule. 
Ribavirin, a guanosine analogue, is phosphorylated within cells and 
incorporated into the RNA of virions, thereby increasing the mutation 
frequency and the infectivity of new virions (Crotty et al., 2001). 
Ribavirin on its own it is largely ineffective but has a synergistic effect 
when combined with interferon (McHutchison et al., 1998). Recent HCV 
dynamic modelling strongly suggests a mutagenic rather than an 
immunomodulatory action for ribavirin; supporting a synergistic action 
with interferon in the reduction of infected hepatocytes (Dixit et al.,
2004). Studies of viral kinetics reveal at least two phases of viral decay
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on treatment. Phase 1 clearance of HCV represents the direct anti-viral 
effect of interferon, while phase 2 relates to clearance of HCV infected 
cells. Viral response during treatm ent has been shown to predict 
outcomes. Sustained virological response (SVR) is defined as 
undetectable HCV viraemia 24 weeks after the cessation of treatment. 
This is assumed to equate to eradication of HCV. However, there is a low 
recrudescence rate of 1-2%. Early virological response (EVR) is defined 
as undetectable HCV RNA or 2 log drop in viraemia at week 12 of 
treatment. Failure of an EVR predicts failure of an SVR with a high 
specificity, which is useful as a measure to stop further treatm ent (Fried 
e ta /., 2002).
Treatment of acute HCV mono-infection is very effective (Alberti et al., 
2002). In a large study, Jaeckel evaluated immediate interferon 
monotherapy for 20 weeks in a German cohort (n=45) of acute HCV 
patients (Jaeckel et al., 2001). Almost all patients (98% ) experienced a 
SVR, with only one patient failing therapy. Follow-up confirmed that long­
term virological, biochemical and clinical responses were maintained 
(Wiegand et al., 2004). Gerlach and colleagues studied another German 
cohort (n=60) who had treatm ent delayed by 3 to 6 months to allow for 
spontaneous HCV eradication (Gerlach et al., 2003). Approximately half 
of the patients spontaneously cleared HCV and in those that were then 
treated with interferon monotherapy, 81% had an SVR. These results are 
comparable to the Jaeckal study, suggesting that a short delay before 
therapy does not significantly impact SVRs and may reduce patients' 
exposure to expensive and potentially toxic treatm ent. Hofer et al. has 
suggested by viral kinetic studies of acute hepatitis C that viral 
persistence at day 35 was likely to become chronic and treatment should 
be initiated at this stage (Hofer et al., 2003). Pegylated interferon has 
also been shown to be successful. An Italian group treated 16 patients 
with documented acute HCV treated fo r 6 months with pegylated 
interferon (Santantonio e ta /., 2005). The SVR was 94%, with one patient 
failing therapy. Combination pegylated interferon and ribavirin for acute 
HCV has not yet been widely studied.
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Large multinational studies have now demonstrated the effectiveness of 
pegylated interferon-a and ribavirin in chronic HCV infection. Two seminal 
studies evaluated the two currently available forms of pegylated 
interferon. Manns et al. (n = 1530) compared combination pegylated 
interferon a-2b 1.5 mcg/kg/week plus ribavirin 800mg/day to standard 
interferon plus ribavirin (Manns et al., 2001). The SVR was higher in the 
pegylated interferon arm, particularly in those infected with genotype 1 
HCV. The overall SVR was 54%, while it was 42% for those with 
genotype 1 HCV and 82% for those with genotype 2/3. In post-hoc 
analysis, SVRs were higher in patients who received >10.5 mg/kg of 
ribavirin. Similar results were obtained by Fried et al. (n = 1121) studying 
pegylated interferon a-2a plus ribavirin compared to standard interferon 
plus ribavirin (Fried et al., 2002). The SVR in patients who received 
pegylated interferon was 56% versus 44% in the standard interferon arm 
(p=0.01), with SVR for those with genotype 1 being 46% and those with 
genotype 2/3 being 76%. These treatm ents have been shown to be 
effective in bridging fibrosis and cirrhosis. Finally, economic analyses 
have demonstrated that the treatm ent is cost-effective (Salomon et al., 
2003; Siebert et al., 2003). As a result, a combination pegylated 
interferon and ribavirin is now the standard of care for individuals with 
chronic HCV.
Virological factors are the most im portant predictors of treatm ent 
response. A number of pretreatment factors have been associated with 
higher SVRs. These include HCV genotype 2 and 3, lower HCV viral load 
(<800 000 IU /m l), minimal liver fibrosis, female sex, age less than 40 
years, and ethnicity. Most studies to date do not demonstrate an 
improvement in virological response with more than 24 weeks of 
combination therapy for individuals with genotype 2/3 HCV (McHutchison 
et al., 1998). Poynard et al. using multivariate analysis found that 
genotype 2/3, viral load less than 2 x 106 copies/ml, age less than 40 
years, female sex, and minimal fibrosis were associated with better SVRs 
(Poynard et al., 1998). Finally, McHutchison and colleagues demonstrated 
the importance of compliance with treatm ent (McHutchison et al., 2000).
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SVRs were significantly better in patients who took more than 80% of 
their treatm ent 80% of the time compared to patients who were less 
compliant than this. The maintenance of the full dose of ribavirin also 
appears to be important (Shiftman et al., 2004).
1.3 HCV/HIV co-infection
1.3 .1  Epidemiology o f H C V /H IV  co-infection:
Given the shared transmission routes for HIV and HCV, it is not surprising 
that co-infection is common. The WHO estimate that approximately 10 
million people worldwide are HCV/HIV co-infected, while up to 48% of 
European HIV patients in the multinational CAESAR study were co­
infected (Amin et al., 2004). In the CAESAR study the strongest predictor 
of HCV/HIV co-infection was HIV exposure category, with an odds ratio of 
365 (Cl 179-742) for IVDU compared to homosexuals. The prevalence of 
HCV/HIV was low (3.7% ) among homosexual men without reported 
IVDU. The UK has lower co-infection rates compared with Europe because 
of lower IVDU; the prevalence has been estimated to be 9% of the 
London HIV population (Mohsen et al., 2005). In this London cohort, the 
prevalence of co-infection varied with transmission factor, from 82% 
among those with a history of IVDU, 32% in those who had received 
blood products, 3.5% and 1.8% among those with homosexually and 
heterosexually acquired HIV respectively. Both HIV infection and high- 
risk homosexual practices probably contribute to increased HCV sexual 
transmission (Thomas et al., 1995; Hershow et al., 1998). Sexual rather 
than parenteral risk factors appear to be associated with the recent rise 
in acute HCV in HIV-positive individuals in London (Browne et al., 2004; 
Danta et al., 2005a).
1 .3 .2  Influence o f H IV  on HCV:
HIV is associated with higher HCV viral loads and an accelerated rate of 
liver injury (Eyster et al., 1994). In contrast to HCV mono-infection, liver 
injury in HCV/HIV co-infection is relatively rapid, with a median time to 
cirrhosis of 10 years (Soto et al., 1997). In a study of the liver histology 
of 914 patients, HCV/HIV co-infected patients had more severe fibrosis
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with Metavir stages: FO (no fibrosis) in 10%, FI (minimal fibrosis) in 
33%, F2 (portal linking fibrosis) in 22%, F3 (bridging fibrosis) in 22% 
and F4 (cirrhosis) in 13% (Martin-Carbonero et al., 2004). Fibrosis 
progression rates (change in fibrosis stage units per year) were 
calculated for HCV/HIV co-infected and HCV mono-infected patients. The 
French group found that the rate was significantly faster in the co- 
infected cohort than in those infected with HCV alone (0.153 vs 0.106 
units per year, p<0.001) (Bedossa & Poynard, 1996; Benhamou et al.,
1999). In addition to previously recognised factors such as age at HCV 
infection and alcohol, the accelerated injury appears to be related to 
lower CD4 counts (Benhamou et al., 1999). Haemophilic patients with 
HCV-related cirrhosis were shown to be more likely to develop 
decompensated liver disease if HIV-positive than if HIV-negative patients 
with rates of 50% versus 13% at 2 years and 70% versus 40% at 5 
years (p=0.005) (Martino et al., 2002). This translated into higher 
m ortality rates among this group. In a cohort of HCV infected 
haemophiliacs in the UK, HCC occurred earlier and with increased 
frequency if the patients were co-infected with HIV (Darby et al., 1997). 
In a meta-analysis comparing HCV/HIV co-infected to HCV mono-infected 
patients the relative risk of cirrhosis with HIV co-infection was 2.07 (95% 
Cl 1.40-3.07) and that of hepatic decompensation was 6.14 (95%  Cl 
2.86-13.20) (Graham et al., 2001). I t  should be noted that many of 
these studies were carried out before the introduction of HAART.
1 .3 .3  In fluence o f HCV on H IV :
In contrast to the clear impact of HIV on HCV the influence of HCV on 
HIV remains controversial. A number of studies have examined this issue 
but are confounded by the introduction of HAART in 1996. The influence 
can be examined using either clinical (AIDS defining illnesses) or 
immunological (CD4 counts) parameters. In the post-HAART era two 
large studies have suggested a more rapid progression of HIV disease in 
those co-infected with HCV (Greub et al., 2000; De Luca et al., 2002). 
The Swiss Cohort study followed 3111 patients starting HAART, of which 
1157 were HCV/HIV co-infected (Greub et al., 2000). The relative risk of 
an AIDS-defining illness was 1.7 (Cl 1.26-2.3) in HCV-positive versus
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HCV-negative individuals; this was independently associated with HCV 
seropositivity. The authors attributed this difference to a slower rise of 
CD4 count on starting HAART. This was supported by the Italian anti- 
retroviral-nai've cohort study, which found that progressing to an AIDS- 
defining illness was independently associated with HCV seropositivity (De 
Luca et al., 2002). Other studies have provided evidence that HCV 
infection induces a defect in immune reconstitution in response to 
HAART, as the rise appears to be blunted in HCV infected patients 
(Soriano et al., 2001; Macias et al., 2003). However, there are two large 
studies that have shown no difference in progression (Rancinan et al., 
2002; Sulkowski et al., 2002). In the USA, Sulkowski et al. studied 1955 
patients infected with HIV, 44.6% were also infected with HCV, and found 
no difference between HCV-positive and HCV-negative patients in the ir 
progression to AIDS (Sulkowski et al., 2002). While there was an initial 
difference between the groups, this disappeared when adjusted for 
exposure to HAART. In contrast to the Swiss Cohort study the follow-up 
was shorter and significantly less patients were on HAART. In the 
Sulkowki study, progression to AIDS was more rapid and an HCV effect 
may have been missed because of the latency of HCV-related morbidity. 
A French cohort found no increase in overall m ortality among HCV/HIV 
co-infection (Rancinan et al., 2002). However, only 600 HCV positive 
individuals were enrolled. While it is difficult to compare these four 
studies, the CD4 recovery was different between the studies showing an 
interaction between HCV and HIV and the studies refuting the 
interaction; this may relate to HAART exposure. A number of 
mechanisms have been postulated to explain the possible detrimental 
effect of HCV on HIV (Soriano et al., 2004b). HIV replication may be 
enhanced by the non-specific immune activation with chronic HCV. 
Infection of lymphocytes by HCV could lead to CD4 depletion and also 
blunt the CD4 response to HAART, as suggested in the Swiss Cohort 
study. Finally, the increased hepatotoxicity could result in more frequent 
HAART discontinuation with its impact on HIV.
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1 .3 .4  Highly active an tire trov ira l therapy (HAART) and  
H C V /H IV  co-infection:
Antiretroviral therapy is important for the control of HIV, however, its 
effect on HCV is less clear. HIV treatm ent has been reported to improve 
the course of HCV in co-infected patients. Improved survival in a cohort 
of 285 German haemophilic co-infected patients suggested that HIV 
treatm ent reduced liver-related m ortality (Qurishi et a!., 2003). The liver- 
related mortality rates were: 0.45, 0.69, and 1.70 per 100 person years 
for the HAART, antiretroviral therapy (ART) and untreated groups 
respectively. However, the effect of HIV treatm ent reported in this study 
may have resulted from survivorship bias; those surviving longer would 
have been more likely to receive HAART (Sabin et al., 2004). There is 
evidence that protease inhibitors (PI) may slow the fibrosis progression 
rate. In a French cohort (n = 182) the Metavir fibrosis rate in patients 
receiving a PI and those not receiving these drugs was 0.095 and 0.154 
fibrosis units per year respectively (p=0.002) (Benhamou et al., 2001). 
The estimated difference in cirrhosis at 15 years in the PI group 
compared with the non-PI group was 13% (p<0.001) respectively. In 
contrast to this, Macias et al. reported increased fibrosis with the use of 
nevirapine in HCV co-infected patients (Macias e ta /., 2004). Patients with 
low CD4 counts commencing HAART are also at risk of immune 
reconstitution, which may increase fibrosis progression. Benhamou et al. 
found that a baseline CD4 count <200 cells/pl was independently 
associated with a threefold increase in the development of cirrhosis after 
initiation of ART (Benhamou et al., 2001).
Both HCV and HAART are associated with hepatic injury, mitochondrial 
toxicity and metabolic abnormalities. The presence of HCV increases the 
risk of hepatotoxicity related to antiretroviral therapy by 2-3 fold (Saves 
et al., 1999; Nelson et al., 2005). Sulkowski et al. demonstrated that 
severe hepatotoxicity (ALT >5.1 x upper lim it of normal) occurred in 
10.4% of patients taking HAART with either HBV or HCV and HIV co- 
infection (Sulkowski et al., 2000). Both full-dose ritonovir and nevirapine 
(during the first 12 weeks of treatm ent) have been associated with
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increased hepatotoxicity (Sulkowski et al., 2000; Martinez et al., 2001). 
Inhibition of mitochondrial DNA synthesis can lead to lactic acidosis. 
Mitochondrial damage is also associated with hepatic steatosis. Hepatic 
steatosis is now recognised as a pathogenic mechanism causing hepatic 
inflammation and fibrosis This is particularly associated with the 
nucleoside analogues didanosine (dd l), stavudine (d4T) and zidovudine 
(AZT) (Walker et al., 2004). Hepatic steatosis is also linked to metabolic 
changes that can occur with HCV and Pis. Theoretically, steatohepatitis 
could worsen the HCV injury, particularly in genotype 3 HCV, which is 
independently associated with steatosis. Steatosis may also affect 
response of HCV to interferon and ribavirin (Kaserer et al., 1998).
Recently, the British HIV Association (BHIVA) has published it's 
guidelines for the management of HCV/HIV co-infection (Nelson et al.,
2005). They advise that HCV should be treated early, if possible before 
the need for ART as this reduces the risk of toxicity associated with 
concurrent HIV therapy. Prior to treatm ent co-infected patients should 
have a CD4 count >200 cells/pl as lower counts are associated with 
poorer HCV responses (Garcia-Samaniego et al., 2002). Therefore, ART 
should be initiated to attain a CD4 count >200 cells/pl before HCV 
treatm ent is commenced. This contrasts with the USA and Canada where 
HIV treatm ent initiation is recommended at higher CD4 counts (Braitstein 
e ta /., 2004). The rationale is to reduce the risk of immune reconstitution 
injury and improve the response to HCV treatment. Antiretrovirals 
associated with specific toxicities such as didanosine, stavudine, 
nevirapine and full-dose ritonovir should be avoided. The association 
between nevirapine and increased fibrosis led BHIVA to recommend that 
it is only used where necessary in HCV/HIV co-infection (Macias et al.,
2004). Finally, after starting ART HCV disease should be monitored 
closely for progression and complications, particularly in those patients 
with low CD4 cell counts.
1 .3 .5  Treatm ent o f HCV in H IV  Co-infection:
Theoretically, there may be problems assessing early virological 
responses in HCV/HIV co-infected patients. This is due to differences in
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viral kinetics of HCV in HIV-positive patients. Both phase 1 and 2 HCV 
RNA decay curves are slower in the HIV-positive patient (Torriani et al., 
2003; Talal et al., 2004). However, Torriani and collegues found that 
failure of an EVR was 98% predictive of failure of an SVR in the largest 
clinical trial of co-infected patients (Torriani et al., 2004). These results 
are the same as in HCV mono-infected patients. Interestingly, the slower 
phase 2 HCV kinetic decline may impact on the length of HCV treatm ent 
and some have suggested this may lead to an increase rate of relapse of 
HCV after treatment (Soriano et al., 2004a). Im portant interactions have 
been identified between HAART and combination HCV treatm ent. 
Ribavirin increases the intracellular phosphorylation of didanosine (dd l). 
This increases the risk of mitochondrial toxicity, and has been associated 
with multiorgan dysfunction and lactic acidosis (Lafeuillade et al., 2001). 
Based on the use of the data from RIBAVIC study, there is now an FDA 
recommendation against the combination of ribavirin and ddl. BHIVA 
recommend avoiding the combination of zidovudine (AZT) or ddl with 
ribavirin therapy (Nelson et al., 2005).
Acute HCV in H IV  co-infection:
Preliminary treatm ent results of interferon with or w ithout to ribavirin for 
acute HCV in HIV co-infection has emerged from the recent UK epidemic. 
Treatment of a London cohort of 27 HIV-positive patients with acute HCV, 
defined as documented seroconversion of anti-HCV antibody and positive 
HCV viraemia, for 24 weeks with combination pegylated interferon a-2a 
plus ribavirin resulted in a SVR of 59% (n = 16) (Gilleece et al., 2005). 
These results were supported by a smaller German case series (Vogel et 
al., 2005). A significant proportion of the UK cohort eradicated HCV prior 
to treatment, probably pointing to the necessity to delaying treatm ent for 
a short period (12 weeks) to allow spontaneous clearance. While the SVR 
is lower than among individuals with acute mono-infection treated with 
interferon monotherapy, these rates are significantly higher than those 
among chronically co-infected patients treated with combination 
pegylated interferon and ribavirin (Jaeckel et al., 2001; Fried et al., 
2002; Torriani eta !.,  2004).
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Chronic H C V /H IV  co-infection:
Three large randomised controlled tria ls have examined the effect of 
combination pegylated interferon-a plus ribavirin for treatm ent of chronic 
HCV/HIV co-infection. In contrast to HCV mono-infection, high relapse 
rates have been reported after 24 weeks of treatm ent for HIV-positive 
patients infected with genotypes 2 or 3. Consequently, 48 week therapy 
was used in these studies. The APRICOT study (n=868) compared the 
efficacy of 48 weeks of pegylated interferon a-2a (180 meg weekly) plus 
ribavirin (800mg daily), pegylated interferon a-2a (180 meg weekly) plus 
placebo, or interferon a-2a (3 million IU three times a week) plus 
ribavirin (800 mg daily) (Torriani et al., 2004). Patients treated with 
pegylated interferon a-2a plus ribavirin had significantly higher overall
SVR rates compared with pegylated interferon a-2a alone or standard
interferon plus ribavirin (40% versus 20% and 12% respectively,
p<0.001). In the pegylated interferon a-2a plus ribavirin arm the SVR for 
those infected with genotype 1 was 29% and for those infected with 
genotypes 2 and 3 was 62%. Failure of an early virological response was 
predictive of treatm ent failure. The side-effects were comparable
between the different arms and there were no significant adverse effects 
of therapy on the HIV parameters.
The French RIBAVIC study (n=412) randomised co-infected patients to 
48 weeks of Ribavirin 800 mg plus either pegylated interferon a-2b 
(1.5pg/kg weekly) or standard interferon a-2b (3 million IU three times a 
week) (Carrat et at., 2004). The overall SVR was better in the pegylated 
interferon a-2b arm (27% versus 20%, p=0.047). In the pegylated 
interferon arm the SVR for those infected with genotypes 1/4 was 17% 
and for those infected with genotypes 2/3 was 44%. In the Aids Clinical 
Trials Group (ACTG) study 133 (ACTG 133) patients were randomised to 
receive either pegylated interferon or standard interferon with dose 
escalating ribavirin (Chung et al., 2004). The overall SVR for the 
pegylated versus the standard interferon group was 27% versus 12%
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(p=0.03). In the pegylated interferon arm the SVR was 14% for those 
infected with genotype 1 and 71% for those infected with genotypes 2/3.
While the outcomes of treatm ent of dually infected patients are lower 
than in HCV mono-infected patients, these studies have demonstrated 
that pegylated interferon and ribavirin is an effective therapy for the co- 
infected patient (Fried et al., 2002). In summary, the studies have 
demonstrated overall SVRs ranging from 27-40%. The SVR for genotype 
1 HCV ranges from 14-29% and for genotypes 2/3 from 44-71%. It  is 
often difficult to compare studies and the reason for the variation 
between these studies is debatable. The SVRs in the RIBAVIC study were 
significantly lower than those in the APRICOT study. This may have been 
the result of the high frequency of discontinuation in the RIBAVIC study 
due to side-effects of the regime and the proportion of intravenous drug 
users enrolled. There was also a significant difference in the proportion of 
individuals with severe fibrosis at randomisation (bridging fibrosis or 
cirrhosis), which was more prevalent in the RIBAVIC than the APRICOT 
cohort (40% vs 15%). Advanced fibrosis is known to be a predictor of 
poor virologic response (Manns et al., 2001; Myers et al., 2003). A 
number of reasons have been suggested to explain the poorer treatm ent 
responses in co-infected patients (Brau, 2003). These include higher HCV 
viral loads, increased HCV quasispecies diversity and lower dosing of 
ribavirin due to intolerance. In those tha t do not have a SVR, HCV 
treatm ent was shown to improve histology in 34% of patients (Chung et 
al., 2004).
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1.4 Objectives
The objective of this study was to analyse three linked aspects of the 
epidemic of HCV in the HIV population of South-East England.
The major focus of the thesis is the characterisation of the epidemiology 
of acute HCV in the HIV population through linked molecular and clinical 
studies. The association with high-risk sexual practices and sexually 
transmitted infections suggests that, in contrast to the normal parenteral 
route of HCV transmission, sexual factors may be important in the recent 
epidemic. A phylogenetic study of the E1/E2 region of the HCV genome 
from identified cases explores the thesis of recent HCV transmissions. 
Phylogenetic analysis of the HCV genome has previously been used to 
determine viral relatedness and provide evidence of HCV transmission 
within populations (Cochrane et at., 2002). A case-control study using a 
specifically designed questionnaire instrument was performed in parallel 
to elucidate relevant transmission factors. Matched controls were 
generated from the same HIV clinics as the patients. By demonstrating 
transmission, and identifying the responsible factors, public health 
interventions can be developed to focus on specific measures to prevent 
further infections.
By Seeff's criteria, this cohort is ideally suited to describe the natural 
history of HCV/HIV co-infection (Seeff, 1997). The cohort has acute 
disease documented by seroconversion of anti-HCV and/or HCV RNA. 
Clinically the cohort covers the spectrum of acute disease from the 
asymptomatic presentations to icteric acute hepatitis. Since the m ajority 
of individuals were diagnosed as outpatients there would appear to be no 
bias towards severe disease. The clinical course of these patients has 
been recorded over this time. As part of the case-control study, HCV 
negative controls have been matched to these patients. This provides an 
accurate picture of the early clinical course of HCV in HIV-positive 
individuals. A proportion of the cohort has been treated and study of this 
group provides valuable data on the influence of standard HCV treatment 
in early co-infection.
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Cell-mediated immunity is the most im portant immunological mechanism 
for control of HCV. HIV infection causes a cell-mediated immune defect. 
The immunological responses in HIV co-infection have not been well 
studied. Multiple longitudinal blood samples have been collected from 
patients in the acute phase of HCV infection to study these responses. 
Using qualitative lymphocyte assays a picture of cell-mediated immune 
responses will be developed. These are correlated with both HCV 
evolution and clinical outcome over the early phase of the infection.
This cohort provides a unique opportunity, through the characterisation 
of the epidemiological, clinical and immunological aspects to improve our 
understanding of both HCV mono- and co-infection.
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Chapter 2: Molecular Epidemiology
2.1 Introduction
Evolution is founded on the concept tha t organisms share a common 
ancestor and diverge through time. Phylogenies are an attempt to 
reconstruct this evolutionary history; thus sensitive molecular PCR 
techniques have transformed phylogenetic studies in viral infections as 
viral evolution is particularly suited to this type of study. Phylogenetic 
studies of viruses use accumulated genetic divergence over time to 
understand the origin and spread of the virus. In contrast to the 
evolution of eukaryocytic DNA, viral evolution is rapid, prone to mutation 
and can therefore be studied in a relatively short time frame. These 
studies exploit statistical dependencies among sequences sharing a 
common ancestor. Of particular relevance to this thesis, transmission 
patterns can be established and evolutionary histories of epidemics can 
be reconstructed. Dramatic advances in phylogenetic analysis have also 
resulted from increased computational speed, more realistic DNA 
modelling, and better computer programs.
2 .1 .1  Viral evolution:
Viral evolution depends upon genetic mutation as a result of change in 
the nucleotides (adenine (A), guanine (G), thym idine (T) and cytosine 
(C)) tha t make-up the DNA or RNA genome. Four processes can 
contribute to viral evolution. Adaptive (Darwinian) evolution describes the 
genetic change resulting from external selection pressure, which leads to 
phenotypic change. Mutations will predominate where there is a 
concomitant survival or fitness advantage. Different sequences of 
nucleotides can code for the same amino acid (AA); for example GCC and 
GCA code for alanine. A nucleotide change which results in a different AA 
(a phenotypic change), is termed a non-synonymous change. However, if 
the nucleotide substitution does not result in phenotypic change this is 
termed a silent or synonymous change. By looking at the ratio of the 
number of non-synonymous to synonymous changes (dN/dS), evidence 
of positive selection pressure (dN/dS >1) can be found. The HVR1 in the
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E2 region of the HCV genome is an example of a region under strong 
positive selection pressure from the immune system in acute infection 
(Farci et al., 2000).
In contrast to adaptive Darwinian evolution, the neutral theory of 
evolution, proposed by Kimura, holds tha t the great majority of genetic 
diversity is caused by random fixation (the nucleotide substitution 
becomes a universal feature of the population), through sampling drift, of 
selectively neutral mutations under continued mutation pressure 
(Kimura, 1991). These mutations have little  effect on the phenotype, 
biology or fitness of either the species or the individuals that make up the 
species, and become fixed by chance. Kimura's view is based on 
nucleotide sequences coding AAs leading to synonymous/non- 
synonymous change. He proposed that the mutations are selectively 
neutral or slightly deleterious and are maintained by a balance between 
mutational input and random extinction. Spontaneous nucleotide 
substitution leads to a new allele, which is then subject to drift. These 
new alleles or mutations usually decline or disappear, but very 
occasionally they become 'fixed'. In this way the neutral substitutions 
accumulate and contribute to the evolution of the genome. Neutral 
sequence change accounts fo r the vast m ajority of the genetic divergence 
between the geographically or epidemiologically separated HCV 
genotypes (Simmonds, 2004). While there is up to 35% variation in the 
nucleotide sequence of the HCV genome between genotypes, the 
replication cycle and infection in humans remains very similar. The rate 
at which these single-nucleotide differences occur, termed the 'molecular 
clock', is determined by the HCV RNA polymerase. HCV mutates at rates 
a million times faster than DNA organisms; the result of short generation 
times and lack of proof-reading activity in the RNA polymerase (Saitou & 
Nei, 1986). The molecular clock for HCV has been estimated by 
sequencing longitudinal samples from infected individuals. In a study of 
American and Japanese patients chronically infected with HCV, Tanaka et 
al. calculated the mean evolutionary rate of all codon substitutions within 
the combined nucleotide sequences was 0.67 (0.53-0.79) x 10'3 per site 
per year (Tanaka et al., 2002). The rate for synonymous substitutions
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was higher than non-synonymous, supporting the neutral theory of 
evolution.
Transmission events are another im portant source of viral heterogeneity. 
During the passage of virus from one host to another there is an extreme 
evolutionary bottleneck, as only a few randomly selected virions are 
transferred. This arbitrariness contributes to a high rate of evolution 
because only the transferred virions can replicate to produce a persistent 
progeny population with further transmission of HCV. At the time of 
infection the majority of patients have a few HCV particles. In a study of 
12 individuals with primary infection, Herring and colleagues found that 
only 4 of the 12 had been infected with multiple infectious particles at the 
tim e of infection, based on evaluation of the HCV quasispecies and known 
mutation rate of HCV (Herring et al., 2005).
Finally, recombination can produce viral mutation. This occurs when 
genetic material is passed between different viral genomes, usually as a 
result of template-switching during RNA genomic replication. While 
recombination is common with HIV it is rare in HCV infection, and has 
only been described in Russia and Peru (Colina et al., 2004; Kalinina et 
al., 2004).
2 .1 .2  Phylogenetic studies:
Phylogenetic studies of genetic sequences have two components. One is 
a phylogenetic tree, which is a topographical description of the 
relationships between the sequences and has the form of branching 
lineages connected by nodes. The horizontal distance is a visual 
representation of genetic distance; internal nodes are the points where 
lineages branch or diverge. Terminal nodes are situated at the end of the 
branches and represent the individual sequences or taxa. A tree is rooted 
if it has a node designated as the ancestor of the sequences that make­
up the tree, giving the tree a temporal polarity from past to present. A 
group of taxa (>2 sequences) are considered monophyletic if they all 
derive from the same ancestor; also termed a clade. Often this is 
determined by comparing the sequences of interest (the 'ingroup'; in this
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case the sequences of acute HCV in the HIV-positive individuals) to other 
sim ilar but unrelated sequences (the 'outgroup'). The second component 
is the model used to describe how sequences evolve by nucleotide or 
amino acid change along the branches of the tree. Evolutionary models 
can be either empirical or parametric. Empirical models use properties 
calculated through comparison of large numbers of observed sequences. 
Parametric models use chemical or biochemical properties of DNA or AA 
to describe the evolution through time of the sequences. These models 
allow a genetic distance between two sequences to be estimated, 
measuring the expected number of nucleotide substitutions per site that 
have occurred on each lineage between them and their most recent 
common ancestor.
Nucleotide substitution parameters are fundamental to these evolutionary 
models. The rate of evolutionary change, the 'molecular clock', was 
initially proposed to be constant (Zuckerkandl & Pauling, 1965). 
However, it is now clear that the "molecular clock seems to tick at 
different rates" with a number of factors influencing the nucleotide 
substitution rate; these parameters can be defined in the evolutionary 
models (Lio & Goldman, 1998). First, base frequency can be defined, 
which describes the frequency of purines; adenine (A) and guanine (G), 
and pyrimidines; thymidine (T) and cytosine (C), over all sequenced sites 
and over the tree. Certain bases may be more likely to arise when 
substitutions occur. Second, base exchangeability parameters can be 
used to describe the relative rate of bases substituted for each other. 
This incorporates the different tendency for transitions and transversions. 
A transition is a change between a nucleotide of the same chemical type 
(purine to purine or pyrim idine to pyrim idine). A transversion is a change 
from one to the other (purine to pyrim idine or pyrimidine to purine). 
Transitions are more common than transversions (Brown & Simpson, 
1982). Another parameter relates to the nucleotide mutation rate which 
varies across the HCV genome, termed rate heterogeneity. I t  is usually 
described by a gamma distribution for a non-symmetric distribution. In a 
review of variation among cloned HCV sequences, Smith et al. estimated 
sporadic nucleotide substitutions across the genome: 5' Untranslated
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region (UTR) 0.08-0.72 x 10'4, NS3 0.71 x 10'4, E2 0.61-1.42 x 10‘4, 
NS5A 0.43 x 10'4, NS5B 0.17-0.37 x 10'4 per site per year (Smith et a/., 
1997). The high rate of change in the E2 region relates to the HVR1.
Models have also been developed based on codons to describe the
evolution of sequences in terms of DNA substitutions and the selective 
forces acting on proteins. The third codon site, where 70% of mutations 
are synonymous, evolves nine times faster than the second codon site, 
where all changes are non-synonymous (Stum pf & Pybus, 2002).
Nucleotide replacement is a dependent random event, described as a 
Markov process, where future possibilities are determined by its most 
recent values.
Using these evolutionary models different methods can estimate the 
phylogeny. Typically, the methods either grow the tree progressively 
during analysis (distance-based) or perform an exhaustive search of all 
the possible tree topologies (character-based). I t  must be understood, 
however, that a derived tree is a hypothesis of a relationship between the 
sequences rather than the actual tree. Furthermore, estimates of
evolution are based on representative sequences and often not the entire 
population. Distance-based methods infer the relatedness between 
sequences by calculating the pairwise distance between them and 
tabulating a distance matrix. The distance between them is a measure of 
the ir genetic difference and this makes up the matrix. The tree is 
calculated by progressive clustering from this distance matrix. This model 
describes how the nucleotide substitutions have occurred since they last 
shared a common ancestor. A tree is then drawn from the data with the 
more similar sequences clustering more closely than less similar 
sequences. Distance methods include the Unweighted Pair Group Method 
(UPGMA) and Neighbour-joining (NJ) approach.
Character-based methods search for the optimal tree among the total 
number of possible trees; and infer relationships more closely from 
observed sequence. These include maximum likelihood (ML), maximum 
parsimony (MP) and Bayesian methods. The ML estimation of phylogeny 
is a statistical method which gives the most probable tree for the
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observed data using the specified model of evolution. For the ML method, 
the user can determine the evolutionary parameters. The strength of the 
ML method is that because it is statistically based, estimates are 
statistically consistent and comparisons between trees, parameters and 
models can be made. The problem with ML methods is they are 
computationally demanding due to the number of tree topologies 
generated; these methods are practical for a few hundred sequences at 
most. Maximum parsimony holds that the simplest hypothesis is most 
likely to be correct. To explain the data, this method uses the least 
number of evolutionary steps to create trees. This method can be 
problematic if there is large variability between the sequences. However, 
it is suited to sequenced-based analysis of large numbers of sequences. 
Bayesian methods employ probability theory and the Markov Chain Monte 
Carlo methods to analyse and search fo r the best set of trees. The 
method of analysis is dependent upon the number of trees. I f  there are 
fewer than 10 taxa then an exhaustive tree search can be performed. 
However, as the number of taxa increases, the number of possible trees 
increases exponentially; even with n = 10 taxa, the number of possible 
trees exceeds 2 x 106 (Felsenstein, 1978). Consequently, with larger 
groups of sequences heuristic methods are used to simplify the 
computations. Heuristic methods use problem solving techniques in which 
the most appropriate of several trees found by alternate methods is 
selected at successive stages of a program for use in the next step of the 
program.
I t  is important to be able to test the generated trees, or chosen 
parameters and models. The introduction of likelihood frameworks has 
allowed statistical comparison of different models. The likelihood of a 
hypothesis is defined as the probability of the data given that hypothesis. 
The hypotheses in phylogenetic studies are the reconstructed trees and 
parameters of the evolutionary models. Different hypotheses have 
different likelihoods: the higher the likelihood, the more plausible the 
generated data. Statistical methods now exist to estimate these 
likelihoods, typically requiring computations that account for the 
unobserved sequences at the internal (ancestoral) nodes of hypothesised
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trees. These likelihoods can also be used to compare evolutionary 
models. Likelihood ratio tests (LRT) are a class of powerful statistical 
tests that compare ML values of competing hypotheses. Another analytic 
method is non-parametric bootstrapping, which is used as a test of the 
inferred evolutionary tree. This is a numerical re-sampling method in 
which a new sequence alignment is compiled from the original alignment 
by random sampling with replacement. A column of nucleotides is chosen 
randomly and placed in a new alignment and then this is repeated; up to 
1000 times. The frequency with which a specific branch is found after 
analyses of these pseudoreplicates is used to assess the reliability of the 
relationship of the branches. A bootstrap score >70 represents a cluster 
with robust statistical support (McCormack & Clewley, 2002). Sequences 
derived from this branch are considered monophyletic.
Population dynamic studies analyse sequences to give estimates of 
temporal change in population size, population structure and substitution 
rates. Evolutionary trees spanning longer periods of time are inferred 
from DNA sequences. These analyses use node height or branch length of 
the tree. Models used for this sort of analysis include birth-death and 
coalescence models. Assumptions are made that at any point in time all 
the lineages in the trees are assumed to behave according to the same 
stochastic rules, although these rules can change through time. A 
relationship between node height and speciation (new lineages) and 
extinction (loss of lineages) exists. As the birth rate (speciation) 
increases, the nodes are more frequent closer to the present, while an 
increase in death rate (extinction) leads to the nodes being situated 
closer to the root. However, studying trees that represent individual taxa 
belonging to the same population, a coalescent model is more 
appropriate. Coalescence describes the relationship between the 
demographic history of a large population and the shared ancestry of 
individuals randomly sampled from it; represented in a tree. During 
analysis of the tree, a number of different lineages can be followed. This 
number decreases when there is a common ancestor (a coalescent event) 
or increases when there is a sampled individual (a sample event). 
Because the probability that a coalescent event occurs at a particular
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time is inversely proportional to the population size at that time, the 
pattern of observed coalescence and sampling events can be used to 
estimate the demographic history of the population. A molecular clock is 
fundamental to this analysis as it combines temporal information with the 
genetic information of the sequences. Using the nucleotide substitution 
rate the date of origin, also termed 'the most recent common ancestor' 
(TMRCA), of clusters can be calculated. This correlates with the entry of 
the virus into the transmission cluster. HCV is suited to population 
dynamic analysis as it has very short generation times, which generate 
many mutations. Because the mutation rate is so high, shorter sequences 
can be used in these analyses. The temporal information in sequences 
from multiple time-points enables phylogenies to be calibrated in 
calendar timescales from which, the tim ing of epidemiological events can 
be inferred, and in conjunction with coalescent theory, enables past 
epidemiological dynamics to be estimated.
A phylogenetic analysis therefore involves a number of steps. First the 
relevant sequence of interest is identified. The region needs to have 
enough variability that differences will exist to differentiate between the 
individual viruses. The length necessary will be in part determined by the 
assay and the viral dynamics. High mutation rates allow shorter 
segments to be examined. Finally, there needs to be data available on 
unrelated sim ilar regions to produce the comparative 'outgroup'. The 
HVR1 and NS5B regions of the HCV genome have been used extensively 
for this type of molecular epidemiological study. With the interest in the 
immunological aspect of acute infection, the E1/E2 region of the genome, 
which incorporates the hypervariable region (HVR1) was chosen. This 
longer segment of sequence increases the robustness of the analysis. 
Im portantly, there are many E1/E2 sequences available publicly (on 
Genbank/Los Alamos HCV sequence bank) for comparison. Finally, work 
has already been done that has identified the rate of nucleotide 
substitutions of the E1/E2 region. I t  has also been recommended that the 
HVR1 is suited to analysis of more recent HCV transmission, while 
analysis of the more conserved and longer NS5B sequence was the 
choice for the examination of transmission in the more distant past
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(Smith & Simmonds, 1997). Interpretation of the final trees and 
population dynamics will provide detailed insights into this epidemic at a 
molecular level.
2.2 Aims
This phylogenetic study had two aims:
1. To determine if there is evidence at a molecular level for 
transmission of HCV in the HIV population. Through an analysis of 
E1/E2 homology and comparison with sim ilar but unrelated 
sequences, a search for monophyletic transmission clusters 
(clades) was performed. I f  found these data would provide 
powerful evidence for transmission.
2. A population dynamic analysis was performed on the largest 
monophyletic cluster to understand the evolution and dynamics of 
the HCV transmission.
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2.3 Methods
2 .3 .1  Study cohort:
The study cohort consisted of HIV-positive patients diagnosed with acute 
HCV infection. Acute HCV was defined as a documented positive anti-HCV 
seroconversion following a negative assay within the prior 6 months; or 
detection of HCV-RNA by PCR following a negative assay within the prior 
6 months; or a positive HCV-RNA by PCR and a more than 10-times the 
upper lim it of normal (ULN) rise in serum alanine aminotransferase (ALT) 
with documented normal ALT during the preceding year. All the cases 
were recruited from three large urban HIV clinics in South-East England: 
the Ian Charleston Day Centre at the Royal Free Hospital (RFH); the 
Koebler Centre at the Chelsea and Westminster Hospitals (CWH); and the 
Elton John Centre at Brighton and Sussex General Hospital (BSH). These 
centres treat substantial numbers of patients with HIV, providing both 
inpatient and outpatient services. The study began enrolling patients in 
late 2003 and patients have been enrolled both retrospectively and 
prospectively. Patients had been diagnosed with HCV between 1999- 
2005. Patients participating in the phylogenetic study, gave informed 
consent for blood samples and clinical information to be obtained and 
analysed. All these cases have been enrolled into the study under the 
approval of each unit's local research ethics committee (LREC references: 
RFH 6148; CWH 3247; BSH B03/83) and the Central Office for Research 
Ethics Committees (COREC).
Specific clinical viral testing was performed using the following: anti-HCV 
was tested with Vitros ECI ELISA (Ortho-Clinical Diagnostics, USA). I f  this 
was positive but the HCV RNA negative then a Chiron HCV RIBA (Chiron, 
USA) was performed to confirm a true positive anti-HCV assay. Up until 
March 2004, HCV RNA was tested with Bayer branched DNA or Bayer 
TMA assay (Bayer, Germany) with a lower lim it of detection of 615 IU /m l. 
Since March 2004 an automated Abbott system has been used, initially 
Abbott LCX HCV PCR (Abbott, USA) with a lower lim it of detection of 50 
IU/m l and then Abbott Real Time HCV PCR with a lower lim it of detection
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of 23 IU /m l. The genotype was determ ined using a Bayer AutoLiPA 
(Bayer, Germany) on samples that were HCV RNA positive.
2 .3 .2  Target genome:
HCV RNA isolation and preparation
The firs t HCV RNA positive serum sample tha t was available was used for 
the phylogenetic analysis. These samples were obtained from each 
centre's virology service and had been stored at between -4 to -20°C. 
Some had been stored for up to 4 years before analysis.
QIAamp Viral RNA Mini Kits (QIAGEN™) were used for extraction of the 
HCV RNA from serum according to manufacturer's instructions. The 
technique uses silica-gel based membrane to actively bind the RNA. 
Briefly, the samples were lysed under highly denaturing conditions to 
inactivate RNA-ases and ensure isolation of HCV RNA. Serum was used to 
lim it the amount of cellular DNA as DNA is not separated with these kits. 
Aliquots of 140pl of serum were used for the extraction. The extracted 
RNA samples were eluted to 50pl in water and stored at -80°C.
Reverse-transcription polym erase chain reaction (RT-PCR):
The development of the polymerase chain reaction (PCR) technique in the 
1980s has allowed rapid advances in the field of molecular biology. 
Thermostable DNA polymerase is utilised to extend sequences from 
synthesised oligonucleotide primer pairs, which are designed to flank an 
area of interest. The PCR mixture is heated to separate the double 
stranded DNA and then cooled to a specific temperature to allow the 
primers to anneal to a DNA strand. A fu rther rise in temperature allows 
extension to take place from the 5' end of each primer. The reaction is 
then heated which separates the newly formed DNA from its template 
and the cycle is repeated. Each cycle, at optimum conditions, allows the 
number of copies of the region of interest to be doubled and this 
exponential increase in DNA continues until the DNA polymerase is 
exhausted, or the primer pairs become lim iting.
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The addition of a reverse transcriptase step before PCR is carried out, has 
allowed the amplification and quantitation of RNA as well as DNA by this 
method. Reverse transcriptase is an enzyme utilised by RNA viruses to 
convert the ir genomic material (i.e. RNA) into transcribable DNA within 
the host cell. I f  added to RNA isolated from cells or tissues of interest, 
along with suitable primers to initiate reverse transcription, it will 
produce cDNA that can then be used in a subsequent PCR. Primers can 
be either random (which will produce cDNA of all the mRNA in the 
sample) or sequence specific which produces cDNA only from mRNA 
containing the sequence of interest.
Reverse transcription was carried out using a Superscript™ First Strand 
Synthesis System (Invitrogen, UK). Briefly 50ng random hexamer 
primers (Amersham Bioscience, UK) were added to lOpI of extracted RNA 
and the mixture was heated to 65°C for 5 minutes. 9pl of the following 
mix was added; lx  First Strand Buffer, 500pM dNTP's, 40units RNaseOUT 
ribonuclease inhibitor (Invitrogen, UK), 50units Superscript II M-MLV 
reverse transcriptase. The reaction was then incubated at 37°C for 60 
minutes and terminated by heating to 70°C for 5 minutes. The cDNA was 
stored at -20°C until use.
N ested E 1 /E 2  PCR:
Nested PCR was performed using primers to amplify the E1/E2 section of 
the HCV genome (Farci e ta /., 1992). The product was 575 basepairs (bp) 
in length. The following primers were used:
• F1E2 (between nucleotides 1285-1304): 5'-caccgcatggcatgggatat
• R1E2 (between nucleotides 1881-1862): 5'-ggggctgggagtgaagcaat
• F2E2 (between nucleotides 1291-1310): 5'-atggcatgggatatgatgat
• R2E2 (between nucleotides 1865-1846): 5'-caagcaatataccggacaca
To prevent contamination during the PCR each step the recommendations 
of Kwok were followed (Kwok & Higuchi, 1989).
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The first PCR reaction was carried out as follows; lx  Taq buffer, 1.5mM 
MgCI2, 0.2mM dNTP, SOpmole F1E2 and R1E2, 1 unit Platinum Taq 
polymerase (InVitrogen, UK) and 5pl cDNA in a total volume of 50pl. The 
reaction was heated to 94°C for 15 minutes to activate the polymerase, 
35 cycles of denaturing at 94°C for 30 seconds, annealing 54°C for 30 
seconds and extension at 72°C for 1 minute. A terminal extension step of 
72°C for 4 minutes was included to ensure complete synthesis of the 
double stranded amplicon.
The second PCR reaction was then carried out using the nested primers 
F2E2 and R2E2 using the same conditions and adding 2pl of first round 
product.
Gel electrophoresis:
Once the reaction had been completed the reaction was subjected to 
agarose gel electrophoresis. The expected size of the PCR product was 
575 bp in length.
The gel electrophoresis was performed as follows:
A 1.5% w /v agarose gel was prepared in lx  TBE Buffer (0.89 M Tris, 0.89 
M Boric Acid, 0.02 M EDTA) and melted in a microwave at full power. 
Once cooled to 50°C 1 pi of ethidium bromide solution (0.05 pg/m l) was 
added and the gel poured into a perspex mould with a gel comb in situ 
and left to set. The PCR reaction was then added to 8pl of 6x Loading 
Buffer (15% w/v Ficoll 400, 0.06% w /v Bromophenol Blue, 30mM EDTA- 
Tris pH 8.0). The samples were added to the wells and the gel subjected 
to electrophoresis at constant voltage of 80-100volts. Appropriate size 
markers were included in each run. A fter completion the gel was 
visualised by ultra-violet trans-illum ination on a UVP EpiChemi II 
Darkroom (UVP Laboratory Products, USA) and a digital image saved. 
Following confirmation of a product of appropriate size, the bands were 
excised under ultraviolet visualisation and purified using a QIAquick PCR 
purification kit (QIAGEN™, UK) and manufacturer's instructions. The 
purified DNA was eluted in 30-40pl of elution buffer (lOmM Tris-HCI pH 
7.6). Once purified the E1/E2 DNA was stored at -80°C until sequencing.
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Sequencing o f the PCR p ro d u c t-E l/E 2  region:
The 575bp E1/E2 DNA amplicon was directly sequenced using forward 
and reverse PCR primers. Sequencing was performed by The Sequencing 
Service (School of Life Sciences, University of Dundee, Scotland, 
www.dnaseq.co.uk) using Applied Biosystems Big-Dye Ver 3.1 chemistry 
on an Applied Biosystems model 3730 automated capillary DNA 
sequencer. 20ng of purified DNA and 3.2pmoles of primer were included 
in each sequencing reaction. The primers' sequences were not included in 
the final analysed section, leaving a 495 bp sequence.
Cloning o f E 1 /E 2  region to assess consensus sequence:
I t  is now acceptable to use the direct sequence of the purified amplicon 
which represents the consensus sequence (Odeberg et al., 1995). To 
determine that this was the case with our samples we compared the 
consensus sequence from direct sequencing to cloned individual 
sequences from a number of individuals.
The 575 bp E1/E2 amplicon was cloned into pCR 4.0 TOPO vector using a 
TOPO TA Cloning® kit (Invitrogen, UK), following the manufacturer's 
instructions throughout. This method is suitable for Taq polymerase 
generated amplicons as it has a non-template-dependent terminal 
transferase activity, which adds a single adenosine to the 3' end of the 
PCR product. The vector provided has an overhanging thymidine residue, 
allowing efficient binding of the vector and PCR product. The kit utilises 
Vaccinia topoisomerase, which specifically cleaves the phosphodiesterase 
backbone after 5'-CCCTT in one strand and a covalent bond is then 
formed between the 3' end of the PCR product and the topoisomerase. 
The plasmid construct is then transfected into E.coli (TOPIO). The vector 
contains a lethal gene ccdB fused to the C-terminus of the LacZa 
fragment which is disrupted by the insertion of the PCR DNA; only E.coli 
with the recombinant will grow.
Briefly, 4pl of eluted E1/E2 cDNA was mixed with lp l of salt solution and 
then lp l of TOPO® vector was added. This was incubated for 5 minutes 
at room temperature (22°C) and then placed on ice. 2pl of the reaction
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was then added to chemically competent TOPIO E.coli and incubated on 
ice for 20 minutes. The cells were heat-shocked for 30 seconds at 42°C 
and again transferred to ice. 250pl of SOC culture medium (2% Tryptone, 
0.5% Yeast Extract, lOmM NaCI, 2.5mM KCI, lOmM MgCI2, lOmM MgS04, 
20mM glucose) was added to each tube and then placed in a rotary 
incubator for 1 hour at 37°C. 10 and 50pl volumes of each reaction were 
then spread evenly on LB agar selection plates (1% Tryptone, 0.5% 
Yeast Extract, 1% NaCI, 15g/L Agar, 50pg/m l ampicillin pH 7.0) and 
incubated at 37°C overnight.
Plasmid purification and sequencing:
At least 10 colonies were picked from each plate and re-cultured in 1.5ml 
of LB medium (1% Tryptone, 0.5% Yeast Extract, 1% NaCI pH 7.0) 
containing 50pg/ml Ampicillin at 37°C. Plasmids were purified from the 
cultures using a QIAprep™ kit (QIAGEN, UK) according to the 
manufacturers instructions, and stored at -20°C. 300ng of the purified 
plasmid was sequenced at The Sequencing Service (School of Life 
Sciences, University of Dundee, Scotland, www.dnasea.co.uk) using M13 
forward and reverse primers (sequence was 535bp in length).
2 .3 .3  Ph ylogenetic analysis:
Sequence alignm ent:
The amino acid sequences were aligned and then converted to nucleotide 
sequences. This gives an in-frame alignment. The beginning of the E l 
region was identified as an alignment point because the divergence at 
this point is generally low. Nucleotide sequences were edited and 
compiled using the Lasergene software (DNASTAR Inc, USA). The patient 
sequences were then aligned along with a data set of the same HCV 
region (n = 330) collected from GeneBank ('www.ncbi.nlm.nih.Qov) and 
Los Alamos HCV Sequence Database (www.hcv.lanl.aov).
Phylogenetic reconstruction:
The Neighbour-joining (NJ) method was used to reconstruct the 
phylogenetic relationship of the sequences. This method was developed 
by Saitou and Nei (Saitou & Nei, 1987). The NJ methods reconstructs the
64
phylogenetic trees based on the principle of minimum evolution or 
maximum parsimony which chooses the tree that requires the smallest 
amount of evolutionary change. Simply, the NJ method starts with a star 
shape of the sequences. A distance parameter is then defined between 
the sequences and this is entered into a distance matrix. Neighbours are 
defined as sequences connected through a single interior node in an 
unrooted bifurcating tree. The two sequences with the lowest distance 
between them are defined as the initial neighbours. Then the distance 
matrix is re-calculated to define the distance between the new node and 
the other sequences. Then a new neighbour is defined and this process 
continues until all the sequences lie in the tree. The NJ method provides 
not only the topology but also the branch lengths of the final tree.
Using a NJ method the genetic distances were calculated using maximum 
likelihood, under a Hasegawa Kishimo Yano (HKY) model with a gamma- 
distribution model of rate heterogeneity among sites (Hasegawa et al., 
1985). The HKY model uses base frequency and transversion/transition 
parameters for nucleotide substitution models. The phylogenetic trees 
were mid-point rooted using the estimated genetic distances. Unrelated 
sequences of the same region were extracted from GenBank and the Los 
Alamos HCV Sequence Database. A fter identification of the largest clade, 
the tree was re-estimated using PAUP* software for the computational 
analysis (Swofford, 2003). PAUP* uses a maximum likelihood (ML) 
approach. The statistical robustness of the ML topologies was assessed 
by bootstrapping with 1000 replicates. The dynamics of the largest clade 
were explored following the application of a molecular clock using both 
coalescent theory and life-death plots. The date of origin of each HCV 
cluster, which approximates the year of entry of HCV into the cluster, 
was estimated using a molecular clock approach. First, an evolutionary 
rate for our specific region of E1/E2 was estimated using the method of 
Verbeeck et al. (Verbeeck et al., 2006). Dates of origin for each cluster 
were subsequently calculated using a Bayesian MCMC approach in Beast 
v l.3  (Drummond & Rambaut, 2003). The final trees were interpreted in 
the context of the available clinical, epidemiological and serological data.
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2.4 Results
2.4 .1  P atien t cohort:
Serum was analysed from 111 HIV-positive patients who had been 
diagnosed with acute HCV. The patients were recruited from: the RFH 
(n = 50), CWH (n = 50) and BSGH (n = l l ) .  The clinical and demographic 
data is outlined in Table 2.1. All the cases were HIV-positive men with a 
median age of 35 years. Their HIV was well controlled with 57% on 
HAART and a median CD4 498 cells/pl. The majority (83% ) had genotype 
1 with high HCV viral loads (median HCV viral load 6.1 log IU /m l). The 
median peak ALT was 285 IU /m l.
T a b le  2 .1 : P h y lo g en e tic  s tu d y  p a t ie n t  p a ra m e te rs .
A ll RFH CW H BSGH
Num ber 111 50 50 11
Median Age (years) 36 (24-58) 35.2 35 42
Male sex (% ) 100 100 100 100
Median peak ALT ( IU /m l) 285 (22-5104) 394.5 256.5 310
HCV genotype 1 (% ) 83% 84% 84% 73%
Median HCV viral load (log 6.1 (3.0-7.6) 6.0 6.4 6.1
IU /m l)
Median H IV  length of infection 4.1 (0-19.1) 4.0 4.2 1.9
(years)
Median CD4 (c e lls /p l) 498.5 (33-2715) 549 433.5 496
HA AR T(% ) 57 61 54 53
2 .4 .2  Sequences:
Of the 111 patients' sera, complete E1/E2 sequences were obtained from 
93 patients. The sequences analysed were 495 base-pairs long, spanning 
the E1/E2 region, including the HVR1, of the HCV genome. There were a 
total of 87 genotype 1 sequences (genotype la  n=80; genotype lb  
n=7); and 6 genotype 3a sequences. Of the 18 samples that could not be 
sequenced 6 were genotype 1, 6 non-genotype 1, and 6 could not be 
genotyped.
66
Figure 2.1: Gel of E1/E2 product following nested PCR.
Figure represents an example of a gel with the E1/E2 product (575bp 
length) situated near 600 molecular weight band.
Comparison of the divergence between the direct sequences and the 
cloned sequences was made. Between 6-12 cloned sequences were 
compared to the direct sequence from the same time-point from 7 
random patients from RFH. All were genotype 1 HCV (six la  and one lb ). 
The data are presented as a phylogenetic tree with the direct and clonal 
consensus sequences analysed by the Clustal method (Figure 2.2). When 
the median percentage divergence of the clones was compared with the 
direct consensus sequence for 7 patients there was no significant 
difference (p=0.25) (Table 2.2). Therefore, given that there was no 
significant difference between the two methods, the use of direct 
sequencing was validated in this study.
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F ig u re  2 .2 : P h y lo g en etic  t re e  o f d ire c t and  consensus o f clones  
fro m  7 p a tie n ts .
Figure represents the phylogenetic tree using the Clustal method of the 
direct sequences and consensus of the clones from the same time point 
in 7 patients. The percentage (% ) nucleotide difference is the horizontal 
branch length.
T a b le  2 .2 : P e rc en tag e  d iv e rg e n c e  b e tw e e n  d ire c t seq uences and  
in d iv id u a l c lone seq uences.
Table outlines the percentage divergence between the direct and 
consensus of clones from the same time point using the Clustal method 
with weighted residues. Comparison of the median divergence was made 
by Mann-Whitney U test.
Divergence between direct and individual cloned sequences (range) (% )
Patient 1 0.0 (0-0.6)
Patient 2 0.0 (0-0.6)
Patient 3 0.4 (0.2-0.8)
Patient 4 0.0 (0)
Patient 5 0.0 (0-0.8)
Patient 6 0.4 (0.2-0.4)
Patient 7 0.0 (0-0.6)
P = 0 .2 5 *
^comparison of median divergence using Mann-Whitney U test.
19 4 % divergence
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2 .4 .3  Phylogenetic analysis:
A total of 93 sequences were aligned and analysed as the 'ingroup'. The 
sequences were analysed in the ir relevant subtypes and compared to 
unrelated sequences downloaded from GenBank and the Los Alamos HCV 
Sequence Database. A total of 330 E1/E2 unrelated sequences were 
downloaded and used for the 'outgroup'; 96 genotype la , 183 genotype 
lb , and 51 genotype 3a sequences.
The genotype la  maximum likelihood phylogenic tree, using an HKY and 
gamma model with NJ bootstrap values (1000 replicates) included 80 
patient sequences and 96 unrelated sequences downloaded (Figure 2.3). 
Within the tree there were 5 monophyletic clusters, which included 73 of 
the sequences. The largest cluster is composed of 43 patient sequences 
(46% of all the amplified study cohort sequences). The bootstrap value of 
the root branch was 83%, strongly supporting the relationship of these 
sequences in the cluster. The second cluster had 7 cohort sequences with 
a 100% bootstrap value at its root. The third cluster had 9 cohort 
sequences and a bootstrap value of 99%. The fourth cluster had 3 cohort 
sequences with a bootstrap value of 100%. The fifth cluster contained 11 
cohort sequences and a bootstrap value of 76%. The bootstrap values of 
between 76-100% support the robustness of the relationships of these 
monophyletic groups. There were 7 sequences that did not form part of a 
cluster with any of the other cases, suggesting that they are unrelated.
The genotype lb  maximum likelihood phylogenic tree, using an HKY and 
gamma model with NJ bootstrap values (1000 replicates) included 7 
cohort sequences and 183 unrelated sequences (Figure 2.4). All the 
cohort sequences formed a monophyletic clade. This had a bootstrap 
value of 100%, which strongly suggests that this is a true relationship.
The genotype 3a maximum likelihood phylogenic tree, using HKY and 
gamma model with NJ bootstrap values (1000 replicates) included 6 
cohort sequences and 51 unrelated sequences (Figure 2.5). The 3a 
phylogenetic tree revealed one monophyletic clade consisting of four 
sequences. The bootstrap value was 74% suggesting this is a
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monophyletic clade. There were two sequences lying separately, although 
one was situated close to the one patient cluster.
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Figure 2.3: Genotype la  maximum likelihood phylogenetic tree.
Maximum likelihood phylogeny of the subtype la  sequences. Case 
sequences are in red and unrelated reference sequences in black. Each 
HCV cluster among HIV positive MSM is identified and a bootstrap value 
is given at the root of each cluster. Each sequence's centre of origin is 
given: # = RFH , « = CWH, *  = BSGH.
Cluster 1 (n=7)
100
;e rr
Cluster 2 (n=43)
Cluster 3 (n=9)
100. Cluster 4 (n=3)
Cluster 5 (n=11)
H
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Figure 2.4: Genotype lb  maximum likelihood phylogenetic tree.
Maximum likelihood phylogeny of the subtype lb  sequences. Case 
sequences are in red and unrelated reference sequences in black. The 
HCV cluster among HIV-positive MSM is identified and a bootstrap value 
is given at it's root. Each sequence's centre of origin is given: « = RFH , 
■ = CWH, *  =BSGH.
Figure 2.5: Genotype 3a maximum likelihood phylogenetic tree.
Maximum likelihood phylogeny of the subtype 3a sequences. Case 
sequences are in red and unrelated reference sequences in black. The 
HCV cluster among HIV-positive MSM is identified and a bootstrap value 
is given at the root of the cluster. Each sequence's centre of origin is 
given: •  = RFH , ■ = CWH/ *  = BSGH.
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  14 Jan02 •
-  3 Nov03 •
13 Apr03 •
55 JunOQ ■
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The origin of all the sequences are indicated in the phylogenetic trees and 
outlined in Table 2.3. Only the genotype 3a cluster is composed of 
sequences from a single geographic unit (RFH). All the other clusters 
contain sequences from at least two of the HIV units that participated in 
the study. This would suggest tha t there was significant mixing of 
patients transm itting HCV between these units.
T a b le  2 .3 : O rig in  o f seq u en ces  in eac h  m o n o p h y le tic  c lu s te r.
Table outlines the origin of the sequences for each clade and each HIV 
unit participating in the study.
Cluster RFH CWH BSGH
la  n = 43 21 18 4
la  n = 7 5 2 0
la  n = 9 2 5 2
la  n = 3 1 2 0
la  n= 11 2 6 3
lb  n = 7 4 2 1
3a n = 4 4 0 0
Ungrouped* n = 9 4 5 0
Total n = 93 43 40 10
*sequences not forming part of any cluster.
The multiple monophyletic clusters in the phylogenetic analysis provides 
strong evidence of common source transmission of related viruses in 
these groups.
2 .4 .4  Population dynamics:
To understand the dynamics of the HCV transmission, a molecular clock 
was applied to all the clusters (Figures 2.6-2.8). The median date of 
origin for each cluster was estimated based upon the E1/E2 nucleotide 
evolution rates calculated by Tanaka and colleagues (Tanaka et at., 
2002). The median estimated date of origin for each cluster is given in
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Table 2.4 Four of the seven clusters have origins in the mid-1990s, 
implying the onset of transmission of these lineages around this time. 
The m ajority (64% ) of all lineage divergences have occurred since 1995, 
indicating increased transmission from this time. HCV entered cluster 2, 
the largest cluster, in the early 1960s and since this time there has been 
a constant rise in the number of new lineages with an increased 
frequency of nodes (divergence events) at more recent time-points. A 
large subclade has its ancestoral node approximately 20 years ago, 
suggesting a change in the transmission. A log scale of the number of 
lineages over time suggests tha t the rate of new lineages is increasing, 
consistent with an increase in the transmission rate (Figure 2.9). There 
has been an approximately 1 logio increase in lineages over the last 30 
years.
Attempts were made to model the dynamics of the infection in the largest 
cluster using both coalescent theory and a life-death plot. Unfortunately, 
problems related to the proportion of the HIV-population with acute HCV 
that had been sampled led to im plicit assumptions in both models not 
being met. As a result neither model generated interpretable results. 
These issues will be explored in detail in the discussion.
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Figure 2.6: Genotype la  clusters w ith molecular clock applied.
A molecular clock using nucleotide substitution rates based on the E1/E2 
region of the HCV genome has been applied to all the genotype la  
clusters to examine the evolution through time of these sequences. 
Shaded area represents last 10 years with horizontal scale (blue) in 
years.
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Figure 2.7: Genotype lb  cluster w ith  molecular clock applied.
A molecular clock using nucleotide substitution rates based on the E1/E2 
region of the HCV genome has been applied to the genotype lb  cluster to 
examine the evolution through time of these sequences. Horizontal scale 
(blue) in years.
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Figure 2.8: Genotype 3a cluster w ith  molecular clock applied.
A molecular clock using nucleotide substitution rates based on the E1/E2 
region of the HCV genome has been applied to the genotype 3a cluster to 
examine the evolution through time of these sequences. Shaded area 
represents last 10 years with horizontal scale (blue) in years.
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T a b le  2 .4 :  D a te  o f o rig in  fo r  each  id e n tif ie d  HCV c lu s te r.
Cluster HCV
subtype
Num ber of 
sequences
Year of origin 
(C l) *
Number (% )  
of divergence  
events since 
1995
1 la 7 1994
(1988-1998)
5 (83)
2 la 43 1962
(1946-1972)
21(50)
3 la 9 1995
(1991-1998)
6(75)
4 la 3 1995
(1990-1998)
1 (50)
5 la 11 1983
(1974-1989)
8 (80)
6 lb 7 1999
(1996-2001)
6(100)
7 3a 4 1982
(1971-1989)
2 (66)
^Estimated using a Bayesian MCMC approach in BEAST vl.3.
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F ig u re  2 .9 : P lo t o f log n u m b e r o f lin e a g e s  o v e r t im e  in c lu s te r 2.
The number of lineages at 10 yearly intervals has been plotted on a log 
scale from the estimated entry of the virus into this population in 1962.
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2.5 Discussion
Phylogenetic analysis is a powerful tool for the study of viral transmission 
and HCV is ideally suited to this type of analysis. The recent epidemic of 
acute HCV in HIV-positive men presented a unique opportunity to explore 
the molecular epidemiology of HCV infection in this HIV population. The 
reconstructed phylogenetic trees reveal multiple monophyletic clades, 
which strongly suggests common source transmission within these 
clusters. However, before discussing these results in detail, a number of 
lim itations need to be explored.
2 .5 .1  Lim itations:
Sequences were not obtained from all the serum samples derived from 
cases enrolled into the study. Of the 111 serum samples, 93 (84%) 
sequences were obtained. All the serum samples (collected between 
1999-2005) had been reported to be HCV RNA positive by the respective 
virology laboratories. Failure to amplify E1/E2 sequences from these 
samples could relate to problems with either the stability of nucleic acid 
in the sample and/or the amplification reaction. I t  should be stated that 
the missing sequences were of various genotypes and from different HIV 
units. While strengthening some of the clusters, these sequences would 
not have strongly influenced the final epidemiological conclusions.
HCV may not have been isolated from the serum as a result of the 
collection and storage method of the blood from the patients. Storage of 
whole blood or serum at room temperature has been shown to reduce 
the yield of cDNA over tim e (Cuypers et al., 1992). Within two weeks of 
whole blood stored at room temperature there was a 3-4 log decrease in 
the yield of HCV cDNA. There was also a small drop in blood refrigerated 
at 4°C. The samples used in this study were clinical samples and the 
collection/storage history was not known. Some samples may have been 
left at room tem perature for significant periods. There are two 
hypothetical reasons this may have reduced the yield of HCV. I t  is 
recognised tha t haem molecules, released following haemolysis, can 
inhibit the activ ity of Taq polymerase, which was used in all our PCR
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reactions (Cuypers et al., 1992). Second, activation and lysis of 
granulocytes liberates proteases and nucleases, which digest viral 
particles, thereby potentially reducing the RNA within the sample. 
Interestingly, this effect is more pronounced at 4°C than at room 
temperature. To optimise yield, the recommendation is immediate 
separation of serum and freezing of the sample.
Problems related to the amplification reaction may have contributed to 
some of the samples not yielding E1/E2 sequence. The nested E1/E2 
primers used were derived from genotype 1 HCV (Farci et at., 2000). 
Theoretically, this could have impacted the yield of other HCV genotypes. 
However, a number of genotype 3 sequences were amplified and 
conversely, a number of genotype 1 samples were not amplified. To 
avoid false negative amplification, a number of different primers designed 
specifically for genotype 3 HCV were used with no improvement in the 
amplification of these samples. In addition, the reaction was manipulated 
by changing the annealing temperatures and magnesium ion 
concentrations, again with no improvement in the yield of E1/E2 
sequence.
Phylogenetic analysis is based on the genetic differences between DNA 
sequences. However, nucleotide substitution errors can occur as a result 
of errors introduced during the amplification reaction when using reverse 
transcriptase (RT) or Taq polymerase. High error rates have been 
reported and so these need to be considered. The resulting nucleotide 
substitutions may be misinterpreted as viral heterogeneity, particularly 
with cloned sequences. I t  has been estimated that the error rate is 
between 0.5-1%  of the sequence (Koop e t al., 1993). Specifically, the 
estimated error rate fo r RT is 10'4 and for Taq is 0.2-2 x 10'4 errors/base 
pair (Lundberg et al., 1991; Barnes, 1992). These reaction-related error 
rates are compounded by repeated cycles of PCR; 35 cycles were used in 
each PCR step in this study. The reported variation between studies may 
also relate to the amount of template used in the RT or PCR reaction. A 
large amount of template would lead to saturation after only a few 
cycles. This reduces the effective number of cycles and the number of
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errors would be less. Using consensus sequences analysis in part corrects 
for this, however, in this study it was not possible to differentiate 
spontaneous from experimental nucleotide substitutions, although the 
patterns of phylogeny argue against undue amplification errors.
Contamination is always a consideration when analysing PCR-based 
sequence data. As a measure of internal consistency, the sequence data 
was compared to the reported genotype fo r that clinical sample. Overall, 
the sequences were consistent w ith the genotyping. However, there were 
two samples which had been classified as a genotype 4, using Bayer 
autoLiPA, that were situated in the genotype la  tree. Unfortunately, the 
result of the original genotyping could not be checked, but presumably 
the sequencing was the more accurate result. The NS5B region could 
have been used as a control fo r contamination by comparing the NS5B 
tree topology with the reconstructed E1/E2 trees. However, there was 
consistency between the direct and cloned sequences obtained through 
different PCR reactions performed at different times. This comparative 
data, showing no significant difference between the direct and clonal 
sequences, also validated the use of direct sequencing fo r this 
phylogenetic study.
2 .5 .2  D etailed  Discussion:
Phylogenetic studies can provide powerful and unique evidence for a 
defined route o f transmission through the analysis of viral homology. 
Monophyletic clades or clusters are sequences that share a common 
ancestoral root, implying tha t they are more closely related to one 
another than sequences situated outside of this group. The likely 
explanation for sequence homology of a cluster is common source 
transmission of HCV. In this analysis, the three reconstructed 
phylogenetic trees revealed seven monophyletic clusters, which included 
84 patient sequences. The largest cluster, cluster 2 (n=43), was 
composed of ju s t under half the total number of amplified patient 
sequences. The robustness of the sequence relationships in these clusters 
is supported by high bootstrap values of the ancestoral branch. These 
tree topologies suggest tha t there are a number of different HCV variants
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co-circulating in the HIV-positive population of London and Brighton. 
Significantly, the clusters cross both genotype and subtype of HCV. This 
is strong molecular evidence for transmission within these groups.
Interestingly, every cluster except the genotype 3a clade contained 
sequences from at least two of the three participating HIV units, with no 
specific geographic clustering. This reveals sim ilar lineages of HCV are 
co-circulating between patients seen in the different HIV units. This is 
evidence tha t transmission is occurring between individuals from these 
different units or from a source common to the three units. Brighton and 
London are geographically close cities, and there is significant movement 
between these urban centres tha t would contribute to the transmission of 
HCV. To explore the specific interactions, performing contact tracing and 
sexual networks studies would have provided a significantly more 
detailed insight into these interactions between the individuals from the 
different units, particularly those contributing to the transmission 
clusters. Unfortunately, this was beyond the scope of this study. A way of 
expanding the study would be to enrol HIV-positive individuals diagnosed 
with acute HCV from other centres, as cases have also been reported 
from other centres in London and Manchester. Similar cohorts have also 
been described in urban centres in Europe. Given the increased 
movement between the UK and Europe this could be an important 
opportunity fo r understanding the flux of HCV transmission. The evidence 
that there is transmission occurring between patients at geographically 
separate units has im portant implications fo r the development of any 
public health intervention, which would need to have a broad geographic 
focus encompassing related urban centres.
The dates of origin and proportion of sequence divergence of the 
transmission clusters provides strong evidence of increased HCV 
transmission since the mid to late 1990s. Four of the seven clusters have 
their date of origin in the mid-1990s. The m ajority (64%) of the 
sequence divergence occurred since 1995. Interestingly this coincides 
with the introduction of effective treatm ent for HIV (HAART), which was 
associated with significant behavioural changes in homosexual men. The
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largest cluster, cluster 2, had the earliest entry of HCV in the early 
1960s. Examining the number of divergent events over time in this 
cluster suggests tha t there has been a constant increase in transmission 
events over tim e, particularly since the 1970s. Since that time it appears 
the infection rate has increased by approximately 1 log over the last 30 
years (log number of new lineages over tim e). Within this clade, a large 
subclade diverged approximately 30 years ago involving 37 of the 43 
sequences. I t  could be hypothesised tha t this represents a change in 
transmission pattern, related to a patient and/or environmental factor. 
Interestingly, the 1970s was a period where many social changes 
afforded both HIV and HCV a number o f amplification opportunities: 
multiple sexual partnering in gay men of North American and Europe 
increased dramatically; concomitantly STIs increased; numbers using 
illicit drugs soared in the industrialised world; and the global blood 
product industry expanded dramatically (Garrett, 1995). Unfortunately, 
the modelling of the population dynamics could not provide further 
insights
The population dynamic studies were problematic and complex and 
required some intrinsic assumptions w ithin the models. The fundamental 
problem was one of sampling. Both coalescent theory and birth-death 
plots make assumptions about the proportion of the study population tha t 
has been sampled fo r analysis. Coalescent theory assumes that the 
sample is a fraction of a percentage of the whole population. In contrast, 
birth-death modelling assumes a high proportion (100%) sampling. Birth 
(speciation) and death (extinction) rate of lineages are estimated from 
node height or frequency. As the death rate increases the nodes move 
distally to the tips, as the earlier sampled lineages are more likely to 
become extinct. However, as the birth rate increases the nodes also 
move closer to the tips, w ith the emergence of new lineages. 
Unfortunately, birth-death analysis could not mathematically differentiate 
between the two. However, clinical data would strongly suggest that 
there has been increased incidence of acute HCV, which equates to an 
increase in the birth rate as the reason for the increased frequency of 
distal nodes. The birth-death plots assume that the majority of
84
sequences have been sampled and modelling fails when only a proportion 
is sampled. In contrast to this, the coalescent model implicitly assumes 
that the genealogy represents a small random sample from a large 
population. The nodal frequencies of such phylogenies depend on the 
dynamics of population size through time. Our cohort probably had a 
significantly higher proportion of sampling than is assumed by coalescent 
theory. Consequently, provisional modeling suggested a recent downturn 
in rate of infection which is not consistent with the clinical epidemiology. 
I t  is not yet clear what the denom inator is for the study population (what 
proportion of the cohort has been diagnosed), but given that HIV-positive 
individuals are regularly screened in the clinics it is likely that a 
significant proportion (>5%  and <100% ) has been diagnosed.
When exploring the reasons fo r an epidemic, three areas need to be 
considered which could contribute to the increased spread of an infection. 
These include the infectious agent, the patient population and the 
environment; any or all of these factors could be contributory. The HCV 
clusters identified cross both genotypes and subtypes of HCV, which 
suggests that the recent epidemic is not due to a specific viral change. 
This implies tha t the recent transmission of HCV is more likely associated 
with patient and/or environmental factors. While this phylogenetic 
analysis provides strong evidence fo r HCV transmission in the study 
population, it does not provide insight into the specific transmission 
mechanisms. These factors were explored in a questionnaire based case- 
control study, detailed in the next chapter (Chapter 3).
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Chapter 3: Case-control Study
3.1 Introduction
There is strong evidence from the molecular epidemiological analysis that 
transmission of HCV is occurring in the HIV-positive population of South- 
East England. Common source transmission has been demonstrated 
through the phylogenetic analysis of the E1/E2 region of the HCV 
genome. Modelling of the dynamics o f this transmission suggest that the 
rate of transmission is increasing, particularly since the mid-1990s. 
Furthermore, the molecular HCV clusters, which cross subtype and 
genotype, suggest this epidemic is not due to a hepatitis C viral change, 
but rather to patient and/or environmental factors. Given the clinical 
impact of HCV/HIV co-infection, it is im portant that the reasons for this 
increase in transmission are identified. While HCV transmission is usually 
parenteral, prelim inary data have suggested that the recent increase in 
HCV transmission in the HIV population is not due to IVDU (Browne et 
al., 2004).
As discussed in the introduction (Chapter 1), permucosal transmission of 
HCV remains controversial. Sexual transmission accounts for a proportion 
of HCV transmission but it is unclear how large this proportion is in 
different populations. Some have suggested that the higher prevalence of 
anti-HCV in the HIV population reveals increased sexual transmission. 
However, both HIV and HCV share common transmission routes. A recent 
study from the Swiss cohort of HIV-positive men found increased anti- 
HCV rates in those with high-risk sexual exposure when IVDU was 
excluded as a risk factor (Rauch et al., 2005). In the UK general 
population there has been an increase in high-risk sexual behaviour 
demonstrated by the National Survey of Sexual and Lifestyles (Natsal) 
2000 study which reported an increased prevalence of high-risk 
behaviour compared with data collected in 1990 (Johnson et al., 2001). 
This may explain the observed increase in acute sexually transmitted 
infections (STIs) over the same period reported in UK genitourinary 
medicine (GUM) clinics between 1990 and 1999; an overall rise of 20% in 
men and 56% in women (PHLS (England, 2000). High-risk sexual
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behaviours have also increased in men who have sex with men (MSM). 
High-risk practices in MSM include unprotected anal intercourse (UAI), 
rimming (anal/oral sex play), fisting (insertion of the hand into the anus), 
use of sex toys and sadomasochistic practices. Contributing to high-risk 
sexual activities is 'sero-sorting,/ a form of 'negotiated safety', as a 
means of risk reduction, where MSM have sex with men of same HIV 
status. High-risk sexual behaviours also frequently co-exist with 
recreational drug use. However, the interaction between sexual 
behaviour and drug use is controversial and complex. This chapter will 
describe the clinical epidemiological analysis tha t was performed to 
elucidate the putative transmission factors in this cohort. Key to this is an 
assessment of sexual and drug behaviour.
Epidemiological studies aim to  achieve precision in estimating sources of 
infection and modes of spread. A key challenge in identifying putative 
transmission factors, particularly related to sexual and drug behaviour, is 
in generating unbiased and precise measures. A questionnaire based 
case-control study is an effective method of delineating transmission 
factors, particularly in the setting of rare acute diseases such as HCV. 
Early case-control data suggested a link between high-risk sexual 
practices and HCV transmission (A lter e ta /.,  1989b). Case-control studies 
compare the difference in previous exposure to factors in a group with a 
condition to a group w ithout the condition; in this study HIV-positive 
individuals with acute HCV were compared to HIV-positive individuals 
w ithout HCV. The difference between the proportions in each group 
exposed to a particular risk factor can then be calculated. Controls should 
have the same probability of exposure to the factor of interest, if there is 
no relationship between the factor of interest and outcome, and should 
therefore come from the same risk population. The most efficient case- 
control study has equal numbers of cases and controls. However, when 
the number of cases is small, statistical power can be gained by 
increasing the number of controls. The largest gain in power is obtained 
by adding an extra control per case (2:1 ratio). Matching is a method 
whereby the cases are individually matched by a confounding variable 
(for example; age or sex) to each control. By forcing the cases and
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controls to become more homogenous for confounding factors, matching 
increases the power of the study to find a true relationship with other 
transmission factors. These are retrospective studies because the 
information about risk factor exposure is obtained from the past history 
of the patient. As with all studies there are inherent measurement biases 
that need to be understood.
There are a number of reasons why case-control studies of sexual and 
drug behaviour may be biased. Measurement error can occur as a result 
of: sampling procedures or respondent variables such as survey 
response, participation, reporting and recall bias, and questionnaire 
design. Sampling procedures can produce bias because the sampled 
population is not representative o f the true population. For example, 
there is evidence that volunteers in studies have a different experience 
and attitude to sex than the general population (Strassberg & Lowe, 
1995; Dunne et at., 1997). Whilst random sampling is the best method, 
this is not appropriate fo r all studies, particularly when studying specific 
questions in a high-risk group. By definition, case-control studies are not 
random.
A high response rate improves the representativeness of the study and 
reduces participation bias. As a result, the generalisability of the results 
improves. A significant proportion of people refuse to participate in 
studies of sensitive topics such as sexual and drug behaviours (Dunne et 
al., 1997). Reasons fo r non-participation vary but may include difficulties 
with contacting participants, refusal to take part, or refusal by 'proxy' if 
the participant is ill, or has literacy/language barriers. Many individuals 
refuse to participate before they are aware of the topic of the survey 
(Catania et a!., 1992). Participation bias occurs when there are 
systematic differences between those who respond to the questionnaire 
and those who do not. Factors that have been associated with this bias 
include sex, age, social class, beliefs and behaviour. With respect to 
surveys of intimate information such as sexual or drug behaviour, some 
have suggested participation bias increases while others have not 
reported this (Biggar & Melbye, 1992). In addition, there maybe certain
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questions which individuals systemically are more or less likely to 
respond to. Copas and colleagues found that older age, ethnicity and 
comprehension were associated with not answering more detailed 
questions in the British Natsal survey (Copas et al., 1997).
Recall bias is the result of systemic differences between the cases and 
controls response to particular questions. The reporting of sexual 
behaviour has been shown to vary w ith a number of factors including 
age, ethnicity, number of partners and the time frame of reporting 
(McFarlane & St Lawrence, 1999). Reporting frequency (e.g. number or 
frequency of events) may be less reliable than incidence (e.g. firs t time 
of event). There is more consistency reporting number of partners than 
number of acts (Jeannin et al., 1998). Furthermore, the length of time 
elapsed and whether the behaviour is common also affects the accuracy 
of reporting (Saltzman et al., 1987). Inaccuracy and underreporting 
increases when attempting to recall events further back in time (Kauth et 
al., 1991). Differences also exist in reporting between the sexes, as men 
tend to report a higher number of partners in surveys compared to 
women. This probably represents a social desirability bias. However, in 
case-control studies many of these factors are controlled and are not an 
issue with this study.
Obviously, the design, content and method of administration of the 
questionnaire instrum ent may contribute to measurement bias. These 
factors are affected by the literacy of the respondent, the complexity of 
the questions, and the definition of terms. The method of administration 
is important, and can either be self- or interviewer-administered. Overall 
response rates tend to be lower w ith self-administered questionnaires 
(Catania e ta /., 1990). This may relate to the motivation to complete the 
questionnaire. In contrast, interviewer based surveys generally have 
higher response rates and more flexib ility  in the interpretation of the 
questions. However, when dealing with sensitive behaviours, self­
completion questionnaires may result in more valid reports than with 
interviewers (Catania et al., 1995). Computer assisted interviews have 
been used to improve responses. Comparative studies of computer
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assisted versus self-completion surveys have demonstrated that 
computer-assisted interviews have the potential to improve the quality of 
the data and increase the respondents willingness to report sensitive 
behaviours (Turner e t al., 1998).
Methods have been suggested to identify and reduce some of these 
biases. To determine representativeness the study cohort can be 
compared with the population from which it is derived. The overall 
response rate provides evidence of the likely size of the participation 
bias. Improving response rates will reduce participation bias; incentives 
have been used such as payment. Better interviewing techniques and the 
use of computer assistance have improved results. Validity describes the 
extent to which an instrum ent measures what it purports to measure. 
The external valid ity of a questionnaire can be assessed by comparison to 
existing data. For example, the rate of STIs reported by respondents in a 
study can be compared to rates in the UK HIV-population. Objective 
measures such as rates of STIs from the laboratory or drugs screened 
from urine can also be used. Internal consistency of the instrument can 
be assessed by crosschecking questions within the questionnaire, looking 
for logical agreement. Re-administration of the questionnaire has been 
used to assess the stability of responses. However, this is both time and 
resource intensive.
This chapter describes the case-control study that was designed to 
explore the transmission factors fo r HCV in this cohort. While assessing 
the standard risk factors for HCV, the study also focused on potential 
permucosal factors as transmission routes for HCV.
3.2 Aims
Using a case-control study with a specifically designed questionnaire 
instrument, the putative factors will be identified for the recent 
transmission of HCV in the HIV-positive individuals.
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3.3 Methods
3 .3 .1  Study cohort:
There was a clear methodological process for performing the 
questionnaire-based case-control study. This involved identifying the 
study population and sample, determ ining the method of data collection, 
designing the questionnaire instrum ent, running a pilot study, performing 
the actual case-control study, and the statistical analysis.
All the identified cases were homosexual HIV-positive MSM, so the study 
population was defined as all HIV-positive MSM in South-East UK. The 
cases were derived from the cases identified in the phylogenetic study 
( n = l l l ) ,  outlined in section 2.4.1. The case definition was defined in 
section 2.3.1. HIV-positive controls were identified from each of the HIV 
clinic's databases. Due to the small num ber of cases, two controls were 
matched to each case to increase the power of the study. Controls were 
matched for: age ± 5 years, length of HIV infection ± 1 year, 
homosexuality, race, and HAART status (ever/never exposed). HCV 
negativity was based on previous testing; a specific test was not carried 
out as part of this study. Individuals matched on all these criteria from 
the HIV clinic database were recruited. I f  they refused to participate in 
the study then the next matched control was approached and so forth.
Demographic parameters of the study cohort were compared with the UK 
Collaborative HIV Cohort (CHIC) database. The CHIC study is a 
collaboration of six of the largest HIV clinics in the UK including the RFH, 
CWH and BSGH. This study was initiated in 2001 with the aim of 
establishing a large database of HIV infected individuals in order to 
provide detailed clinical data on large numbers of patients in the UK. The 
HCV study cohort was compared with the RFH, CWH and BSGH patients 
in the CHIC database. Permission was obtained from CHIC investigators 
at these clinics.
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3 .3 .2  Q uestionnaire instrum ent:
Based on data suggesting tha t self-administered questionnaires improve 
responses when evaluating sensitive behaviours, this method was used 
for the data collection. A questionnaire was specifically developed using 
two validated questionnaires to inform its design. First, the National 
Survey of Sexual and Lifestyles (Natsal) instrum ent was used (Johnson et 
al., 1994). This study was a UK-wide self-administered questionnaire 
study of the sexual behaviours and attitudes of the general population. I t  
was initially performed in 1990 and re-done in 1999/2000. The 
questionnaire was obtained from the lead investigator, Professor Anne 
Johnson, Head of the Department of Primary Care and Population 
Sciences, Royal Free and University College Medical School, London. The 
Urban Men's Health survey (UMHS), an American instrument from San 
Francisco, was a telephone-adm inistered questionnaire examining the 
lifestyles of urban gay men. I t  was obtained from one of the lead 
investigators, Dr Diane Binson, Assistant Adjunct Professor, Center for 
AIDS Prevention Studies, University of California, San Francisco.
The questionnaire designed fo r this study assessed six areas of over the 
12 months preceding the diagnosis of HCV: place of meeting, sexual 
practices, drug practices, alcohol use, STIs and attitudes/understanding 
of HCV (Appendix A). A 'date of interest' was specified on the front of the 
questionnaire, which referred to the date when the case was diagnosed 
with HCV. Cases were specifically instructed to answer the questions 
referring to this date throughout the questionnaire. The matched control 
was given the same 'date of in terest' as their case. This attempted to 
control for any temporal changes in behaviour as a confounding factor 
and also to reduce the possible impact of recall bias that may have arisen 
if controls were systematically describing their behaviour over a more 
recent time period than cases. A 12-month period of time from the 'date 
of interest' was chosen because the exact date of transmission was often 
unclear. I t  was also im portant to understand risk behaviour over a 
significant period before the diagnosis was made.
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Participants were asked about the ir sexual behaviour and practices, 
including high-risk mucosally traum atic practices. This section included 
questions about where MSM met other men and the number of partners 
that they had sex with. Participants were then asked about the number of 
partners with whom they had participated in each particular practice. 
There is evidence that this is more accurately recorded than frequency of 
acts in questionnaires (Jeannin e t al., 1998). Each of the practices was 
defined in the questionnaire using simple term inology. Participants were 
also asked about public and group sex practices, as these practices are 
common among the MSM com m unity and are potential sources of high- 
risk behaviour. Finally, given the relationship between sexual practices 
and drug use, data was collected on participation in sexual activity under 
the influence of alcohol and drugs.
Alcohol use was explored using the Alcohol Use Disorders Identification 
Test (AUDIT) (Saunders e t al., 1993). This was developed initially by the 
World Health Organisation (WHO) fo r use in primary care. The AUDIT 
instrument consists of 10 questions with scaled responses to specific 
questions regarding alcohol consumption. A score of >.8 is highly 
sensitive fo r hazardous drinking. I t  was designed to provide information 
on drinking behaviour over the preceding 12 months. I t  has previously 
been incorporated into validated questionnaires and is sensitive for the 
detection of hazardous drinking. Recreational drug use was explored by 
collecting data on individual drugs and the ir frequency of use. Data on 
the route, method of adm inistration and shared routes of administration 
was also collected.
Standard HCV transmission risk factors were evaluated, including IVDU, 
blood product transfusions, tattoos and body piercings. Given the 
relationship between sexual risk behaviour and STIs, a lifetime history of 
STIs was obtained, including herpes, syphilis, gonorrhoea, non-specific 
urethritis (NSU), genital warts, hepatitis B (HBV) and hepatitis A (HAV) 
infection. Finally, general questions were asked about participants 
attitudes and understanding of HCV using a scaled response to specific 
statements about HCV.
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Before the questionnaire was finalised it was reviewed by a number of 
colleagues, including clinicians, epidemiologists, psychologists, and 
nurses. A small pilot study was performed on six randomly selected 
subjects in the Ian Charleston Day Centre (RFH). The questionnaire took 
between 20-30 minutes to complete. The questionnaire was successfully 
completed and was not modified after the pilot analyses.
The questionnaire was administered in the participating HIV clinics. 
Identified cases and controls were approached at clinic visits where they 
were introduced to the questionnaire e ither by myself or a clinic nurse 
who had been instructed on how to introduce the study. Each case was 
given a packet containing the questionnaire, an introductory letter and 
information sheet. There was also a self-addressed envelope for returning 
the questionnaire. Each questionnaire was coded with a unique identifier 
for the participant's anonym ity. Following the introduction and the 
participant reading the patient information sheet, the patient was 
consented as per protocol. In addition, the 'date of interest' was 
explained to the patients in the information letter, in the instructions on 
the questionnaire and by the person introducing the study. The same 
process was used at each of the clinics. I f  a patient had consented to 
take part in the study but the ir questionnaire was not returned the case 
or control was approached again at the ir next clinic appointment. The 
questionnaire study packets from those individuals who refused were 
discarded. The study was run between August 2004 and August 2005. 
The entire study was approved by each of the local ethics committees 
and was overseen by Central Office fo r Research Ethics Committees 
(COREC).
3 .3 .3  S tatis tical analysis:
Comparison of variables was related to case/control status. Initia lly, 
univariable analysis was performed to compare proportions using Chi- 
squared or Fisher's exact test as appropriate. Numerical values were 
compared using Mann-Whitney U test. Factors found to be associated 
with the case/control status in univariable analyses (p<0.05) were then
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entered into a multivariable logistic regression model to examine 
independent associations, w ith adjusted odds ratios generated as the 
measure of association. However, before variables tha t were significant in 
the univariable analysis were entered into the multivariable analysis, they 
were assessed for correlation with other variables. This was an attempt 
to simplify the number of variables tha t were entered into the final 
model. Because of the high correlation of many of the factors considered, 
for example individual sexual practices or illic it drugs used, these were 
categorised by number of d ifferent sexual practices participated in and 
number of d ifferent drugs used in the preceding 12 months rather than 
specific practice. Factors were included in a forwards fashion based on 
the overall p-value for all categories of a factor. A Pearson chi squared 
goodness-of-fit test was used to  assess the final model. Missing data was 
accounted fo r by including an unknown group for each category in the 
analysis. Values were considered statistically significant if the p<0.05 or 
if the 95% confidence intervals did not cross unity. Statistical analysis 
was performed using SAS (version 8).
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3.4 Results
3 .4 .1  Study cohort:
Overall, 190 individuals completed the questionnaire: 60 cases and 130 
controls. Of 111 patients enrolled into the phylogenetic study, 60 patients 
returned questionnaires; a participation rate of 54%. The participating 
cases came from : RFH n=45, CWH n = 10, and BSGH n = 5. Of 130 
controls entered into the study, these were recruited from : RFH 122 and 
CWH 8. No controls were recruited from BSGH. Attempts to match two 
controls to one case were made. At least one control per case was 
matched successfully for 52 (87% ) of the cases. At least two controls 
were matched per case successfully for 43 (72% ) cases. The
demographics of the cases and controls are outlined in Table 3.1. Table 
3.2 outlines the comparison between the case-control, phylogenetic and 
CHIC populations from the clinics. There were no significant differences 
between the cases and controls w ith respect to the median 'date of 
interest', median age, median duration of infection, percent ever exposed 
to HAART, median CD4 count (ce lls/p l), and percentage with HIV RNA 
<50 copies/ml. With respect to the standard HCV transmission risk 
factors (Table 3.3), there was a trend towards a higher proportion of 
IVDU in the preceding 12 months in the cases versus controls (17.2% 
versus 6.6%, p=0.08). However, the m ajority of cases (82.8% ) did not 
have this as a risk factor. A greater proportion of cases compared to 
controls had had a percutaneous piercing in the ir lifetime (70% versus 
52%, p=0.03).
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Table 3.1: Patient demographics of case-control study cohort.
All patients Controls Cases p-value*
Number of patients 190 (100.0) 130 (68.4) 60 (31.6)
(%  of total)
Median (range) date of 
interest
10/03
(01/01-08/05)
09/03
(10/01-8/05)
11/03
(01/01-8/05)
Median (range) age 
(years)
36 (22-58) 36 (22-58) 36 (24-58) 0.76
Median (range) time 
since first positive HIV 
test (years)
4.5 (0-18.7) 4.5 (0-18.2) 3.7 (0-18.7) 0.44
Median (range) time 
since first visit (years)
0.1 (0-18.9) 0.1 (0-16.1) 0.0 (0-18.9) 0.24
Number (% ) ever 
exposed to HAART
131 (68.9) 91 (70) 40 (66.7) 0.77
Median (range) CD4 
count at time of interest 
(cells/mm3)
517
(27-1854)
521
(27-1854)
514
(61-1382)
0.76
Number (% ) with HIV 
RNA < 50 copies/ml at 
'date of interest'
88 (54) 59 (51.8) 29 (59.2) 0.38
* P-values calculated using Chi-squared test or Mann-Whitney U test as 
appropriate.
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T a b le  3 .2 :  C o m p a ris o n  o f c a s e -c o n tro l, p h y lo g e n e tic  and  C H IC  
p o p u la tio n s .
Case-control Non-participant CHIC cohort
cohort cases (MSM)
Number of patients 190 51 4479
Median age (years) 36 (22-52) 35 (24-55) 40 (18-77)
Median duration of HlV(years) 4.4 (0-18.7) 6.2 (0-19.2) 7.3 (0-22.0)
Number receiving HAART (% ) 116 (61) 27 (52.9) 3401 (75.9)
Median CD4 count (cells/pl) 517(27-1854) 462 (33-2715) 425 (0-2494)
Number HIV RNA <50 77 (52.7) 27 (52.9) 2627 (60.4)
copies/ml (% )
T a b le  3 .3 :  S ta n d a rd  HC V r is k  fa c to rs  o f  cases and  co n tro ls .
Cases
(n=60)
Controls
(n=130) P-value*
IDU in prior 12 months (% ) 10 (17.2) 6 (6.6) 0.08
Tattoo (% ) 36 (60) 57 (43.9) 0.06
Transfusion (% ) 10 (16.7) 10 (7.7) 0.11
Percutaneous piercing (% ) 42 (70) 68 (52.3) 0.03
* P-values calculated using Chi-squared test.
3 .4 .2  Univariable analysis o f questionnaire results:
Question 1 examined where cases and controls met other men. The 
univariable analysis revealed tha t cases met other men more frequently 
in three areas. The median number of times in the 12 months preceding 
the diagnosis of HCV where cases versus controls met other men more 
frequently were: private parties (4 versus 2.5 times, p=0.04), sex 
clubs/bathhouses/sauna (3.5 versus 1 times, p=0.01), and internet sites 
(50 versus 7 times, p=0.003) (Table 3.4).
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T ab le  3 .4 :  P lace w h e re  m en m e e t o th e r  m en .
Represents the median number of visits by cases and controls to meet men in specific locations over the preceding 12 
months for cases and controls.
All patients Controls Cases p-value p-value
Ever visited Median (range) 
no. times
Ever
visited
Median 
(range) no. 
times
Ever visited Median 
(range) no. 
times
(ever
visited)*
(no.
times)*
a) Bar, nightclub, 
danceclub
171 (90.5) 20 (0-250) 115 (88.5) 20 (0-250) 56 (94.9) 20 (0-200) 0.26 0.84
b) Private parties 132 (71.0) 3 (0-100) 82 (65.1) 2.5 (0-50) 50 (83.3) 4(0-100) 0.02 0.04
c) Sex club, 
bathhouse, sauna
114 (60.3) 2(0-150) 69 (53.5) 1 (0-52) 45 (75.0) 3.5 (0-150) 0.008 0.01
d) Public cruising area 79 (41.8) 0 (0-80) 49 (38.0) 0 (0-80) 30 (50.0) 0.5 (0-50) 0.16 0.37
e) Internet sites 125 (66.1) 12 (0-1000) 76 (58.9) 7 (0-400) 49 (81.7) 50 (0-1000) 0.004 0.003
* The proportions who have ever visited each location are compared using Chi-squared tests (or Fisher's exact test if 
appropriate); the number of visits in the two groups is compared using Mann-Whitney U test.
The cases had significantly more partners (Table 3.5) than controls. The 
median number (range) of partners of the cases versus controls in the 
preceding 12 months was 30 (0-1000) versus 10 (1-800), p<0.001. The 
m ajority of these were "one-n ight stands" for both cases and controls. 
There was no difference in the proportion of men that did not have sex in 
the preceding 12 months between the cases and controls (4.2% vs 6.2%,
p=0.08).
T a b le  3 .5 :  M ed ian  n u m b e r o f s e x u a l p a rtn e rs .
Gives the median and range of number of different sexual partners in the 
preceding 12 months. Of the total number of partners, the number of 
one-night stands is given.
All patients Controls Cases p-value
Median
(range)
Median
(range)
Median
(range)
Sex 15 (0 -1000 ) 10 (0 -1000 ) 30 (1 -800) 0.0001
One-night
stands
10 (0 -1000) 8 (0 -1 0 0 0 ) 20 (0 -400) 0.0001
In d iv id ua l sexual practice:
Question 4 examined individual sexual behaviour over the 12 months 
preceding the diagnosis of HCV. The univariable analysis revealed that 
significantly more cases participated in high-risk sexual behaviour and 
with more partners than the controls (Tables 3.6). While there was a 
trend for active and passive unprotected oral intercourse with ejaculation 
to be more common in cases, this difference was not significant (62.7% 
versus 47.1% , p=0.07; 50.9% versus 35.3%, p=0.07, respectively). 
There was no difference between cases and controls with respect to 
protected (safe) anal intercourse (A I). However, cases were more likely 
than controls to have had unprotected receptive and insertive AI (89.8% 
versus 50.4% , p<0.001; 83.1 versus 47.9% , p<0.001, respectively). 
Furthermore, cases participated in other mucosal traumatic sexual 
practices, including rimming, fisting, use of sex toys and sadomasochism, 
more frequently than controls. The most significant practices associated 
with case/control status were insertive and receptive fisting and use of
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sex toys (74.6%  versus 26.3% , p<0.001; 57.6% versus 12.6%, 
p<0.001; 78% versus 42.9% , p<0.001, respectively). The median 
number of partners fo r these three practices were also higher in the 
cases than the controls over the 12 months preceding the diagnosis (2 
versus 0 men, pcO.OOl; 1.5 versus 0 men, pcO.OOl; 4 versus 0 men, 
pcO.OOl, respectively).
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T ab le  3 .6 :  In d iv id u a l sex u a l p rac tices .
Gives the number of cases and controls participating in each sexual practice and the median (range) number of different
partners for each practice of those who participated in the preceding 12 months.
All patients Controls Cases p-value p-value (no.
Ever Median (range) 
no. men
Ever Median (range) 
no. men
Ever Median 
(range) no. 
men
(ever)* men)*
a) Active oral sex, 
no ejaculation
169 (94.9) 12 (0-400) 112 (94.1) 10 (0-250) 57 (96.6) 20 (0-400) 0.73 0.0004
b) Active oral sex, 
ejaculation
93 (52.3) 1 (0-300) 56 (47.1) 0(0-100) 37 (62.7) 3 (0-300) 0.07 0.002
c) Active oral sex, 
condoms
17 (9.6) 0 (0-20) 12 (10.1) 0(0-10) 5 (8.5) 0 (0-20) 0.94 0.81
d) Passive oral sex, 
no ejaculation
161 (91.0) 10 (0-200) 109 (91.6) 10 (0-200) 52 (89.7) 19 (0-150) 0.89 0.01
e) Passive oral sex, 
ejaculation
72 (40.5) 0 (0-50) 42 (35.3) 0(0-30) 30 (50.9) 1 (0-50) 0.07 0.02
f) Passive oral sex, 
condoms
13 (7.3) 0 (0-20) 11 (9.2) 0 (0-10) 2 (3.4) 0 (0-20) 0.22 0.17
g) Receptive anal 
sex, no ejaculation
113 (63.5) 2 (0-300) 60 (50.4) 1 (0-80) 53 (89.8) 10 (0-300) 0.0001 0.0001
h) Receptive anal 
sex, ejaculation
88 (49.4) 0 (0-450) 42 (35.3) 0 (0-100) 46 (78.0) 3 (0-450) 0.0001 0.0001
All patients
Ever Median (range) 
no. men
Controls
Ever Median (range) 
no. men
Cases
Ever Median 
(range) no. 
men
p-value
(ever)*
p-value (no. 
men)*
i) Receptive anal 
sex, condoms
127 (71.4) 2 (0-150) 83 (69.8) 2 (0-150) 44 (74.6) 4 (0-50) 0.62 0.13
j )  Insertive anal 
sex, no ejaculation
106 (59.6) 1.5 (0-130) 57 (47.9) 0 (0-50) 49 (83.1) 10 (0-130) 0.0001 0.0001
k) Insertive anal 
sex, ejaculation
73 (41.0) 0 (0-50) 39 (32.8) 0 (0-50) 34 (57.6) 1 (0-40) 0.003 0.0003
1) Insertive anal 
sex, condoms
122 (68.9) 2(0-200) 82 (68.9) 2 (0-200) 40 (69.0) 2.5 (0-70) 1.00 0.78
m) Passive rimming 150 (84.3) 5 (0-160) 92 (77.3) 3 (0-160) 58 (98.3) 10 (0-150) 0.0007 0.0001
n) Anal rimming 146 (82.0) 3.5 (0-150) 92 (77.3) 2(0-120 54 (91.5) 7 (0-150) 0.03 0.0001
o) Insertive fisting 
- with gloves
75 (42.4)
5 (6.7)
0 (0-180) 31 (26.3)
2 (6.5)
0 (0 -50) 44 (74.6)
3 (6.8)
2 (0-180) 0.0001 0.0001
p) Receptive fisting 
- with gloves
49 (27.5)
o ( - )
0(0-180) 15 (12.6)
o ( - )
0 (0-20) 34 (57.6)
0( - )
1.5 (0-180) 0.0001 0.0001
q) Sex toys 
- sharing
97 (54.5)
38 (39.2)
1(0-130) 51 (42.9) 
12 (23.5)
0 (0-100) 46 (78.0)
26 (56.5)
4(0-130) 0.0001 0.0001
r) S&M 
- piercings
42 (23.7)
4 (9.5)
0 (0-50) 22 (18.6) 
0( - )
0 (0-50) 20 (33.9)
4 (20.0)
0 (0-30) 0.04 0.02
* The proportions who have ever had each type of sex are compared using Chi-squared tests (or Fisher's exact test if appropriate); the
number of men in the two groups is compared using Mann-Whitney U test.
While there was no significant difference between the participation of 
cases and controls having sex in public places, the cases were involved in 
more high-risk practices than controls in public places (Table 3.7).
T a b le  3 .7 :  P u b lic  sex  p ra c tic e s .
Gives the number of cases and controls participating in sex in public 
places in the preceding 12 months. Of those participating, the number 
(percentage) of those involved in the specified high-risk sexual activities 
is given.
Sex in a public place
All
patients
Controls Cases p-value
Any sex 113 (63 .5 ) 70 (58 .8) 43 (72.9) 0.10
Receptive anal intercourse, 
no condoms
61 (54 .0 ) 27 (38 .6) 34 (79.1) 0.0001
Insertive  anal intercourse, 
no condoms
61 (54 .0 ) 29 (41 .4 ) 32 (74.4) 0.001
Receptive fisting 19 (16 .8 ) 4 ( 5 . 7 ) 15 (34.9) 0.0002
Insertive  fisting 21 (18 .6 ) 7 (10 .0 ) 14 (32.6) 0.006
G roup s e x  p ra c tic e s :
The cases were more likely to have participated in group sex than
controls in the 12 months preceding the diagnosis of HCV (88.1% versus 
52.5%, p<0.001). Cases participating in group sex were also more likely 
to be involved in unprotected receptive and insertive anal intercourse 
(94.2%  versus 41.3% , pcO.OOl; 84.6%  versus 47.6%, pcO.OOl, 
respectively) and receptive and insertive fisting (55.8%  versus 14.3%, 
pcO.OOl; 67.3% versus 15.9% , pcO.OOl, respectively) when compared 
with controls (Table 3.8).
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T ab le  3 .8 : G ro u p  s e x  p ra c tic e s .
Gives the number (percentage) of cases and controls participating in 
group sex in the preceding 12 months. Of those participating, the 
number (percentage) of those involved in the specified high-risk sexual 
activities is given.
Sex in a group of > 2  people
All patients Controls______ Cases______ p-value
Any sex 115 (64 .3 ) 63 (52 .5 ) 52 (88.1) 0.0001
Receptive anal 
intercourse, no 
condoms
75 (65 .2 ) 26 (41 .3 ) 49 (94.2) 0.0001
Insertive anal 
intercourse, no 
condoms
74 (64 .4 ) 30 (47 .6 ) 44 (84.6) 0.0001
Receptive fisting 38 (33 .0 ) 9 (14 .3 ) 29 (55 .8) 0.0001
Insertive fisting 45 (39 .1 ) 10 (15 .9 ) 35 (67.3) 0.0001
Drugs and alcohol use:
There was no difference between the cases and controls with respect to 
sex under the influence of alcohol. However, significantly more cases 
than controls engaged in sex under the influence of recreational drugs 
(91.7% versus 61.5% , p<0.001) (Table 3.9). The AUDIT survey did not 
reveal any significant differences in hazardous alcohol use between the 
cases and controls (median AUDIT score fo r cases 4 versus controls 6, 
p=0.12) (Figure 3.1). Overall recreational drug use was higher in the 
cases than controls in the preceding 12 months (96.7% versus 70.9%, 
pcO.OOl). The drugs more frequently used by cases compared with 
controls were: poppers, ecstasy, psychedelics, methamphetamines
(crystal m eth), ketamine and Gamma Hydroxy Butyrate (GHB) (Table 
3.10). There was no difference in the use of heroin between the cases 
and controls. While there was no difference in the oral, nasal or 
intravenous route of taking drugs, there was more anal use of drugs in 
the cases (42.1%  versus 20.5% , p=0.009) (Figure 3.2). Interestingly, 
cases were more likely to share the implements for the intranasal and
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rectal routes of adm inistration more than controls (79.3 % versus 
48.9%, p<0.001; 21.4%  versus 5.4% , p=0.007, respectively) (Figure 
3.3).
Previously, more cases had used intravenous drugs than controls (23.3% 
versus 7.7%, p=0.005). There was no difference between cases and 
controls in terms of sharing needles, concerns about recreational drugs 
use or receiving money for drugs or sex.
T ab le  3 .9 :  S ex  u n d e r th e  in flu e n c e  o f  a lco h o l and  d rugs .
Gives the number (percentage) of cases and controls participating in sex 
under the influence of either alcohol or illic it drugs in the preceding 12 
months.
All
patients Controls Cases p-value
Sexual activity w ith  a 
man w hilst feeling  
effects of alcohol
124 (65 .3 ) 88 (67 .7 ) 36 (60 .0) 0.38
Sexual activity w ith  man  
whilst feeling effects of 
drugs
135 (71 .1 ) 80 (61 .5 ) 55 (91.7) 0.0001
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Cases n=60 
Controls n=130
I
Controls
F igure  3.1 : M edian A U D IT  scores fo r  cases and con tro ls .
Represents the median AUDIT questionnaire score for hazardous 
drinking. A score of >.8 has a high sensitivity for hazardous drinking.
Table 3 .10 : R ecrea tio na l d rug  use.
Outlines the percentage of cases and controls using specific illicit drugs in 
the preceding 12 months.
Cases % Controls % P-value*
Any 96.7 70.9 <0.001
Methampheta mines 56.9 24.2 <0.001
Ketamine 82.8 48.4 <0.001
GHB 51.7 25.3 0.002
Poppers 89.7 67.4 0.003
LSD 34.5 13.7 0.005
Ecstasy 82.5 60 0.006
Cocaine 79.3 64.2 0.07
Cannabis 69 70.5 0.98
Heroin 6.9 8.4 0.98
Amphetamine 10.3 10.5 1.0
* P-values calculated using Chi-squared test.
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Oral Nasal Injection Other
Figure 3.2: R outes o f re c re a tio n a l d rug  use in the  preced ing 12 
m onths.
Bars represent the percentage of cases and controls using recreational 
drugs by each route in the preceding 12 months. Other includes intra- 
anal.
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Oral Nasal Intravenous Other
Figure 3.3: Routes o f sha red  d rug  im p le m en ts .
Bars represent the percentage of cases and controls sharing specific 
routes of drug adm inistration in the preceding 12 months. Other routes 
includes intra-anal.
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S exua lly  tra n s m itte d  in fe c tio n s :
The cases had more lifetime STIs than the controls (92% versus 78%, 
p=0.005). The infections that occurred in a larger proportion of cases 
than controls were syphilis (42%  versus 19%, p=0.001), gonorrhoea 
(73% versus 48%, p = 0.002), and non-specific urethritis (55% versus 
33%, p=0.007).
Cases n=55 
Controls n=100
Figure 3.4: Lifetime sexually transm itted infections (STIs).
Bars represent the percentage of cases and controls ever having had 
STIs and the differences in specific infections between cases and 
controls.
A ttitu d e s  and  b e lie fs  a b o u t HCV:
Question 21 examined attitudes and beliefs about HCV. The most 
significant differences arose in a question about the availability of 
treatment and a vaccine fo r HCV (Table 3.11). The cases were more 
likely to know that treatm ent for HCV was available and that a vaccine 
was not available. Furthermore, cases were more likely to believe that: 
"Someone with HCV can feel fine" and that "alcohol should not be drunk 
if you have liver problems". Both groups believed that HCV could be
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transmitted sexually. They also believed that there is a negative 
interaction between the viruses.
3 .4 .3  M ultivariab le analysis o f  questionnaire results:
The multivariable analysis was complex. To simplify the number of 
variables, new variables were created which indicated the number of 
different responses that each individual had given to each question (e.g. 
the number of different types of locations that they had gone to in the 
previous 12 months, the number of different types of oral sex that 
someone had experienced over the past 12 months, the number of 
different drugs experienced etc.). A fter generating these variables, the 
patients grouped into between 3-5 categories for each variable that 
included roughly equal numbers of patients (or that were biologically 
reasonable). The percentage of cases fo r each category for each variable 
was used to determine how well each of these new categorical variables 
discriminated between cases and controls. Where adjacent categories 
discriminated sim ilarly, the groups were combined to reduce the number 
of categories. Table 3.12 summarises the final categorical variables that 
were generated.
Once these variables had been created, correlation was assessed. Groups 
of similar variables were included in multivariable logistic regression 
models to try  to fu rthe r reduce the number of variables. Initia lly, 
variables that related to drug use were considered (ANY11A, NASALGRP, 
ORALDRGRP, OTHERGRP) as well as the two existing variables that asked 
whether patients had ever shared drug implements for nasal or other 
use. Of these, only NASALGRP came out as significant. Sexual 
behaviours were then considered (ORALGRP, ANALGRP2, FISTGRP, 
TOTALSM, SEMENGRP, BLOODGRP), and of these, only ANALGRP2 and 
FISTGRP were significant. Finally, a model was fitted that included both 
Q3AGRP and Q3BGRP -  of these, Q3BGRP seemed to be the stronger 
predictor of case/control status.
Therefore, the variables NASALGRP, ANALGRP2, FISTGRP and Q3BGRP 
were included in the same model -  at this stage, both NASALGRP and
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Q3BGRP became non-significant, suggesting tha t exposure to drugs that 
are used nasally and the number of one-night stands were weaker risk 
factor than exposure to high-risk sexual behaviours. The remaining 
variables were added in turn to a model containing ANALGRP2 and 
FISTGRP. The vast m ajority of them did not add significantly to these 
two variables. However, when GROUP2 was added to the model, 
GROUP2 was highly significantly associated with case/control status, 
whereas ANALGRP2 and FISTGRP became non-significant. Despite these 
two variables being strong predictors of case/control status, having group 
sex seems to discrim inate better. Therefore, the final model revealed that 
participation in group sex w ith more then 3 high-risk sexual behaviours 
(UAI and fisting) was strongly associated with acute HCV infection. The 
estimated odds ratio is 23.5 (95%  confidence interval 9.47-58.33) (Table 
3.13).
I l l
Tab le  3 .1 1 :  A tt itu d e s  a n d  b e lie fs  a b o u t  HCV.
Presents the mean and median scaled responses ('Strongly ag ree '= l to 
'Strongly disagree'=4 and 'Do not know '=5) to specific statements about 
HCV.
All patients Controls Cases p-value
non-
parametric
p-value
parametric
Median Mean Median Mean Median Mean
a) Hepatitis C is 
an important 
health problem.
1 1.14 1 1.17 1 1.08 0.14 0.10
b) Someone 
with HCV can 
feel fine.
2 1.81 2 1.89 2 1.66 0.03 0.05
c) HCV can be
transmitted
sexually.
1 1.37 1 1.38 1 1.33 0.62 0.59
d) HCV can 
make HIV 
worse.
1 1.40 1 1.31 1 1.59 0.02 0.01
e) HIV can 
make HCV 
worse.
1 1.46 1 1.42 1 1.54 0.29 0.29
f) There is 
treatment 
available for 
HCV.
2 1.85 2 1.99 2 1.60 0.0001 0.0004
g) There is a 
vaccine 
available for 
HCV.
3 3.24 3 3.03 4 3.60 0.0002 0.0001
h) Most patients 
with HCV have 
chronic 
(persistent) 
infection.
2 2.26 2 2.24 2 2.28 0.62 0.80
I) HCV can 
cause the liver 
to stop working.
2 1.61 2 1.62 2 1.58 0.98 0.70
j) Alcohol 
should not be 
drunk if you 
have liver 
problems.
1 1.46 1 1.40 1 1.61 0.05 0.04
*  P-values calculated using Mann-Whitney U or unpaired t-test test as appropriate.
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Table 3.12: Creation of new variables for multivariable analysis.
New variable name New categories New Variable name Controls; n (% ) Cases; n (% )
Percentage of 
group who are a 
case
p-value
Number of locations 0-2 LOCATIONS 44 (33.9) 7(11.7) 13.7
visited in previous 12 3-4 69 (53.1) 32 (53.3) 31.7
months 5 17 (13.1) 21 (35.0) 55.3 0.0002
Number of sexual <2 Q3AGRP 22 (18.3) 1 (1.7) 4.4
partners in past 12 2-6 26 (21.7) 8 (13.6) 23.5
months 7-14 21 (17.5) 9 (15.3) 30.0
15-30 27 (22.5) 17 (28.8) 38.6
>31 24 (20.0) 24 (40.7) 50.0 0.002
Number of one-night <2 Q3BGRP 31 (26.1) 3 (5.2) 8.8
stands in past 12 2-6 21 (17.7) 6 (10.3) 22.2
months 7-14 27 (22.7) 13 (22.4) 32.5
15-30 17 (14.3) 14 (24.1) 45.2
>31 23 (19.3) 22 (37.9) 48.9 0.001
Number of different 0-3 ORALGRP 36 (27.7) 8 (13.3) 18.2
oral sexual risks 4 33 (25.4) 12 (20.0) 26.7
5 34 (26.2) 17 (33.3) 33.3
6-8 27 (20.8) 23 (38.3) 46.0 0.03
Number of different 0-2 ANALGRP2 68 (52.3) 7(11.7) 9.3
anal sexual risks 3-6 62 (47.7) 53 (88.3) 46.1 0.0001
Number of different 0 FISTGRP 61 (51.3) 8 (13.6) 11.6
fisting/sex toy risks 1 31 (26.1) 8 (13.6) 20.5
2-3 27 (22.7) 43 (72.9) 61.4 0.0001
New variable name New categories New Variable name Controls; n (% ) Cases; n (°/o)
Percentage of 
group who are a 
case
p-value
Any S&M No TOTALSM 96 (81.4) 39 (66.1) 28.9
Yes 22 (18.6) 20 (33.9) 47.6 0.04
Number of different 0-5 SEMENGRP 44 (33.9) 4 (6.7) 8.3
semen risks 6-7 26 (20.0) 10 (16.7) 27.8
8-9 25 (19.2) 13 (21.7) 34.2
10-11 24 (18.5) 18 (30.0) 42.9
12-14 11 (8.5) 15 (25.0) 57.7 0.0001
Number of different 0 BLOODGRP 57 (47.9) 8 (13.6) 12.3
blood risks 1-2 45 (37.8) 20 (33.9) 30.8
3-4 17 (14.3) 31 (52.5) 64.6 0.0001
Number of types of sex None or 1 type only PUBLIC2 107 (82.3) 27 (45.0) 20.2
in a public place 2 types 17 (13.1) 19 (31.7) 52.8
3/4 types 6 (4.6) 14 (23.3) 70.0 0.0001
Number of types of sex None or 1 type only GROUP2 94 (78.3) 11 (18.6) 10.5
in a group 2 types 14 (11.7) 15 (25.4) 51.7
3/4 types 12 (10.0) 33 (55.9) 73.3 0.0001
Any use of marijuana No ANY11A 28 (29.5) 18 (31.0) 39.1
Yes 67 (70.5) 40 (69.0) 37.4 0.98
Number of different 0-1 NASALGRP 33 (34.7) 5 (8.6) 13.2
intranasal drugs* 2-3 37 (39.0) 16 (27.6) 30.2
4-6 25 (26.3) 37 (63.8) 59.7 0.0001
Number of different 0 ORALDRGRP 37 (39.0) 8 (13.8) 17.8
oral drugs 1-2 58 (61.1) 50 (86.2) 46.3 0.002
Number of different 0 OTHERGRP 65 (68.4) 29 (50.0) 30.9
'other' drugs 1-3 30 (31.6) 29 (50.0) 49.2 0.04
Table 3.13: Final m ultivariable model.
Number of types of sex in a 
group
Odds ratio 9 5 %  Cl p-value
None or 1 1 - -
2 9.16 3.51-23.90 0.15
3/4 23.50 9.47-58.33 0.0001
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3.5 Discussion
Using a specifically designed questionnaire the case-control study 
identified a number of putative factors associated with the recent 
epidemic of acute HCV in HIV-positive individuals. In contrast to the 
usual parenteral routes of HCV transmission, permucosal factors are 
significantly associated w ith this epidemic. These factors will be discussed 
following an outline of the lim itations of the study. The discussion will 
attempt to disentangle the complex interaction between these and other 
factors.
3.5 .1  Lim itations:
There are several lim itations in the methodology, which need to be 
understood when examining these findings. Retrospective data collection 
is an obvious lim itation, which could potentially lead to recall bias. In 
order to lim it the potential for this bias, cases and controls were given a 
'date of interest', which was the date of diagnosis of HCV for cases or the 
matched date for the ir control. By definition, there was no difference 
between the median 'date of in terest' fo r cases and controls. There was 
also no difference in the recall period between the 'date of interest' and 
date that the questionnaire was completed for cases and controls (456 
versus 500 days, p=ns). However, th is was a long recall period, which in 
itself may have led to inaccuracies in the estimated numbers and events. 
I t  is also possible tha t there could have been systematic differences in 
the recall of events between the cases and controls. For example, the 
cases' knowledge of the HCV diagnosis may have led to better recall of 
potential transmission events around the time of HCV acquisition. In 
contrast, the controls may have had more difficulty recalling specific 
events over the same period. I f  controls underestimated risk behaviour 
over this period, this would have exaggerated differences between the 
two groups. Given the incubation period of HCV and inaccuracy in the 
estimated infection date, a 12-month period from the date of diagnosis 
was used to study transmission factors. Twelve months is, however, a 
long period of time to estimate drug and sexual behaviours and may 
have contributed to inaccuracies in the recall of events. Finally,
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significant drug use during this period may have compromised the 
accurate recall of events.
As with any case-control study, participation bias is important. The 
overall response rate was low at 54% (60/111 cases) and there are a 
number of reasons for this. The response rate was different between the 
three institutions; the m ajority of cases and controls were recruited from 
the RFH. At the RFH the response rate was 88% (44/50) for the cases. In 
contrast, the response rate at the BSGH was 54% (6/11) and 20% 
(10/50) at CWH. There were no controls recruited from BSGH and only 8 
from CWH. The m ajor reason fo r th is was logistic difficulties with 
recruitment and follow-up of the cases at these centres. No specific 
individual was identified at these centres to complete questionnaires. I t  
was not clear tha t there were any reasons tha t patients and controls from 
these centres were less likely to  respond to the questionnaire. A 
comparison between the phylogenetic study and case-control populations 
did not reveal any significant differences. In addition to the logistic 
problems, reasons fo r the cases not returning questionnaires included 
refusal to participate, and lack of fu rthe r clinic attendance or follow-up.
The study participants were recruited from large urban HIV units in 
London. Controls were appropriately recruited from the clinics databases, 
representing the same population from which the cases were derived. 
HIV-positive men not attending these hospital-based clinics would include 
men with early HIV managed by a local clinic or GP, disenfranchised 
groups such as IVDUs and im m igrants, and undiagnosed HIV-positive 
men. This urban study population may not be representative of the wider 
HIV-positive MSM population. The comparison with the CHIC cohort of 
MSM suggests that the study cohort is younger and more recently 
infected with HIV (higher CD4 counts and less likely to have been on 
treatment. I t  is also not clear whether the study population is similar to 
other cohorts of acute HCV in HIV-positive men in large European urban 
centres such as Paris, Berlin or Amsterdam. However, all these groups 
described sim ilar high-risk sexual transmission risk factors. Therefore, 
the generalisability of the results would be affected by the fact that the
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majority of patients come from  one centre and that they may not be 
representative of the w ider HIV-positive community.
Finally, the sample size (n = 60) was relatively small which limited the 
analysis. An attem pt to control fo r confounding factors was made by 
matching two controls to each case. Unfortunately, while the majority 
(87%) of cases could be matched to at least one control, this was 
incomplete. However, there was no significant difference in any of these 
parameters between the cases and controls when the groups were 
compared. There were a large number of factors tha t were identified as 
significant on the univariable analysis. I t  is usually accepted that for each 
factor in a multivariable model at least 10 cases are required. In addition, 
many of the significant factors were highly correlated adding further 
complexity to the m ultivariable analysis. In some respects the studied 
behaviours are so inter-re lated tha t it is impossible to disentangle them. 
Therefore, rather than attem pt to identify specific behaviours associated 
with acute HCV infection, the study revealed general patterns of 
behaviour associated with the transmission of HCV.
3 .5 .2  D etailed  discussion:
I t  is noteworthy that all the cases identified have been HIV-positive MSM. 
This is despite the fact tha t all the cases came from HIV clinics that treat 
substantial numbers of heterosexual HIV-positive patients. This suggests 
that factors specific to MSM are im portant in the recent transmission of 
HCV.
A key finding in this study is tha t parenteral risk factors did not explain 
the vast m ajority of the HCV transm ission; only 6.6% controls versus 
17.2% cases (p=0.08) had IVDU as a risk in the preceding 12 months. 
Therefore, 82.8% of the cases did not have this as a risk factor, which is 
the reverse of the more usual current pattern of HCV transmission. In 
this cohort, permucosal factors were significantly more important. For 
permucosal transmission of HCV to occur there needs to be disruption of 
the mucosal barrier w ith exposure to infected body fluids. There are a 
number of possible mechanisms identified in this study that could disrupt
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the mucosa. I t  could arise through mucosally traumatic sexual practices 
or instrumentation used when sharing drugs. In addition, STIs leading to 
mucosal/skin lesions could potentiate transmission. Second, these 
disrupted mucosa need to be exposed to infected body fluids, which can 
occur in a number of ways. Unprotected intercourse would lead to 
exposure to semen or blood. Recently, a group has demonstrated that 
HCV/HIV co-infection leads to detectable and higher concentrations of 
HCV in the semen compared with HIV negative men (Briat et at., 2005). 
Oral sexual practices would lead to exposure to saliva from which HCV 
has also been isolated. I t  is also plausible tha t blood or secretions related 
to shared drug implements and sex toys is another potential source.
It  has been assumed until recently tha t individuals did not purposely seek 
to have unprotected sex. However, HIV seroconcordant sexual partnering 
has changed sexual behaviour. Unprotected intercourse between HIV 
seroconcordant men can be considered a 'harm reduction7 strategy. In 
the MSM community it is now recognised that some individuals 
intentionally seek unprotected intercourse; termed 'barebacking7. 
However, unprotected sex puts these men at increased risk of STIs and 
HIV superinfection. Macdonald and colleagues at the Health Protection 
Agency, UK, found tha t the rates of HIV and other STIs, including 
syphilis, gonorrhoea, genital herpes and chlamydia, have increased 
substantially in the MSM com m unity (Macdonald et al., 2004). The rates 
in London were twice those of other parts of the UK. Interestingly, there 
has been a disproportionate rise in the diagnosis of syphilis in MSM 
compared to heterosexual men in the UK, driven by large outbreaks in 
London and Manchester (Simms et al., 2005). HIV-positive men are a 
group prone to high-risk sexual activities. Repeated surveys of the 
homosexual community in London suggest that there is increasing risk 
behaviour in this group (Nardone et at., 1997; Dodds et a!., 2000). High- 
risk sexual behaviours include: multiple partners, unprotected anal 
intercourse (UAI), and other mucosally traum atic sexual practices such 
as fisting, rimming, use of sex toys and sadomasochic practices. In a 
cross-sectional cohort study of gay men (n=8052) from venues in London 
between 1996 and 2000, Dodds and colleagues reported increasing levels
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of UAI (Dodds et al., 2004). H IV -positiv ity is important and one study 
reporting sexual practice of HIV-positive MSM over the preceding 3 
months found that if the ir partner was HIV-positive unprotected anal 
intercourse occurred in 91%  of partners as opposed to 34% of HIV- 
negative or unknown status (McConell J, 2003). Halkitis and colleagues 
studied HIV-positive seroconcordant MSM in an attempt to determine 
factors predicting high-risk behaviours (Halkitis et al., 2005a). The three 
factors associated with high-risk behaviours were: lack of belief that STIs 
and HIV superinfection were a problem; less evaluation of sexual 
behaviours with more hedonistic expectations and higher level of sexual 
compulsivity; and recreational drug use. The same research group 
analysed the practice of intentional unprotected intercourse 
('barebacking') and found tha t this was associated with higher levels of 
sexual compulsivity, lower responsibility for safer sex and increased drug 
use (injection and non-in jection) (Halkitis et al., 2005b). Those 
identifying as 'barebackers' have more risk in terms of substance abuse, 
HIV transmission behaviours and combining drug use with sexual risk 
taking.
Sexual partners sought via the internet was an important factor in our 
study that was highly associated with the cases. This supports the 
increasing evidence that the internet is an emerging risk environment for 
STIs. McFarlane and colleagues found tha t individuals (n=135) seeking 
sexual partners on the internet were more likely to have had an STI, 
have a greater number of partners, be MSM and have HIV-positive sexual 
partners (McFarlane et al., 2000). They concluded that the internet has a 
role in the solicitation of high-risk sex and is a potential risk factor for 
STI/HIV. In a study of an outbreak of syphilis in the New York MSM 
community, the internet was determined on multivariable analysis to be 
an independent risk factor fo r transmission of syphilis (Wong et al., 
2005). The internet provides a convenient and confidential way of 
meeting sexual partners. HIV-positive men may be able to disclose their 
status in a relatively safe environment thereby establishing 
seroconcordance more easily. While it is controversial if the internet leads 
to an overall increase in high-risk behaviour, there is good evidence that
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in HIV-positive MSM it does increase risk behaviour (Bolding et al., 2005; 
Hospers et al., 2005). The cases in the study met men via the internet 
seven times more often than controls in the 12 months preceding the 
diagnosis of HCV. The strong correlation between being a case and 
meeting men on the internet supports the hypothesis that that the 
internet is an environment tha t fom ents high-risk sexual behaviours. 
Seroconcordance was not assessed in this study. I t  is likely that the high- 
risk behaviours were in HIV-positive seroconcordant couples. 
Seroconcordant coupling was controlled to some extent by using HIV- 
positive controls. Therefore, the internet probably represents an 
epiphenomenon, associated w ith HCV transmission by a third direct 
transmission factor, such as high-risk sex.
It  is also apparent tha t the cases sought sexual partners offline. They
met men significantly more often at sex clubs, bathhouses, saunas and 
private parties. This may be indicative of sexual compulsivity and is 
consistent with the higher number of partners. The questionnaire 
instrument was not designed to identify where specific sexual partners of 
the study cohort came from . Cases in our study had significantly more
partners than the controls, the m ajority  of partners in both groups
however, were once only "one-n ight stand" partnerships.
Observational studies from  other European groups have suggested that 
sexual factors are im portant in the recent increase in HCV transmission in 
HIV-positive men (Gambotti et al., 2005; Gotz et al., 2005). Our case- 
control study revealed distinct differences between the cases and controls 
with respect to the ir individual sexual practices. A larger proportion of 
cases participated in high-risk sexual practices and with more partners 
than controls. The unsafe sexual practices of unprotected anal 
intercourse (UAI), rim m ing, fisting and sharing of sex toys were all 
associated significantly w ith acute HCV infection. Theoretically all these 
practices could be associated w ith permucosal transmission of HCV as a 
result of mucosal trauma and exposure to infected secretions. The sexual 
factors identified in our study are highly inter-related and many would 
probably occur during the same session. The questionnaire did not
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examine the pattern of sexual behaviour during these sexual encounters 
and there maybe a specific pattern to these behaviours. As a result the 
analysis has not been able to separate one from the other. To delineate 
this, specific qualitative research would be needed to evaluate in detail 
the behaviours of those involved in these practices. I t  should be stated 
that the controls also had a significant level of risk with more than one 
third participating in UAI. I t  would be inform ative to prospectively follow 
the controls who reported significant risk identified by the questionnaire 
for future incidence of HCV infection.
Group sex is a situation where these sexual factors could potentially 
amplify HCV transmission. Group sex practices were more common in the 
cases than controls. Of those participating in group sex, higher-risk 
behaviours were more common in the cases than controls with regard to 
UAI and fisting. Group sex is an environm ent that potentially leads to 
explosive transmission of STIs. Individuals are exposed to high-risk 
practices with multiple partners, increasing the risk of transmission. I t  is 
conceivable that multiple transmissions could occur in these situations. 
While the study only asked about high-risk practices of UAI and fisting, it 
is likely tha t the other practices were also involved. There is a paucity of 
data on group sex behaviour. C latt and colleagues performed qualitative 
research among HIV-positive MSM participating in group sex parties in 
New York. Sim ilar to our findings, they found individuals used parties as 
a means of serosorting w ith very high rates of unprotected intercourse 
and previous drug use (Clatts et al., 2005). There was little evidence of 
safe sex practice such as condom or glove use in our study. This practice 
is contributing to the increase in STIs and HCV transmission.
It  is unsurprising that there were more STIs in the cases compared with 
the controls. There are two interpretations of this phenomenon. Most 
likely, this is a reflection of the high-risk sexual behaviour of the cases. 
As in our cohort, higher risk sexual behaviour is associated with the 
increased risk of STIs. Key to the transmission of STIs is the number of 
sexual partners. While both cases and controls had a high number of 
median sexual partners, the cases had significantly more (30 versus 10,
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p<0.001). Analysis of the NATSAL study revealed that numbers and 
types of sexual partners were the dom inant individual and population risk 
for the acquisition of STIs (Fenton et a l ,  2005). The study reported a 
disproportionate burden of STIs in highly sexually active individuals, 
those living in Greater London and those having homosexual 
partnerships, w ith almost 50% of the STIs occurring in the <10% of the 
population that reported >10 sexual partners. I t  is possible that STIs 
may also be contributing directly to HCV transmission through 
percutaneous/mucosal lesions and/or the presence of infected 
inflammatory cells. The relationship between STIs and HIV transmission 
has been recognised fo r some tim e (Stamm e ta /., 1988). Certainly, there 
were higher rates of STIs in the cases compared with controls. However, 
it should be noted tha t our questionnaire obtained details of lifetime STIs 
and not STIs in the period before the acquisition on HCV.
Interestingly, there was no difference between cases and controls in 
participation in sex under the influence of alcohol. However, cases were 
more likely to have participated in sex under the influence of drugs than 
controls. 'Club drugs' were more commonly used by the cases, including 
ketamine, metamphetamines, GHB, poppers, LSD and ecstasy. Many of 
these drugs are taken intranasally and this route of drug taking was 
shared significantly more often by the cases than controls. In addition, 
the cases used intra-anal drugs more frequently than controls. 
Unfortunately, it was beyond the scope of the study to explore the 
interaction of drugs and sex at the event-level. This would have required 
an in-depth qualitative analysis of the temporal relationship between 
drug and sexual activity of this group.
There are two possible mechanisms whereby drug use may increase HCV 
transmission. First, sharing of the instrum ent used to take the drugs 
could potentially lead to transmission. Interestingly, both intranasal and 
rectal drug use were more frequently used in the cases than controls. It 
is theoretically possible tha t infected implements led to transmission of 
the infection. However, intranasal transmission of HCV is rare (CDC,
1998). I t  may be tha t the rectal route of transmission occurs in the
123
context of mucosal trauma associated with sex. However, it is more likely 
that the effect of the drugs led to higher-risk behaviours due to 
disinhibition and sexual arousal. 'C lub' drugs have been associated in 
other studies with high-risk sexual behaviour in the MSM community. 
Specifically, the increase in use of metamphetamines (crystal meth) has 
been reported to be contributing to a rise in the incidence of HIV in MSM 
(Boddiger, 2005). One study of crystal meth found that in HIV-positive 
MSM it increased sex through increased confidence, heightened sensation 
and loss of inhibitions (Semple et al., 2002). The dose of drugs and 
proportion of sexual interactions under the influence of the drug was not 
assessed by our questionnaire instrum ent.
Relating these findings to the phylogenetic trees there was no significant 
difference in risk factors identified in the questionnaires in the different 
clades. Among individuals lying separately in the phylogenetic trees 
(n=9), questionnaire data were available for 5. The numbers were too 
small for statistical analysis but descriptively these cases shared many of 
the same risk factors as those who formed part of the transmission 
clusters in the phylogenetic study. I t  is likely that some of these 
individual sequences are part of the same transmission route and that 
the other individuals form ing the rest of the cluster were not identified for 
this study and remain e ither undiagnosed or under the care of a different 
HIV unit.
By definition, the matching in case-control studies controls for the 
matched confounders. As a result, the importance and relevance of HIV 
was not explored in this study. All these cases have been identified in the 
HIV-positive population and it is possible tha t HIV itself may favour the 
transmission of HCV. This is an im portant area of future study.
The interaction between sexual and drug behaviours is complex and 
controversial. Early studies suggested an association between alcohol and 
drug use and HIV seroconversion, UAI, and number of partners. Alcohol 
and drug use are strongly related to high-risk sexual behaviours such as 
inconsistent condom use and m ultip le partners (Siegel et al., 1989;
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Ostrow et al., 1993). This is also the case with MSM (Stall et al., 1986; 
Woody et al., 1999). Studies have consistently shown that non- 
intravenous drug and alcohol use are common in the MSM population 
(Stall & Wiley, 1988; Stall & Purcell, 2000). Data from the Urban Men's 
Health Study in the USA, revealed increased levels of non-intravenous 
drug use in the homosexual com m unity when compared with the 
heterosexual population (Stall et a/., 2001). However, many of the 
studies had methodological problems because they used global measures 
of drug use and did not explore the direct temporal interactions between 
use and sexual behaviour. Our case-control study suffered similar 
problems. When this interaction is explored studies have both supported 
and dismissed a relationship. Overall, there is a lack of data at the event- 
level, describing drug and sexual practices. I f  there tru ly is a relationship, 
then it is unclear whether drugs are used to achieve unprotected sex, or 
whether unprotected sex is the result of clouded judgem ent secondary to 
drug use. Drug use and high-risk sex may also be linked through a third 
variable such as sensation-seeking, im pulsivity or situational factors such 
as going to a bar/c lub /party where both occur. To unravel the complex 
interactions between drug use and sex, qualitative data is needed to 
examine the pattern and reasons fo r the ir use.
The exploration of HCV knowledge revealed very sim ilar results between 
the two groups. The significant differences in median and mean results 
were that cases were more likely to believe that "you could feel fine with 
HCV", "there is treatm ent available fo r HCV", "there is no vaccine for 
HCV", and "alcohol should not be drunk if you have liver problems". 
These beliefs could all be the result of change in understanding following 
the diagnosis of HCV, a problem with retrospective data collection. 
Consequently, it is d ifficu lt to in terpret th is data. The most interesting 
finding, however, was tha t 62% of cases and 62% of controls "strongly 
agreed" tha t HCV could be transm itted sexually. This is important 
because it indicates tha t individuals are aware of this as a route of 
transmission. There would also appear to be a reasonable understanding 
that HCV is an im portant health problem, impacts HIV, develops 
persistence and causes liver disease. Unfortunately, because this was
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evaluated retrospectively, it cannot be ascertained whether the cases had 
a poorer understanding of th is before the acquisition of HCV, which may 
have contributed to transmission. I t  is of concern that cases may have 
had a good understanding of HCV but continued with risky activity. This 
level of insight will have an impact on how public health interventions 
should be focused.
This study has identified a number of potential factors associated with the 
recent transmission of HCV. These transmission factors form a complex 
interaction between sexual and drug risk behaviours. While significant in 
univariable analysis, many of these factors are highly correlated and have 
been difficult to disentangle in the multivariable analysis. The final 
multivariable model identified group sex as the only independent factor 
associated with acute HCV infection in the study cohort. While this is the 
strongest association, in itself it is not a specific mechanism for 
transmission of HCV. I t  is more likely to represent an epiphenomenon 
whereby a th ird factor w ithin the milieu of sexual and drug factors is 
responsible for the HCV transmission. This study suggests that the 
mechanism may be e ither mucosally traum atic sexual practices or the 
sharing of drug implements, both of which biologically could transm it the 
infection. However, to define these specific factors a detailed qualitative 
study at the event level would be required. Figure 3.5 graphically 
represents the study cohort. A number of factors in the univariable 
analysis appear to be contributing to the recent transmission. First, 
mucosal traum atic sexual practices including UAI, rimming, fisting, use of 
sex toys and sadomasochistic practices could all theoretically transm it 
HCV. Internet use may contribute to this by facilitating the access of HIV- 
positive individuals to these high-risk practices. 'Club drugs' may increase 
the participation in high-risk sexual activities. The sharing of drug 
implements, particularly intranasally and intra-anally, may also lead 
directly to HCV infection. Finally, the role of STIs is unclear (represented 
by a two way arrow). They most likely represent the result of the high- 
risk sexual practices. However, STIs may also be potentiating HCV 
transmission through mucosal/skin lesions. Using the factors identified in 
this study, high-risk individuals such as those participating in group sex
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could be identified. These factors need to be the focus of any public 
health intervention to prevent the spread of HCV in the HIV-positive 
population.
F igure 3 .5 :  M o d e l o f v a r ia b le  in te ra c t io n  an d  HCV tra n s m is s io n  in 
H IV -p o s it iv e  M SM .
Describes the complex contribution of factors to HCV transmission within 
the sexual and drug mellieu.
Internet
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Chapter 4: Natural History and Host-Virus 
Interaction in Acute HCV in HIV Co-infection.
4.1 Introduction
The natural history of HCV in HIV co-infected individuals can be better 
understood by studying the interaction between the virus(es) and 
immune response in co-infected individuals. Studies among individuals 
with chronic HCV/HIV co-infection have revealed significant influences of 
HCV on HIV infection and vice versa. As discussed in the introduction the 
liver injury from HCV is frequently accelerated in co-infection. However, 
the acute phase of HCV infection in those with HIV has not been studied 
because it has not often been recognised clinically. This cohort has 
provided the opportunity to study aspects of early phase HCV infection in 
HIV-positive individuals, which may lead to a better understanding of 
factors that are im portant in the long-term  natural history of HCV/HIV 
co-infection.
The definition of acute HCV infection is based on the observation that 
most patients who clear HCV spontaneously will do so in the firs t six 
months of infection; usually w ith in 35 days of the onset of symptoms 
(Gerlach et al., 2003; Hofer et al., 2003). In the largest reported series 
of acute HCV mono-infection, Gerlach and colleagues describe the course 
in 60 consecutive patients. There was a high spontaneous seroconversion 
rate of 44% in sym ptomatic patients w ithin the firs t 3-4 months (Gerlach 
2003). After this tim e there was no spontaneous eradication of HCV. Thus 
successful immune responses to  HCV can be mounted in a proportion of 
individuals.
4.1 .1  C ell-m ediated  im m une responses in acute HCV mono­
infection:
A successful response to HCV requires a strong, broad and sustained 
HCV-specific CD4 T-cell response (Diepolder et al., 1995; Gerlach et al.,
1999). CD4 T-cells are vital fo r prim ing and sustaining CD8 cytotoxic T- 
cells, which leads to control of the infection. Gerlach and colleagues
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demonstrated that patients who failed to clear HCV either did not mount 
CD4 responses or, a fter in itia l virological control, did not sustain these 
responses with a consequent relapse of HCV (Gerlach et al., 1999). This 
finding was reinforced by Thimme and colleagues who analysed CD4 T- 
cell responses in healthcare workers exposed to HCV (Thimme et al.,
2001). Whilst two patients in itia lly  developed strong CD4 T-cell 
responses, following loss of these responses they developed persistent 
infection. These studies were performed on peripheral blood samples; 
intrahepatic CD4 T-cell responses in the acute phase in humans have not 
been studied because liver biopsy is not usually performed early in the 
course of HCV. However, in chimpanzee studies, intra-hepatic CD4 T-cell 
responses were identified only in those animals that controlled HCV 
(Thimme et al., 2002). Post-liver transplantation patients are a suitable 
and accessible study group because they undergo a number of routine 
liver biopsies as part o f the ir routine management. In these patients, in 
whom HCV re-infection is almost universal, HCV specific CD4 T-cell 
responses have been reported in 62%  of the studied patients (Schirren et 
al., 2001). These responses did not, however, correlate with prevention 
of recurrent infection. HCV specific T-cell responses have been identified 
against a wide range of epitopes, particularly the non-structural proteins; 
the most frequently recognized are HCV core (between nucleotides 21- 
40), NS3 1253-1272, NS4 1767-1786 and NS4 1909-1929 (Diepolder et 
al., 1997; Lamonaca et al., 1999). Significantly, these HCV-specific T-cell 
responses are persistent and have been detectable up to two decades 
following resolution of HCV in a group of women tha t had been infected 
from human Rhesus im munoglobulin (Takaki et al., 2000).
The appearance of CD8 T-cells is tem porally associated with control of 
viraemia. Tetramer studies have shown tha t CD8 T-cells can take several 
weeks to expand after the onset of the infection (Shoukry et a!., 2003). 
It has also been shown tha t these cells initially lack effector function, 
with limited production of interferon-y (IFN-y); this increased over the 
next few weeks (Lechner et al., 2000). Analysis of individuals following 
needlestick exposure to HCV found tha t CD8 T-cells at week seven were 
associated with significant elevations of serum ALT, but that they did not
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produce I F N - y .  Later, the CD8 T-cells recovered their ability to produce 
I F N - y ,  which was associated w ith a significant drop in viraemia and 
resolution of liver disease (Thimme et al., 2001). The reason for this is 
not clear. Interestingly, this delay was not apparent if memory T-cells 
responded to HCV (Shoukry e t al., 2003). Chimpanzee studies have 
supported this finding, revealing tha t the expansion of CD8 T-cells is 
associated with an increase in serum aminotransferases and transient 
clearance of HCV from plasma (Cooper et al., 1999; Thimme et al.,
2002). Those animals not developing responses developed persistent 
HCV infection. Sim ilar to CD4 T-cell responses, CD8 T-cell epitopes have 
been identified to all HCV proteins. In those patients spontaneously 
clearing HCV these responses have also been shown to be vigorous and 
multi-specific (Gruener et al., 2000; Lechner et al., 2000). In a study of 
one individual's response to HCV, Gruener and colleagues observed that 
contraction of the CD8 T-cell population responding to a single epitope 
was associated with loss of control of the infection (Gruener et al., 2001). 
Similar to the CD4 T-cell responses, studies have confirmed that CD8 T- 
cell responses are necessarily sustained fo r long-term clearance of HCV 
(Takaki et al., 2000; Thimme et al., 2002).
The importance of cell-mediated im m unity is also demonstrated through 
its role in protective im m unity. In a study of IVDUs, those who had 
evidence of previous exposure to HCV had a lower re-infection rate than 
those not previously exposed (12%  versus 21%) (Mehta et al., 2002). 
There was also a reduced risk fo r the development of chronic infection. In 
chimpanzee studies, animals tha t had recovered from a previous 
exposure to HCV had a shorter course and milder disease when re­
exposed to HCV which correlated w ith a strong memory T-cell response 
and intra-hepatic I F N - y  production (Bassett et al., 2001; Weiner et al., 
2001; Major et al., 2002). Antibody depletion studies of CD4 and CD8 T- 
cells indicate tha t CD8 T-cells are the primary effector cell mediating 
protective im m unity, while the CD4 T-cells are required to support this 
process (Grakoui et al., 2003; Shoukry et al., 2003).
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4 .1 .2  Viral evolution in acu te  HCV:
I t  has been shown tha t HCV genetic changes can inhibit CD4/CD8 T-cell 
recognition (Chang et al., 1997). In teresting ly, this occurs early in the 
infection and over time in chronic HCV mono-infection the virus did not 
diversify further, suggesting tha t viral escape mutations occur in the 
acute phase of infection. In a seminal study, Farci and colleagues
described the role of escape m utation in early HCV infection (Farci e ta /.,
2000). This study examined HCV diversity over time in four distinct 
clinical groups (n = 12 patients); patients with resolved infection,
fulm inant hepatitis, chronic non-progressive HCV, and rapidly progressive 
chronic HCV infection. Patients were studied before and after
seroconversion to anti-HCV. With antibody seroconversion, the resolving 
and fulm inant hepatitis groups had decreased viral diversity, particularly 
in the HVR1, while progressive evolution of the HVR1 of E2 region was 
associated with chronicity. This suggested tha t the HVR1 region is under 
immune selection pressure and may play a role in viral escape. The 
highest rate of mutation was found at moderate levels of immune
response and viral load.
4 .1 .3  H ost-v ira l in teraction :
The relationship between the immune response and HCV diversity can be 
described using a simple model tha t was initially applied to HIV 
(McMichael & Rowland-Jones, 2001) (Figure 4.1). This model contends 
that the level of viral d iversity is determ ined by two factors: the size of 
the replicating viral population and the level of immune pressure. This 
then determines the level of selection pressure on the virus, with 
advantageous variants surviving. The Farci study elegantly confirmed 
that this holds true fo r HCV. This will be explored in this chapter.
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Figure 4.1: Host-viral interaction.
Describes the relationship between the viral load (green) and cytotoxic T- 
lymphocyte activ ity (black) and escape mutations (red).
4 .2  A ims
The aims of th is  section were:
1. To describe the early natural history of acute HCV in HIV.
2. To study the cell-mediated immune responses to HCV during the acute 
phase of infection in HIV-positive individuals.
3. To describe the viral evolution during the acute phase of HCV in HIV- 
positive individuals.
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4.3 Methods
4.3 .1  Clinical cohort:
Patients diagnosed at the Royal Free campus were enrolled into this 
study. The diagnosis o f these patients has been previously outlined in 
Chapter 2. Clinical data was collected on the HCV, HIV and demographic 
parameters. Date of diagnosis was defined as the first documented 
positive HCV RNA, or anti-HCV seroconversion, or peak ALT followed by 
HCV viraemia. A period of 3-6 months before the date of diagnosis of 
HCV was defined as the pre-HCV infection period for the analysis of 
clinical parameters. Self-lim ited HCV was defined as the development of 
persistently negative HCV RNA by PCR and normalization of liver function 
tests w ithout HCV treatm ent. Chronic HCV was defined conventionally as 
persistent HCV viraemia fo r more than six months. Clinical data were 
collected from clinical notes and also downloaded from the Royal Free 
Hospital database. A cohort of acute HCV mono-infected patients was 
used as a control group fo r the immunological study. This was an Italian 
cohort from Vincenza and the serum and PBMCs had been collected in 
Ita ly and sent to the Nuffield Department of Medicine, Oxford for 
analysis. Only basic clinical data were available on this cohort. 
Comparisons were performed using both SAS (version 8) and Prism 
(version 4) software.
4 .3 .2  C ell-m ediated  im m unology:
C ollection  an d  P re p a ra t io n  o f  PBM Cs:
Whole blood samples were collected on a 2-4 weekly basis over the acute 
phase of HCV infection. The PBMCs were prepared as follows:
• 50ml of fresh blood was collected at each tim e-point.
• Blood was layered over Lymphocyte H solution in a 1:2 ratio.
• Lymphocytes separated by centrifuging for 20 minutes at 800g at 
room tem perature (22°C).
• Lymphocytes added to PBS.
• Centrifuged as above.
• Lymphocytes washed and re-suspended in PBS.
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• Lymphocytes counted and re-suspended in 10% DMSO and 90% 
Fetal Calf serum (FCS).
• Samples were placed in cooling box (cooling by 1°C per minute) 
frozen in liquid nitrogen at -80°C
E L IS p o t assay:
ELISpot assays were performed using frozen PBMCs, which were 
analysed for interferon-y ( I F N - y )  production as per manufacturer's 
instructions (MABTECH, Sweden). I F N - y  ELISpot assays are a very 
sensitive ex-vivo measurement fo r low frequencies of cytokine-producing 
cells (potentially down to 1 /300.000).
Briefly, multiscreen filtra tion  plates (M illipore, UK) were coated with 50pl 
monoclonal antibody (m Ab) to I F N - y  (Mabtech) diluted to 15pg/ml with 
sterile filtered phosphate buffer saline (PBS), and left overnight at 4°C. 
Plates were washed w ith 6x 200pl PBS before blocking with 200pl RPMI 
1640 (Life Technologies) plus 10% heat-inactivated FCS (Sigma Aldrich) 
and incubated fo r 3 hours at 37°C. PBMCs were added to the plate at a 
concentration o f 2 x 105 cells/well. Protein or peptide was added to each 
well in duplicate. Peptides were added at a concentration of lOpg/m l and 
proteins at a concentration of lp g /m l. Plates were incubated for 18 hours 
overnight at 37°C with 5% C 02 and 100% humidity. Plates were then 
washed with 6x 200pl sterile filtered PBS before coating with 50pl 
biotinylated mAb (Mabtech) diluted 1 in 1000 in sterile filtered PBS and 
incubated for 2 hours at room tem perature. Plates were washed with 6x 
200ptl sterile filte red PBS before coating with 50pl streptavadin-alkaline 
phophatase (Mabtech) diluted to 1:1000 in sterile filtered PBS and 
incubated for 1 hour at room tem perature. Finally, plates were washed 
with 6x 200pl sterile filtered PBS, and 50pl substrate (BCIP/NBT Biorad) 
was added and incubated until dark spots appeared. Colour development 
was stopped by washing in tap w ater (3 x 200pl/well). The plates were 
left to dry and spots were counted on an ELISpot reader (ELISpot 3.1 SR 
program, AID Reader System, Germany). There is currently no 
consensus on the optimal way to identify and enumerate positive
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responses in an ELISpot assay. In th is study, a test was considered 
positive if the probability of a spot appearing in the test well was 
significantly d ifferent (p<0.05) from the probability of a spot appearing in 
the control well, assuming a Poisson d istribution. Quantification was then 
determined by subtracting the mean background number of spots from 
the mean number of spots in the test well.
C a rb o x y lflu o re s c e in  S u c c in im id y l E s te r  (C F S E ) assay:
Carboxyfluorescein succinimidyl ester (CFSE) is a fluorescent cytoplasmic 
dye tha t can be used to measure cell proliferation using flow cytometry. 
For staining with CFSE (Molecular Probes, USA) PBMCs at a concentration 
of 1 x 107 cells/ml in PBS were incubated at 37°C for 7 min with 0.5pM 
CFSE. Staining was term inated by adding PBS containing 10% pooled 
human serum, cells were washed twice and re-suspended in culture 
medium containing 10% human serum at 2 x 106 cells/ml. Stained cells 
(1 x 106 cells/well, lm L ) were cultured in 48-well plates with medium 
alone, PHA as a positive control, core peptide pools 1-4 (lO pg/m l final 
concentration) and non-structural proteins NS3-5 ( lp g /m l final 
concentration). A recombinant yeast control protein ( lp g /m l final 
concentration; Chiron, USA) and HIV p24 were also included as controls. 
After six days of culture, cells fo r each antigen were transferred into 
FACS tubes, washed in PBS and stained at 4°C with the following 
antibodies: anti-hum an CD4-APC, CD8-PE and Viaprobe (7-AAD) to 
exclude dead cells (BD Pharmingen, UK). The number of cells that had 
proliferated was determined by gating on the lineage-positive CFSE|0W 
subset. A fter normalisation fo r the cell input number the stimulation 
index (SI) was calculated using the following formula:
Number of CD4+ CFSEl0W cells w ith antigen 
Number of CD4+ CFSE|0W cells w ithout antigen
A SI > 2 was considered to represent a positive proliferative response, as 
previously defined (Mannering et a l ,  2003). The CD4 T-cell proliferative
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frequency (% ) was calculated only fo r those where the SI was positive, 
using the following form ula:
______________ Number of CD4+ CFSElow cplk_________________
(Number of CD4+ CFSE|0W cells + num ber of CD4+ CFSEhigh cells) xlOO
The final proliferative frequency (% ) was achieved by subtracting the 
proliferative frequency with antigen from  the proliferative frequency 
without antigen.
4 .3 .3  Virology:
A nalys is  o f  th e  v ira l e v o lu t io n  in  th e  a c u te  p hase  o f in fe c tio n :
To explore the evolution of the virus in the early phase of infection the 
core and E1/E2 regions of the HCV genome were sequenced from 
amplicons at d ifferent longitudinal tim e points. The serum was collected 
at the same tim e as the PBMCs and stored. These were then extracted, 
amplified, cloned and sequenced using the methods described in section 
2.3.2.
The average number of synonymous substitutions per synonymous site 
and the number of nonsynonymous substitutions per nonsynonymous 
site relative to the ancestral consensus sequence were calculated for 
each time point w ithin each individual using SNAP (Synonymous/Non- 
synonymous Analysis Program), which calculates dN/dS rates based on a 
set of codon-aligned nucleotide sequences using the methods of Nei and 
Gojobori (Nei & Gojobori, 1986). The consensus sequence of the first 
time point was used as a reference.
HCV evolution was studied by characterizing the quasispecies' diversity 
and complexity at each tim e-po in t. Genetic diversity, or the Hamming 
distance is defined as the number of amino acid differences between two 
sequences. The mean Hamming distance (that is, the average of the 
values taken for all sequence pairs derived from a single sample) was 
separately calculated using the form ula (1 - s) x 100, where s is the 
fraction of shared sites in two aligned nucleotide sequences (Ganeshan et
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al., 1997). The mean Hamming distance was separately calculated for the 
entire E1/E2 sequence, the HVR1 and the sequence outside the HVR1. 
The complexity of the HCV quasispecies is defined as the number and 
importance of viral variants based on the nucleotide sequence of the 
clones from a single sample.
The core region was analysed using direct sequencing of the same 
longitudinal samples. The reactions were the same as for the E1/E2 
region described in section 2.3.2. The primers used for the nested core 
PCR were:
Core primers (nucleotide position):
• HCVC1 (from nucleotides 62-42):
• HCVC2 (from nucleotides 1291-1269)
• HCVC3 (from nucleotides 51-29):
• HCVC4 (from nucleotides 1262-1243)
cttgtggtactgcctgatagg
cattgcagttcagggccgtgcta
gcctgatagggtgcttgcgagtg
tgccaactgccgttggtgtt
4 .3 .4  S tatis tical analysis:
Clinical parameters w ithin individuals were compared using paired t-tests. 
Differences between groups were determ ined using Student T-test, X2 
test or non-parametric test (Mann Whitney U) where appropriate. 
Statistics were performed using Prism V4 (Graphpad, USA).
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4.4 Results
4.4 .1  N atura l h is to ry  o f  c lin ical cohort:
The early natural history and host-vira l interactions were studied using 
the RFH cohort (n = 55) of co-infected patients. PBMCs were also available 
for comparison from an Ita lian cohort (n=8) of acute HCV mono­
infection. The patient param eters are outlined in Table 4.1. The co- 
infection group used fo r the immunological and virological studies were 
relatively comparable to  the entire co-infected cohort.
Following the diagnosis of HCV, co-infected patients were monitored for 
12 weeks to allow fo r spontaneous seroconversion before initiation of 
HCV combination treatm ent. The median tim e between diagnosis and 
treatment of HCV was 14 weeks. Only 3 (5% ) of the co-infected patients 
spontaneously cleared HCV, which is lower than rates (20-50% ) reported 
for acute HCV mono-infection. The clinical parameters of the individuals 
that spontaneously cleared HCV and those tha t developed persistent 
infection are outlined in Table 4.1. Given the small number of 
spontaneous clearers, a form al statistical analysis was not feasible.
The vast m ajority (95% ) of co-infected patients progressed to persistent 
infection. In teresting ly, the three individuals who cleared HCV 
spontaneously were all jaundiced during the ir acute illness. These 
individuals appeared to  have both higher peak ALT (2258 versus 366 
IU /m l) and CD4 counts (847 versus 549 cells/pl). In contrast, the 
majority of patients who developed persistent HCV were asymptomatic 
with only 3 (6% ) individuals becoming icteric. The m ajority of these 
patients were diagnosed as a result o f the detection of abnormal liver 
function tests. The ALT measurements of the entire cohort are plotted in 
Figure 4.2. Comparison of the co-infected patients with historical controls 
revealed tha t the co-infected patients had higher viral loads (6.0 versus
4.5 log IU /m l) (Gerlach e t a/., 2003) (Figure 4.3). The vast majority 
(95%) of the co-infected patients seroconverted to anti-HCV positive 
during the course of the ir infection.
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The interaction between HIV and HCV was explored by comparing the 
CD4, CD8 cell counts and HIV viral load before and after infection with 
HCV. These are outlined in Figures 4.4-4.6 . There was no significant 
change in the median CD4 and CD8 cell counts in patients on HAART pre- 
and post-HCV (465 versus 568 cells/p l, p=0 .91 / and 1108 versus 1073 
cells/pl, p=0.46, respectively). There was also no significant change in 
the median CD4 and CD8 counts in those not on HAART (518 versus 560 
cells/pl, p=0.44, and 1195 versus 1272 cells/pl, p=0.76, respectively). 
The HIV viral load in patients not on HAART did not change before and 
after HCV infection (4.6 versus 4.9 log copies/m l, p=0.82). The number 
of HIV 'blips', defined as a detectable HIV viral load of between 50-400 
copies/ml followed by a negative HIV viral load, were measured in those 
patients on HAART. In 18 individuals with available measurements there 
were 8 'b lips' found in seven patients between -103 days before HCV to 
+73 days post-HCV. Five (63% ) of the blips occurred between 57-103 
days before HCV infection. There were no reported HIV-related 
complications in the period following the diagnosis of HCV.
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T ab le  4 .1 :  C lin ica l p a ra m e te rs  o f  e n t ire  RFH c o -in fe c te d  and  
I ta l ia n  m o n o -in fe c te d  c o h o rts  a n a ly s e d  in n a tu ra l h is to ry  and  
im m u n o lo g ic a l s tu d y .
RFH cohort Outcome Immunological study
(RFH cohort) patients
Co-infected Persistent Self-limited Co-infected
(RFH)
Mono­
infected
(Italian)
Number (%) 55 (100) 52 (95 ) 3 ( 5 ) 14 8
Median age 35.6 35.3 35.8 35.2 32.5
(years) range (2 4 .9 -5 1 .1 ) (2 4 .9 -5 1 .1 ) (3 1 .2 -3 8 .7 ) (24.9-42.7) (24-76)
Sex male (%) 55 (100) 52 (10 0 ) 3 (100) 14 (100) 5 (63)
Median peak ALT 389 366 2258 427 1290
(range) (IU/ml) (3 6 -5 1 0 4 ) (3 6 -3 0 8 9 ) (1907-5104) (74 -5104) (354-1985)
Median HCV VL 6.0 5.9 6.4 6.3 5.3
(range) (3 -6 .9 ) (3 -6 .9 ) (6 .4 -6 .9 ) (4 .6 -6 .9 ) (4 .3 -6 .7 )
(log IU/ml)
Anti-HCV 52 (95 ) 49 (94 ) 3 (1 0 0 ) 14 (100) Not
seroconversion available
( % )
Genotype (non-1) 11 (20 ) 10 (18 ) 1 (33) 4 (2 9 ) 2 (2 5 )
(°/o)
Transmission Permucosal Permucosal Permucosal Permucosal Parenteral
Factor
Outcome - 3 (5) 0 ( 0 ) 3 (100) 2 (1 4 ) 3 (38)
resolved (%)
Icteric (%) 6 (1 0 ) 3 (6 ) 3 (1 0 0 ) 3 (2 1 ) 4 (5 0 )
Length of HIV 4.6 4.5 5.8 7.1 -
(years) (0 -1 8 .6 ) (0 -1 8 .6 ) (0 -1 0 .3 ) (0 -1 5 .5 )
Median CD4 count 554 549 847 628 -
(range) (cells/pl) (18 8 -1 7 0 5 ) (1 8 8 -1 7 0 5 ) (37 2 -1 283 ) (266-1283)
HIV viral load 4.6 4 .6 5.2 4.4 -
(log copies/ml) (2 .6 -5 .8 ) (2 .6 -5 .8 ) (2 .6 -5 .7 )
HAART (%) 35 (64 ) 33 (63 ) 2 (6 7 ) 9 (6 4 ) -
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Figure 4.2: Lowess spline curve of all ALT measurements (red) in 
patients with acute HCV related to days from diagnosis in 55 co- 
infected patients. ALT ULN = 40 IU /m l .
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Figure 4.3: Median HCV viral load ( IU /m l )  in co-infected patients 
(n = 55) with m ono-infected median viral load (broken blue line) 
from historical controls (n = 5 4 ) (Gerlach et al., 2003).
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Figure 4.4: Median CD4 and CD8 T-cell counts (ce lls /p l) pre-HCV 
( -194  to -54  days) and post-HCV ( -3 0  to + 2 6  days) in patients on 
HAART (n = 24).
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Figure 4.5: Median CD4 and CD8 T-cell counts (ce lls /p l) pre-HCV 
(-176  to -89 days) and post-HCV ( -1 2  to + 8 4  days) in patients not 
on HAART (n = 1 3 ) .
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Figure 4.6: Median H IV  viral load (log co p ies /m l) pre-HCV (-39 8  
to -96 days) and post-HCV (-1 4  to  + 1 0 1  days) in patients not on 
HAART (n = l l ) .
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4 .4 .2  C ell-m ediated  responses:
Cell-mediated responses were assessed using PBMCs collected from the 
co-infected and mono-infected patients. A total of 14 co-infected and 8 
mono-infected patients had PBMCs available fo r analysis. A further two 
patients (patients 15 and 16) had serum that was analysed for viral 
evolution. The clinical parameters of each group are outlined in Table 4.1 
and individual patient characteristics in Table 4.2. The mono-infected 
(controls) and co-infected (cases) were distinct groups. They had 
different routes of HCV acquisition, with the cases acquiring HCV 
permucosally, as described in chapter 3, compared to the Italian controls 
who were infected parenterally. The mono-infected controls were Italian 
hospitalised patients w ith apparently more liver inflammation, although 
this was not significant on comparison of the median ALT between 
controls and cases (1290 versus 427 IU /m l, p=0.79 by Mann-Whitney U 
test). The median HCV viral load was lower in the mono-infected controls 
(5.3 versus 6.0 log IU /m l). In addition, the controls included women 
(n=3). Overall, the spontaneous clearance rate of controls was 
significantly higher than the co-infected patients (37.5%  versus 5%, 
p=0.004).
Cellular immune responses were detectable in some co-infected 
individuals. Comparative examples are given of a mono-infected patient 
and two co-infected patients relating longitudinal viral load, ALT and cell- 
mediated immune responses (ELISpots and CFSE assays) (Figure 4.7).
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T ab le  4 .2 :  C h arac te ris tics  o f in d iv id u a ls  in th e  im m u n o lo g ica l and  v iro lo g ica l s tu d ies . T h e  p a tie n t n u m b ers  a re  
used co n s is ten tly  th ro u g h  th e  ch a p te r.
P a rt A - C o -in fec ted  in d iv id u a ls .
Co-
infected
Patient
Age Symptomatic(Icteric)
HCV
Genotype
HCV
viral
load
(log
IU /m l)
Peak ALT 
( IU /m l)
CD4
(cells/pl)
On HAART 
at
diagnosis
Outcome
(Clear)
Days between peak 
ALT and PBMC 
collection
1 42.7 No 1 6.1 235 362 Yes No 46
2 34.8 Yes 1 6.9 1504 821 Yes No 19
3 32.8 No 1 4.6 2428 712 No No 16
4 35.8 Yes 3a 6.4 5104 847 Yes Yes 2
5 30.6 No 1 6.4 74 544 No No 27
6 31.5 Yes 1 6.9 2258 1283 Yes Yes 129
7 31.2 No 3a 6.3 389 437 Yes No 70
8 37.0 No 1 6.0 349 530 Yes No 15
9 37.5 No 1 5.2 498 266 Yes No 1
10 29.7 No 1 6.3 272 844 No No -5
11 42.5 No 3a 6.7 465 862 Yes No 13
12 24.9 No 1 6.3 384 427 No No -1
13 39.5 Yes 1 6.9 1415 337 Yes No 7
14 35.6 No 4 5.8 89 966 Yes No 76
15 32.0 No 1 6.0 412 740 No No NA
16 34.7 No 1 6.9 2282 1008 yes No NA
Part B- Mono-infected individuals.
Mono­
infected
Patient
Age Sex
Symptomatic
(Icteric)
HCV Genotype
HCV viral 
load (log 
IU /m l)
Peak Al
1 42 M yes la 5.1 1
2 24 M yes lb 5.0 3
3 32 M yes 3a 6.6 3
4 26 F no la 5.5
5 62 M yes 2 4.3 3
6 76 F no lb 6.7
7 33 M no lb ? 3
8 25 F no la ? 3
Fig 4.7: Examples of longitudinal HCV viral load, ALT and cell- 
mediated im m une responses in acute HCV mono-infection and 
H C V /H IV  co-infection.
Example 1 is a mono-infected patient who spontaneously cleared HCV. 
Example 2 is a co-infected patient who had early CD4 responses with 
relative virological control. Example 3 is a co-infected patient with no 
detectable cellular responses and uncontrolled viraemia. Both co-infected 
patients developed persistent HCV infection.
Example 1 Example 2 Example 3
1--------- 1------““ T
CFSE NS 3 6
f t 1 T
i
1
f
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Comparison of IFN-y ELISpots revealed significant differences between 
the cases and controls (Figure 4 .8 ). Unfortunately due to the poor yield 
of PBMCs following freezing and storage, the PBMCs were incubated in 
most cases against pooled core peptides and pooled non-structual 
proteins 3-5. In the final analysis, 14 co-infected individuals were 
compared to 8 mono-infected individuals at the firs t available time-point. 
While more mono-infected PBMCs reacted to the core peptides compared 
with the co-infected individuals th is  was not significant (75% versus 
36%, p=0.18). In contrast, significantly more mono-infected individuals 
had IFN-y responses to the NS3-5 proteins than co-infected individuals 
(75% versus 14%, p=0.008). There was no significant difference in the 
median magnitude of m ono-infected and co-infected individuals to pooled 
core peptides (65 versus 0 SFC/106, p=0.13). However, there was a 
trend to stronger median responses to the pooled NS 3-5 proteins in the 
mono-infected patients compared to  the co-infected patients (35 versus 0 
SFC/106, p=0.06). The individual ELISpot results are outlined in Table 4.3.
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Tab le  4 .3 :  IF N -y  E L IS p o t re s p o n s e s  (S F C /1 0 6) fo r  in d iv id u a l 
p a tie n ts .
Gives the SFC/106 PBMCs fo r each mono-infected or co-infected individual 
for pooled core peptides and NS3-5 proteins.
Co-infected
Patient Core (1 -4 ) NS 3-5
Mono-infected 
Patients Core (1-4) NS 3-5
1 0 0 1 110 35
2 50 300 2 70 0
3 0 0 3 60 20
4 0 0 4 195 150
5 0 0 5 0 0
6 0 0 6 25 170
7 0 0 7 75 35
8 0 0 8 0 150
9 0 0
10 0 0
11 245 327
12 28 0
13 60 0
14 130 0
Median 0 (0-245) 0 (0 -323 ) 65 (0-195) 35 (0-170)
(range)
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Figure 4.8: Comparison of percentage IFN-y ELISpot responses in 
acute HCV in m ono-infected and co-infected individuals.
Comparison of percentage of mono-infected (n=8) and co-infected 
(n = 14) individuals with IFN-y responses to pooled core peptides by 
Fisher's exact test. The lower bar graph presents the IFN-y responses to 
the pooled NS3-5 proteins in the same individuals. The mono-infected 
patients are in blue and co-infected patients are in red.
Core P1-4
P=0.18
Mono-Infection
(n=8)
Co-Infection
(n=14)
NS3-5
P=0.008
Mono-Infection Co-Infection 
(n=8) (n=14)
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CFSE assays have previously been demonstrated to be sensitive for the 
detection of responses to HCV antigens. Figure 4.9 is an example of CFSE 
assays in a mono-infected and co-infected individual demonstrating 
responses. The proliferative assays using CFSE analysed 11 co-infected 
patients and 6 mono-infected patients. Sim ilar to the ELISpot assays, 
the poor yield of PBMCs led to the core peptides and NS3-5 proteins 
being pooled for the incubation w ith antigens. There was no significant 
difference in CD4 T-cell proliferation to core between the co-infected and 
mono-infected individuals (14%  versus 17%, p=0.94). There appeared to 
be a trend to more proliferation to NS3-5 in the mono-infected versus the 
co-infected individuals, although this was not significantly different (50% 
versus 9%, p=0.1). These results are outlined in Figure 4.10. There was 
no significant difference in the median percentage proliferation between 
co-infected and mono-infected individuals with respect to core peptides 
and non-structural proteins (0 versus 0, p = 1.0; 0 versus 1.35, p=0.24, 
respectively). The individual CFSE percent responses are outlined in 
Table 4.4.
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T ab le  4 .4 :  CFSE re s p o n s e s  ( % )  fo r  in d iv id u a l p a tie n ts .
Gives the percentage of CD4 proliferation of PBMCs for each mono­
infected or co-infected individual fo r pooled core peptides and NS3-5 
proteins.
Co-infected
Patient Core (1 -4 ) NS 3-5
Mono-infected
Patient Core (1-4) NS 3-5
1 0 0 2 0 2.7
2 5.3 67 3 0 0
3 0 0 4 0 31
4 0 0 5 0 0
5 0 0 6 0 0
6 0 0 7 5 28.6
7 1.2 0
8 0 0
9 0 0
10 0 0
11 0 0
Median 0 (0-5.3) 0 (0 -6 7 ) 0 (0-5) 1.35 (0-31)
(range)
NS3-5
Co-infected
individualNeg
Mono-infected 
individual
0 .1%
31%
1.7%
CFSE
Figure 4 .9 :  C D 4 T -c e ll p ro l ife r a t iv e  resp o n ses  d e te c te d  in th e  
CFSE assay.
This shows the proliferative responses for a co-infected and mono­
infected individual, w ith a negative control.
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Figure 4 .1 0 : Comparison of percentage CFSE proliferative
responses in acute HCV in m ono-infected and co-infected 
individuals.
Comparison o f percentage of mono-infected (n=6) and co-infected 
( n = l l )  individuals with CFSE responses to pooled core peptides by 
Fisher's exact tes t. The lower bar graph presents the CFSE responses to 
the pooled NS3-5 proteins in the same individuals. The mono-infected in 
blue and co-infected in red.
100-,
90-
Core P1-4
P=0.94
Q. 20- 
10 -
0
Mono-Infection Co-Infection
(n=6) (n=11)
100-,
90-
NS3-5
Mono-Infection Co-Infection 
(n=6) (n=11)
153
4.4 .3  Virology:
Viral evolution was studied in number of different ways. As the majority 
of detectable CD4 T-cell responses in the co-infected patients were to 
core peptides, this region was sequenced. A neighbour joining (NJ) 
phylogenetic tree of the direct sequences from the longitudinal samples 
was constructed (Figure 4.11). This revealed very little diversity, which 
would be expected as this is a relatively conserved region. The median 
time (range) in days between the longitudinal samples within each 
individual was 52 (17-144).
Patient 13 TP 2 
Patient 13 TP 1 
Patient 2 TP 2 
Patient 2 TP 1 
Patient 10 TP 3 
Patient 5 TP 3 
Patient 5 TP 2 
i- Patient 5 TP 1 
I Patient 10 TP 1 
'Patient 10 TP 2
|------------------------------------------------------------------------------------  i Patient 12T P2 Genotype 1
'Patient 12 TP 1
_______ I Patient 8 TP 2
'Patient 8TP 1 
L  rPatient 16 TP3
  Patient 9 TP 2
Patient 9 TP 1 
Patient 16 TP 2 
Patient 16 TP 1
________________________   | Pa,i®nt 7 TP 2 Genotype 3a
'Patient 7TP 1
8% 6% 4% 2% 0%
Figure 4.11: Reconstructed phylogenetic tree of the core region 
from two or more tim e-po in ts  (TP) in co-infected individuals 
(n = 9).
Branch length is % difference in nucleotide sequence.
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Patient 16 TP 2 
Patient 16 TP 3 
Patient 16 TP 1 
Patient 10TP1 
Patient 10 TP 2
Patient 2 TP 2
Patient 8 TP 1 
Patient 8 TP 1
Patient 9 TP 3 
Patient 12 TP 2 
Patient 12 TP 1
Patient 9 TP 1 
Patient 2 TP 3 
Patient 9 TP 2 
Patient 2 TP 1 
Patient 13 TP 1 
Patient 13 TP 2
Patient 15 TP 1 
Patient 15 TP 2
0.05
Figure 4.12: Reconstructed phylogenetic tree  of the consensus 
clone of E 1 /E 2  region from  tw o or more tim e-points (TP) in co- 
infected individuals (n = 8 ).
The E1/E2 region of the HCV genome was evaluated in more detail using 
cloned sequences. Figure 4.12 is the reconstructed NJ tree of the 
consensus sequences from each individual's time-points. This reveals 
more genetic diversity between the samples than the core region. A total 
of 175 cloned sequences from 2-3 tim e-points from 8 individuals were 
analysed. The tim e-points studied ranged from 42 days before to 103 
days after the peak ALT. The mean number of clones per time-point was 
9.2. Each individual's tim e-points are outlined in Table 4.5.
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Table 4 .5: Longitudinal HCV evolution in co-infected patients in early  phase of infection.
Patient
Time-
point
Peak
ALT
(IU/ml)
Days
from
peak
ALT
Closest 
HCV viral 
load (log 
IU/ml)
Days
from
HCV
viral
load
Number
of
clones
dN/dS
E1/E2
dN/dS
HVR1
dN/dS
outside
HVR1
Number 
of HCV 
variants
Mean 
Hamming 
distance % 
(SD)
P-
value**
2 1 1504 -1 6.89 -2 10 0.23 0 0.22 5 0.32 (0.32)
2 33 2.79* -17 8 0.69 4.54 0.23 8 2.43 (1.23) <0.0001
3 61 2.79* 11 8 0.24 0.33 0.21 9 2.51 (2.67) 0.47
8 1 249 23 5.95* 14 9 0.64 0 999" 5 0.64 (0.51)
2 40 5.95* 31 10 0 0 999" 3 0.46 (0.70) 0.04
9 1 498 -23 2.79 -35 6 0 0 0 1 0 (0 )
2 30 2.98* -38 4 0.16 4.55 0.23 4 1.52 (0.51) <0.02“
3 76 2.98* 8 10 0.15 0.21 0 10 16.81 (13.88) <0.0001
10 1 272 -42 6.34* -105 11 0.59 3.84 0.51 10 5.12 (4.75)
2 102 6.34* 39 10 0.17 0.18 0.15 9 0.55 (0.37) <0.0001
12 1 384 -27 6.28 33 11 0.67 999" 0.51 4 1.04 (0.88)
2 103 5.83 -1 12 0.31 999" 1 7 0.58 (0.88) 0.02
13 1 1415 0 6.89 -1 9 0.26 0.71 0.20 7 0.49 (0.30)
2 52 5.46 2 7 0.30 999" 0.30 5 2.48 (2.28) <0.0001
15 1 412 48 6.0* 0 12 0 0 999" 2 0.32 (0.30)
2 101 6.0* 53 12 0.13 999" 0.14 10 18.63 (16.39) <0.0001
16 1 2282 -21 6.89* -1 8 0.31 0.39 0.32 4 0.72 (0.75)
2 0 6.89* 20 8 0.39 0 0.37 5 1.28 (0.86) 0.004
3 52 2.56 8 10 0.22 0.20 0.17 9 4.68 (6.97) 0.42
^signifies same HCV viral load measurement for different time-points within the same patient; “signifies upper limit of calculation; **p-values for pairwise Hamming 
distance to previous time-point; u uses Wilcoxon Sign Rank test; both dN/dS and Hamming distances rounded to two decimal points.
The ratio of non-synonymous to  synonymous nucleotide changes (dN/dS) 
was calculated fo r each tim e-po in t from  each individual. A dN/dS ratio of 
greater than 1 is evidence fo r immune selection pressure resulting in viral 
mutation. The overall E1/E2 dN/dS ratios were all (100% ) less than 1, 
which is strong evidence against significant immune selection pressure 
directed against this region leading to viral mutation. There was no 
significant difference between the mean dN/dS ratios inside or outside 
the HVR1 (211 versus 158, p=0.35). The dN/dS ratios are listed in Table
4.5. There was no correlation between the dN/dS ratio and HCV viral 
load, time from peak ALT, CD4 ELISpot responses or HIV parameters.
The diversity and com plexity of HCV quasispecies were characterised for 
each individual's tim e-poin ts. D iversity was determined by calculating the 
Hamming (genetic) distance, which is the difference between two 
sequences. Complexity relates to the number and importance of the viral 
variants at each tim e-po in t. The mean Hamming distance was calculated 
by performing a pairwise comparison of every clone's amino acid 
sequence for each individual tim e-poin t. The results are outlined in Table
4.5. The Hamming distances ranged from 0-18.63% . There was a 
significant increase in the median genetic distance from the 0.57% at the 
first tim e-point to 2.43%  fo r the subsequent tim e-points, p=0.04. Seven 
patients had an initial genetic d iversity o f less than or equal to 1%. In 
five patients there was an increase in genetic diversity over time, while 
three patients had a decrease in viral diversity over time. The Hamming 
distances are graphically represented in Figure 4.13. These did not 
correlate with peak ALT, CD4 count or HCV viral load. The number of HCV 
variants at each tim e-po in t was determ ined by comparing the nucleotide 
sequence of clones from the same sample. These are outlined in Table 
4.5 and Figure 4.14. There was a trend to an increase in the 
quasispecies' com plexity, from a median of 4.5 variants at the first time- 
point to a median of 8 variants at subsequent time-points, p=0.1. In 
combination with the low dN/dS ratios (< 1 ) fo r the same region, the 
quasispecies data suggests tha t the viral evolution of this region is the 
result of random m utation associated with error-prone viral replication
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rather than specific immune selection pressure, which is consistent with 
the lack of cell-mediated responses.
Finally, the specific site of nucleotide and amino acid substitutions was 
determined. These are represented in Figures 4.15 and 4.16. Many of the 
areas with the most change (a rb itra rily  >2 non-synonymous changes per 
site) are in recognised HCV epitopes as summarised on Los Alamos HCV 
immunology database (Yusim et a l.f 2005). Cytotoxic T-lymphocytes 
epitope sites included in the substitutions are: AA336, 399-404, 408/412, 
460 and 500/501. Changes in recognised antibody epitopes are: AA396- 
404, 408/412, 434-442 and 483, although antibody responses were not 
studied as part of th is thesis. Sites tha t were not in recognised epitopes 
included: AA342, 344, 473, 475, 477, 481.
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Fig 4.13: Longitudinal m ean Ham m ing distance of entire E 1/E2  
sequence related to days from  peak ALT for each patient.
The patients with increasing Hamming distance ove rtim e  are in red and 
those with reducing Hamming distance o ve rtim e  are in blue.
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Fig 4.14: Num ber of HCV variants at each tim e-po in t in each 
individual (n = 8 ).
Each colour represents a d ifferent variant w ithin that individual at that 
time-point. The same colour does not represent the same variant 
between different tim e-poin ts or individuals.
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Figure 4.15: Synonymous and non-synonymous nucleotide
changes by site in E l and HVR1 regions of HCV.
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Figure 4.16: Synonymous and non-synonymous nucleotide
changes by site in E2 region of HCV.
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4.5 Discussion
This cohort has presented a unique opportunity to study the early natural 
history of HCV in HIV-positive individuals. The data presented in this 
chapter indicate tha t the early natural history of acute HCV in HIV co- 
infection is different from  acute HCV mono-infection. The major 
difference was the higher rate of persistence in the co-infected patients. 
This chapter set out to explore why HIV co-infected patients have higher 
rates of HCV persistence by studying the immunological and virological 
responses in acute disease. However, studies of clinical cohorts have a 
number of lim itations tha t need to be discussed.
4.5 .1  Lim itations:
As with the study of other re latively rare conditions, the numbers were 
small. While the number of cases of HCV in HIV-positive individuals is 
increasing, acute HCV m ono-infection is rarely recognised. Consequently, 
the identification of controls was d ifficu lt, particularly for clinical 
comparison. Fortunately, PBMC samples were available from an Italian 
cohort for the cellular assays. However, there were significant differences 
between the mono-infected and co-infected groups. The co-infected 
group was a predom inantly outpatient UK cohort, w ith a broad clinical 
spectrum of HCV ranging from  an acute icteric hepatitis to asymptomatic 
disease and a spontaneous clearance rate of 5%. In contrast, the mono­
infected controls were hospitalised Ita lian patients; the m ajority were 
jaundiced, with a spontaneous eradication rate of 37.5%. In addition the 
transmission routes were different. Both cohorts were patients 
undergoing routine care and as a result, the collection of specimens and 
data in some cases was incomplete. Therefore, direct comparisons were 
difficult and the interpretation of the immune responses needs to be 
cautious. In neither group were the cellular immune responses correlated 
to outcome, but this probably relates to the small number of individuals 
studied. In an effort to standardise the analysis, immune responses were 
related to peak ALT. A larger number of co-infected individuals that 
spontaneously cleared HCV and mono-infected controls would have 
allowed analysis related to outcome to be performed.
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The quality of the PBMCs was poor in many of the samples and as a 
result, the yield of lymphocytes was small. The assays were performed 
on frozen PBMCs tha t had been prepared and stored using standard 
cryopreservation techniques, which have been validated (Valeri & 
Pivacek, 1996). However, there is evidence that frozen samples may 
have different responses and cytokine secretion compared with fresh 
PBMCs. I t  has been demonstrated tha t cryopreservation of PBMCs can 
increase certain cytokine production, such as IFN-y and IL-2, and T-cell 
viability may be reduced compared w ith fresh PBMCs (Venkataraman & 
Westerman, 1986; Venkataram an, 1995). This may then have had an 
effect on our lymphocyte assays. However, while collected at different 
centres, the method of collection and storage was the same for both 
groups. Finally, because the number of PBMCs and samples were limited 
and assays could not be repeated to  check variability. Inter-assay 
variability could have been magnified, particularly in the co-infected 
cohort where the magnitude of PBMC responses was low. For this reason, 
the percentage w ith responses ra ther than the specific magnitude of 
responses was used fo r the statistical comparison of co-infected and 
mono-infected individuals.
An important concept is the compartmentalisation of the immune 
response. This study analysed peripheral PBMCs and there is probably 
discordance between the liver and peripheral blood responses due to the 
different tropism of lymphocytes. Minutello and colleagues described the 
differences in CD4 responses to HCV antigens between intra-hepatic and 
peripheral lymphocytes (M inutello et at., 1993). They found that a 
distinct subset of CD4 T-cells focused against NS4 antigen was found in 
the liver but not peripherally. Nuti et al. found tha t activated intrahepatic 
T-cells are biased towards a T-helper 1 response (Nuti et a!., 1998). 
However, in the acute state the lack of access to liver tissue has meant 
that these studies have not been repeated. While peripheral responses 
are often studied these may not reflect the true responses in the liver.
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Finally, issues related to  the experiments could have influenced the 
results. Genotypic varia tions may alter the cellular responses to 
recombinant proteins. The cellular responses were tested using specific 
genotype 1 recombinant proteins and peptides fo r the ELISpot and CFSE 
assays. Unfortunately, specific non-genotype 1 recombinant proteins and 
peptides were not available. Of the co-infected cohort 29% versus 25% 
of the mono-infected cohort were non-genotype 1. This may have been a 
factor explaining some of the poor responses seen, specifically patient 4 
who cleared genotype 3 HCV but did not develop any detectable CD4 T- 
cell responses. However, both groups had a sim ilar distribution of non­
genotype 1 HCV. Due to the small number of samples, it was not possible 
to assess if there was a statistical difference in the responses of 
genotypes 1 and non-1.
4 .5 .2  D etailed  discussion:
Persistence is the most common outcome of HCV infection. The rate of 
persistence in HIV co-infection (95% ) was significantly higher than the 
Italian mono-infected controls (62% ) and reported historical controls (60- 
80%). This is im portant as it suggests tha t concurrent HIV infection 
favours HCV persistence. Our persistence rate of 95% contrasts with a 
rate of 76% in a s im ilar cohort (n = 50) of HIV-positive MSM with acute 
HCV from another London teaching hospital (CWH). Gilleece and 
colleagues reported a 24% spontaneous clearance rate, associate with 
higher CD4 counts and lower initia l HCV viral loads (Gilleece et a!., 2005). 
They reported HCV RNA results over a median of 14 months follow-up, 
the shortest period was one m onth. I t  is possible that a proportion with 
shorter follow-up may actually have had undetectable but persistent 
viraemia, especially w ith the less sensitive older assays (lower lim it of 
detection= 615 IU /m l). In the largest study of the natural history of 
acute HCV mono-infection, Gerlach and colleagues reported tha t males 
and patients who were not sym ptom atic were significantly less likely to 
spontaneously clear HCV (Gerlach et a!., 2003). All the patients in our co- 
infected cohort were male and the vast m ajority (90% ) were 
asymptomatic, which would favour persistence. Those who cleared HCV 
were all jaundiced and had higher median CD4 counts. The Italian cohort
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would appear to be much more typical o f previously described mono­
infected groups. The be tter rates o f clearance in the mono-infected 
patients may represent a selection bias, as symptomatic individuals are 
probably more likely to clear HCV and present to medical care. However, 
it is also likely tha t specific immunological issues related to the host-viral 
interaction in the co-infected individuals contribute to increase rates of 
persistence.
Given the small numbers in the control group, detailed comparison of 
specific clinical parameters was d ifficu lt. However, it appeared that the 
median HCV viral load was higher by approximately 1 log IU /m l and 
median ALT was lower than both the Ita lian and historical mono-infected 
controls. This would imply poorer control of HCV in the HIV infected 
individual with higher viral replication. The hepatitic lesion in HCV is 
usually immune-mediated and the apparent paradox of accelerated liver 
injury in an immunodeficient state has not been explained. However, it is 
likely tha t the higher HCV vira l loads contribute to this.
With respect to the influence of HCV on HIV parameters some 
observations were made. There were no adverse clinical events related to 
HIV reported during the study period. There appeared to be no short­
term impact of HCV on the CD4/CD8 T-cell counts, with no change before 
or after HCV infection. However, there is a suggestion tha t the HIV viral 
'blips' may occur around the tim e o f infection in those on HAART. There 
were 8 'blips' in seven (39% ) patients over a relatively short period of 
time (260 days). One study detected 27.2%  of patients had an HIV 'b lip ' 
over a median of 485 days fo llow-up (Sklar et al., 2002). The implication 
of HIV viral 'b lips ' is controversial, however it appears that they probably 
do not lead to increased HIV resistance (Nettles et al., 2005). I t  may be 
that the more frequent 'b lips ' in our study represents an early viral 
interaction between HIV and HCV, however, this would require a detailed 
study of the viral kinetics and evolution of both viruses that was not 
performed as part of this thesis. While long-term the influence of HCV on 
HIV remains controversial, it is d ifficu lt to relate findings in the acute 
phase to the long-term  picture.
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Cell-mediated immune responses to HCV are detectable in the early 
phase of infection in co-infected individuals. However, these responses 
lacked the breadth and magnitude tha t is probably necessary for control 
of acute HCV, which may explain the higher rate of viral persistence in 
this cohort. The responses of the co-infected individuals were focused 
against core but not the NS3-5 proteins. I t  has been shown that 
responses to the non-structural proteins are particularly im portant for the 
clearance of HCV (Diepolder et al., 1995). Our data reveal that the defect 
in cell-mediated im m unity occurs early in the course of HCV infection. 
Failure to develop a vigorous, multispecific and persistent cell mediated 
response is postulated to occur as a result of primary T-cell 
failure/exhaustion, T-cell dysfunction, and viral escape mutation 
(Neumann-Haefelin et al., 2005). While any of these mechanisms is 
possible in HIV co-infection, it was beyond the scope of this study to 
explore the specific reasons for this. However, evidence in HCV mono­
infection suggests tha t both primary T-cell failure and T-cell exhaustion 
play a role in failure to control the infection. Studies have shown that 
patients developing chronic infection have weak responses of the CD4 
and CD8 T-cells in the acute phase. Im portantly, if these responses were 
not maintained then persistence developed, which would support the 
hypothesis of CD4 T-cell exhaustion (Gerlach et al., 1999). Furthermore, 
Thimme and colleagues found tha t in health care workers exposed to 
HCV, patients with no significant cell-mediated responses to HCV 
developed persistent infection, suggesting primary T-cell failure (Thimme 
et al., 2001). The underlying mechanisms for this are unclear but it has 
been hypothesised that HCV may in terfer with antigen presenting cells 
(APC) resulting in a failure to prime the T-cells (Sarobe et al., 2002). I t  
has also been suggested that high HCV viral loads may contribute to 
deletion of virus-specific T cells, potentially an im portant reason in co- 
infection where the HCV viral loads are generally higher (Neumann- 
Haefelin et al., 2005).
CD8 T-cell responses were not studied as part of this thesis, however, 
CD8 T-cell dysfunction has also been shown to be important in persistent
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HCV (Lechner et al., 2000; Wedemeyer et al., 2002). The defect can be 
in the ir proliferative, cytotoxicity or cytokine secretion capacity. Early 
recovery of responses led to control of viraemia, while lack of responses 
resulted in persistent disease (Thimme e ta /., 2001). High viral loads may 
lead to T-cell unresponsiveness. This has been shown in murine models 
where CD8 T-cell fail to produce I F N - y  after antigenic stimulation (Zajac 
et al., 1998). T-cell responses have been shown to increase on 
combination interferon and ribavirin treatm ent (Barnes et a/., 2002). I t  
has been suggested tha t impaired T-cell maturation may be important. 
Study of CD8 T-cell surface markers has revealed less differentiated 
phenotypes (CD28+ and/or CD27+) (Appay et a/., 2002). Functionally, 
the production of I F N - y  by CD8 T-cells is initially impaired. Viral factors, 
such as HCV core antigen, may also interrupt cytokine pathways and 
impair T-cell activation, proliferation and I F N - y  production. Finally, it has 
been suggested tha t regulatory (CD4+/CD25+) T-cells suppress I F N - y  
production in CD8 T-cells in chronically infected patients (Accapezzato e t 
a/., 2004). A combination of these mechanisms may contribute to T-cell 
dysfunction contributing to persistent infection. This is an area that 
should be a focus for future immunological work.
The replication of HCV is rapid and error prone and has been shown to 
play an im portant role in the evasion of host immune responses. 
However, the HCV quasispecies' complexity (the number of viral variants 
and the ir importance) and diversity (genetic distance) in HIV has only 
been studied in the chronic state and the data are conflicting. In a study 
of the effect of early HIV on chronic HCV, 10 patients with chronic HCV 
and newly acquired HIV had analysis of HCV diversity determined before 
and after HIV acquisition (Mao et al., 2001). While the results were not 
statistically significant there was a tendency to lower dN/dS ratios 
supporting reduced immune pressure; this was more pronounced in HIV 
rapid progressors. Sherman et al. found the diversity of the HVR1 of E2 
had increased diversity in HIV co-infected (n = 10) patients than HCV 
mono-infected (n = 7) patients (Sherman e t al., 1996). I f  CD4 counts 
were <50 cells/pl the HCV com plexity did not vary between mono­
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infected and co-infected patients (Toyoda et al., 1997). In a Spanish 
study, w ith two samples analysed over a three year follow-up period, 
HCV quasispecies com plexity in the E2 region was increased in co- 
infected patients (Roque-Afonso et al., 2002). A study of 52 patients with 
co-infection to assess whether HCV diversity impacted treatm ent 
outcome, found no difference between co-infected and mono-infected 
HCV viral d iversity (Neau et al., 2003).
Early genetic diversity of HCV arises e ither from inoculation with multiple 
HCV variants, PCR reaction (taq polymerase) errors and/or post- 
infectious viral m utation. Herring and colleagues proposed that a genetic 
diversity of less than 3% supports an oligoclonal inoculum of HCV, 
assuming tha t taq polymerase errors may produce a 1% change and the 
nucleotide substitution rate of the E1/E2 region may produce a 0.47% 
change over 20 days (Herring et al., 2005). In our study of eight 
individuals, seven (88% ) had a genetic diversity of <. 1% at the ir first 
tim e-poin t, suggesting tha t these patients were infected with a small 
number of HCV virions.
The longitudinal quasispecies analysis revealed tha t there was a 
significant increase in HCV diversity and a trend to increased complexity 
over tim e. However, fo r the same region the dN/dS ratios remained low 
(< 1 ). This implies tha t while HCV evolution occurred over time it was not 
driven by immune selection pressure but more likely was the result of 
error prone replication. This is entirely consistent with the lack of immune 
response as demonstrated by the poor cell-mediated immune responses, 
which probably results in the inadequate control of HCV. The CD4 T-cell 
responses elicited in the co-infected patients were primarily against the 
core peptides. Despite this, there appeared to be no significant in tra­
individual change in the core region over time. I t  would be important fo r 
future work to explore the humoral responses in co-infected individuals.
The data presented reveal tha t HIV co-infection has a significant impact 
on the clinical, immunological and virological outcome of early HCV. Co- 
infected patients have significantly higher HCV persistence rates following
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acute HCV. While there was no influence of HCV on objective HIV 
parameters such as CD4/CD8 cell counts and HIV viral load, the median 
HCV viral load was higher in the co-infected cohort. The detectable cell- 
mediated responses in the co-infected individuals lacked the breadth and 
magnitude tha t is probably required to control HCV. While the reason has 
not been elucidated, th is defect was demonstrated early in co-infection. 
This also emphasises the importance of CD4 T-cells in the control of HCV. 
Finally, analysis of viral evolution reveals tha t there is little evidence for 
mutation as a result of immune selection pressure, which is consistent 
with the poor cell-mediated responses described. Future work should 
focus on specific mechanisms of th is early defect, further detailing the 
host-virus interactions. HIV/HCV co-infection represents a m ajor clinical 
issue and one where simple immunologic data in well-defined cohorts 
could provide im portant fu ture insights.
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Chapter 5: Conclusions, Recommendations
and Future Work
5.1 Discussion
Since the identification of the hepatitis C virus in 1989, HCV infection and 
the associated liver-related m orbidity and m orta lity, has been recognised 
as a worldwide pandemic. The Health Protection Agency recently 
addressed the issue of HCV in its report "Hepatitis C in England" (Health 
Protection Agency, 2005a). The focus of this report was on HCV mono­
infection, particularly in IVDUs. However, an im portant subgroup are 
those individuals co-infected w ith HIV. The WHO estimates that 10 million 
people are co-infected worldwide. In the UK approximately 10% of HIV 
patients also have HCV. This is im portant not only because of the burden 
of infection but because of the accelerated course of HCV in HIV co- 
infection. Since the introduction of effective HIV treatments, there has 
been an unmasking of HCV-related m orbidity and m ortality and HCV is 
now a leading cause of death in HIV infected individuals in the developed 
world.
I t  is d ifficult to recognise acute hepatitis C, as the acute infection is often 
asymptomatic. While acute HCV can rarely be recognised clinically it has 
been increasingly diagnosed via surveillance and seroconversion amongst 
HIV-positive individuals in the UK, particularly in London and Brighton. 
Based on the most recent numbers of cases of acute HCV from each of 
the clinics participating in this study (RFH n=55, CWH n=85, and BSGH 
n = 22), more than 1% of these clinics' patient populations have become 
infected with HCV over the study period. This thesis explored two distinct 
aspects of the epidemic. First, the epidemiology was characterised using 
combined molecular (phylogenetic) and clinical (case-control) studies. 
Second, the natural history, cell-mediated responses and viral evolution 
of acute HCV in HIV were described. These studies reveal that acute HCV 
in HIV-positive individuals differs significantly from acute HCV mono­
infection in its epidemiology, natural history, immunology and virology.
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The key conclusions, resulting recommendations and future areas of 
research are discussed.
5.2 Epidemiological aspects
K ey con c lu s io n s :
The epidemiological analyses confirmed that HCV transmission is 
occurring w ithin the HIV-positive MSM population as a result of 
permucosal risk factors. The multiple clusters identified by the 
phylogenetic study of the HCV genome provide strong evidence for 
common source transm ission. Each monophyletic cluster, except the 
genotype 3a cluster, was composed of sequences from at least two of the 
participating centres, supporting transmission between patients from 
geographically d istinct HIV units. This implies tha t any intervention needs 
to include an appropriately broad scope to encompass the at-risk 
population. Finally, the application of a molecular clock to the individual 
clusters suggests tha t the m ajority o f the sequence divergence, equating 
to transmission events, had occurred after the mid-1990s, which 
coincides w ith the introduction of effective HIV treatments. The 
introduction of HAART was associated with an increase in high-risk sexual 
behaviours in MSM. The fact tha t these molecular clusters crossed both 
HCV genotype and subtype, implies tha t the HCV transmission is not due 
to a specific viral change, such as the development of a more virulent 
strain, but tha t patient and/o r environmental factors are contributing to 
the recent infections. The case-control study demonstrated distinct 
differences in risk behaviours between cases and controls, with 
permucosal rather than parenteral factors associated with the recent 
transmission of HCV in th is cohort of patients. These factors include high- 
risk mucosally traum atic sexual and drug practices. I t  should be 
reiterated tha t the control group also had significant risk behaviours. This 
is strikingly d ifferent from the usual epidemiology of acute HCV, where 
the m ajority of HCV is transm itted parenterally via IVDU.
172
R e c o m m e n d a tio n s :
The epidemiologic studies have im portant implications fo r interventions to 
m itigate and control the spread of HCV within the HIV-positive 
population. Given the evidence fo r transmission of HCV, early detection is 
vital. First, there needs to be enhanced surveillance of HCV within this 
population. The three centres involved in the study treat between 30- 
40% of the estimated 22 000 HIV patients in this region. These centres 
introduced annual screening fo r anti-HCV in 2002, following the 
recognition of increased HCV diagnoses. However, this process should be 
expanded to other HIV units. At present the collection of epidemiological 
data has been piecemeal, relying on individual units. I t  is clear that other 
units in the UK tha t were not part of th is study are also seeing a sim ilar 
phenomenon (personal communication with physicians at University 
College Hospital and St Mary's Hospital). The data collection should 
therefore be centralised under an authority such as the HPA to develop a 
clearer picture of the epidemic.
All the cases identified were HIV-positive men suggesting factors specific 
to this particular group are im portant in the HCV transmission. The case- 
control study has identified a number of factors associated with case- 
control status, which could be used to identify high-risk individuals. 
Broadly, these include: high numbers of sexual partners, participation in 
group sex, specific mucosally traum atic sexual practices, use of illicit 
drugs (specifically 'club drugs'), the sharing of drug taking implements, 
and use of the internet to meet other men. These factors could be used 
to identify individuals tha t are at higher risk for the potential acquisition 
of HCV.
Individuals need to be made aware of the transm issibility of HCV through 
the identified specific mucosally traum atic sexual and drug practices. 
Interestingly however, the assessment of attitudes in the questionnaire 
revealed tha t both cases and controls were aware of the potential for the 
sexual transmission of HCV. However, it was less clear whether they 
understood the implications of chronic HCV/HIV co-infection. 
Unfortunately, these data were collected retrospectively. As permucosal
173
transmission of HCV involves disruption of mucosal integrity with 
exposure to infected body fluids, interventions must aim at minimising 
this. Therefore, strategies should focus on reducing exposure to 
traum atic practices, promoting safe (protected) sexual practice through 
the use of condoms and gloves, m inim ising the use of 'club drugs', and 
education about the risk of sharing drug implements, particularly 
intranasally and intrarectally. While the specifics of the how and why 
these behaviours occur were not delineated, our data suggest that many 
of these behaviours are occurring in the milieu of group sex and this may 
be an im portant identifiable m arker of risk around which interventions 
could be focused.
Education and health promotion campaigns need to be aimed at both the 
health professionals and a t-risk individuals. There is growing awareness 
amongst clinicians of the risk of HCV transmission in the HIV-population, 
as a result of peer-reviewed articles, conference presentations and 
internet reports. However, specific programs for the clinicians involved in 
the care of HIV-positive patients are essential, particularly in the urban 
areas. Health promotion campaigns fo r patients would further increase 
awareness of the recent epidemic and its associated behavioural risks 
with the aim of reduced parenteral and permucosal risk exposure.
Specific strategies tha t have been used to prevent HIV/STI transmission 
would obviously be im portant. A ttem pting to fragment sexual networks 
has been effective (W ohlfeiler & Potterat, 2005). Sexual networks 
describe the sexual connection between individuals and the structure of 
these networks is im portant in the transmission of STIs. Through the 
provision of inform ation and education, individuals can become better 
informed in the hope tha t they make decisions that reduce the ir risk of 
exposure. This aims to discourage lower-risk individuals interacting with 
high-risk individuals. Often because sexual networks are difficult to 
identify and because they overlap with social networks it may be more 
straightforward to intervene at the social level. This could, for example, 
involve venues such as sex clubs and the internet, both of which were 
factors tha t were associated w ith case/control status in our study.
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Social interactions via the internet presents a new and significant public 
health challenge. The case-control analysis identified it as the most 
common location where cases m et other men. In relation to STIs, a 
number of internet-based strategies have been used in an attem pt to 
reduce individuals risk exposure fo r individuals. These include online 
partner notification of STIs, access to STI testing, banner advertising of 
health inform ation, chat-room health outreach, internet epidemiology 
studies, behavioural interventions, and member profiles with associated 
computer algorithms (McFarlane e t at., 2005). The outcomes of these 
various interventions have not yet been assessed.
Unfortunately, at present there is evidence that both unsafe sexual and 
drug practices are on the rise amongst MSM. The HPA outlined in a report 
"Mapping the issues" tha t the rate of sexually transm itted infections, 
including HIV, is increasing particularly among MSM (Health Protection 
Agency, 2005b). The data presented in this thesis supports this. 
Furthermore, there is increasing literature on the problem of drug use in 
this population, some suggesting a link between increasing use of crystal 
meth and new HIV diagnoses (Boddiger, 2005). This thesis provides 
further impetus fo r interventions to m itigate the transmission of not only 
HCV but also HIV and STIs.
F u tu re  w o rk :
A collaboration between the identified cohorts in London, the 
Netherlands, France and Germany to extend the molecular phylogenetic 
study has been agreed. The work will be based at the Royal Free and 
University College Medical School. In association with clinical and 
epidemiological data this should provide fascinating insights into the 
interactions of the cohorts and the dynamics of the European epidemic. 
Cases will be enrolled both prospectively and retrospectively. By 
expanding the project, prospective data would be available for better 
stratification of risk. Finally, detailed studies at the event level are 
required to tease out the complex interactions between the sexual and 
drug practices tha t are contributing to the transmission of HCV. This
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would require in-depth interviews w ith individuals with an exploration of 
these behaviours.
5.3 Natural history, virological and immunological aspects
K ey con c lu s io n s :
HCV persistence was the usual outcome in the vast m ajority of co­
infected individuals; these rates are significantly higher than those for 
HCV mono-infection. While the specific mechanisms were not elucidated, 
cell-mediated responses are im portant. The CD4 T-cells lacked the 
magnitude and breadth of response fo r control of HCV. The virological 
data supported this, revealing quasispecies evolution that was not driven 
by immune pressure. Therefore, HIV appears to impact the immune 
system's ability to recognise and eradicate HCV.
Recom m endations:
Treatment algorithms need to be drafted to ensure that infected 
individuals are treated in a tim ely fashion with appropriate antiviral 
regimens, as these evolve, to maximise the chance of viral clearance 
during the acute phase. Based on the high rates of persistence, early 
intervention with combination trea tm ent should be recommended. While 
in HCV mono-infection, deferring treatm ent fo r a period of up to 16 
weeks may be appropriate to  allow for spontaneous eradication, this 
event is rare in HIV co-infection (Gerlach et a!., 2003). Provisional 
treatm ent data reported by our group has shown that co-infected 
individuals w ith acute HCV treated with a combination regime of 
pegylated interferon and ribavirin have higher rates of sustained 
virological response than chronic HCV/HIV co-infection, but lower rates 
than acute HCV mono-infection (Danta et a/., 2005b). Interestingly, 
ribavirin seems to be im portant fo r these outcomes when compared to 
pegylated interferon monotherapy. Therefore, early treatm ent is 
appropriate and should be recommended. Those individuals that cleared 
HCV spontaneously were icteric and had higher CD4 counts. I t  could be 
postulated tha t increasing the CD4 T-cell count with HAART during this 
period may favour eradication of the HCV. However, we did not have
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sufficient data to test th is hypothesis. Finally, there did not appear to be 
any significant interaction between HCV and HIV in the acute phase and 
so no conclusions could be made with regards to the long-term natural 
history.
Future w ork:
The long-term  clinical fo llow-up of this cohort will provide a definitive 
insight into the natural history of HCV in HIV co-infection, in a sim ilar 
way to the German and Irish HCV mono-infected anti-D cohorts. The 
strength of this analysis will be significantly increased by combining the 
European cohorts.
These findings emphasize the potential importance of HCV-specific CD4 
T-cell responses in the control of HCV. Further analysis in particular 
should focus on the influence of HAART on HCV-specific CD4 T-cell 
responses, how this differs from responses to other antigens, and how 
this relates to any changes in HCV viral load observed. Finally, the 
sensitivity of HCV-specific CD4 T-cells in HIV may relate to features of 
the ir site, phenotype, activation status or turnover, which should also be 
studied. This would specifically involve te tram er studies and CD8 T-cell 
responses. In particular, im portant epitopes should be better defined, 
such as the non-structural regions. Humoral immune responses were not 
studied as part of th is thesis. With the development of pseudo-virus 
models relevant antibody responses could be assessed. I f  the number of 
patients who spontaneously eradicate the infection increases (as more 
cases are identified) then specific immune features of these patients 
could also be studied. Combining the immunological studies with analysis 
of the evolution of both HCV and HIV in the acute phase would provide 
important insights into the reasons fo r persistent infection.
5.4 Conclusion
The current epidemic of HCV in HIV-positive individuals is attributable to 
permucosal transmission as a result of high-risk sexual and drug 
practices. The imm unodeficient state associated with HIV results in very
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low spontaneous clearance of HCV and the vast majority of these patients 
become persistently infected with HCV. This epidemic has come about as 
a result of significant change in patient behavioural risk factors. In order 
to m itigate this im portant and ongoing epidemic, these factors need to be 
the focus of a concerted effort on the part of public health specialist, 
clinicians and HIV-positive individuals themselves.
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Appendix A 
Case-control study questionnaire instrum ent
CONFIDENTIAL
HCV/HIV Co-infection Risk Questionnaire 2004
Confidentiality
The questions in this booklet are mostly very personal. Your answers will be treated in strict confi­
dence. When you have finished the questionnaire, put it into the envelope and seal it.
Your name will not be on the booklet or envelope.
How to answer __
Just put a tick in the box opposite the appropriate answer like this: \S\
8 6OR write a number in the box provided, like this:
Not all the instructions apply to you; follow arrows and instructions.
Please ask for help or explanations if you are not sure.
Date of interest is the date of your diagnosis with hepatitis C or an allocated date. 
Importance
It is very important to the study that you answer these questions as honestly and as accurately 
as you can.
Some things may be hard to remember, so please take your time.
Date of Interest Questionnaire Number
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QUESTION 1
We would like to ask you questions about your attendance at places where men go to meet or socialize 
with other men. In the 12 months prior to the date of interest how often have you gone to:
Never
a) A bar, night club, or dance club? □  OR
number of times
Never number ot times
b) Private parties? Q  OR
Never number of times
c) A sex club or bathhouse/sauna? □  on
Never number of times
d) A public cruising area, such as park, beach |— .
or cottage? I I O R
Never number of times
e) Internet sites such as gaydar, gay.com? □  OR
f) other? Pieasg..srecifY
QUESTION 2
In the 12 months prior to the date of interest did you have sex with:
Only men □
Both men and women □
Did not have sex in the last 12 months □ ------------------- GO TO QUESTION 9 (PAGE S)
QUESTION 3
a) In the 12 months prior to the date of interest how many 
men have you had sex with?
write in number
b) In the 12 months prior to the date of interest how many of 
the men you had sex with were one night stands or someone 
you had sex with only once?
write in number
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QUESTION 4
The following questions ask about different sexual activities you have engaged in with other men.
In the 12 months prior to the date of interest, did you perform any of the following sexual activities 
and, if so, with how many different men?
a) Had active oral sex (had his penis in Yes □  -  write in number ,  I I
your mouth) without a condom, with with­
drawal before ejaculation? No [ _ j
b) Had active oral sex where he ejaculated 
in your mouth, without a condom?
c) Had active oral sex where he wore a 
condom?
d) Received oral sex (had your penis in 
his mouth) without a condom, but with 
withdrawal before ejaculation?
Yes □  
No □
Yes □  
No Q
Yes □  
No □
write in numlrer
write in number
write in number
e) Received oral sex where you ejacu- Yes □  -  write in number
lated in his mouth, without a condom?
No Q
f) Received oral sex where you wore a Yes □  -  write in number
condom?
No Q
g) Had receptive anal intercourse with- Yes □  -  write in number
out a condom, without ejaculation
inside you? No Q ]
h) Had receptive anal intercourse with- Yes Q  write in number
out a condom, with ejaculation inside
you? No |_J
i) Had receptive anal intercourse where Yes □  -  write in number 
he used a condom?
No □
j) Performed insertive anal intercourse Yes □  -  write in number
without a condom, with withdrawal
before you ejaculated? No [_J
k) Performed insertive anal intercourse Yes Q ]  write in number
without a condom, with ejaculation
inside him? No [_J
I) Performed insertive anal intercourse Yes □  -  write in number w I I
using a condom?
No □  --------------
3
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QUESTION 4 (Continued)
The following questions ask about different sexual activities you have engaged in with other men.
In the 12 months prior to the date of interest, did you perform any of the following sexual activities 
and, if so, with how many different men?
m) Been rimmed by someone else? Yes □  -  write in number m I I
No □  I--------------------- '
n) Performed rimming on another man?
o) Actively fisted (had your fist in his 
anus) another man?
p) Been fisted (had his fist in your 
anus) by another man?
q) Used sex toys, such as dildoes or 
vibrators?
r) Engaged in bondage and discipline, 
or S&M practices?
QUESTION 5
Yes □  -  write in number 
NO Q
Yes □  -  write in number 
No Q
Were gloves always used?
Yes □  
No □
write in number
Were gbves always used?
Yes □  -  write in number 
No Q
Did you share these sex toys?
Yes Q  
No Q
Yes Q  
No Q
Yes Q  
□No
Yes □  -  write in number 
No □
Yes nDid this ever involve blood 
or piercings? ^  Q
a) in the 12 months prior to the date of interest, did you have sex in a public place, like a park, club, 
or bath house/sauna?
Yes Q  
No Q GO TO QUESTION 6 (page 5)
b) If you had sex in a public place with a man, did you ever engage in:
Receptive anal intercourse without condoms? Yes □
No □
Insertive anal intercourse without condoms? Yes □
No □
Insertive fisting (had your fist in his anus)? Yes □
No □
Receptive fisting (had his fist in your anus)? Yes □
No □
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QUESTION 6
a) In the 12 months prior to the date of interest did you have sex in a group with two or more other people?
Yes Q  
No □
b) If you had sex in a group, did you ever engage in:
Receptive anal intercourse without condoms? Yes □
No □
Insertive anal intercourse without condoms? Yes □
No □
Insertive fisting (had your fist in his anus)? Yes □
No □
Receptive fisting (had his fist in your anus)? Yes □
No □
GO TO QUESTION 7 (below)
QUESTION 7
Are you circumcised? yes [~ j
No □
5
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QUESTION 8
a) In the 12 months prior to the date of interest, have you engaged in any sexual activity with a man while feeling 
the effects of alcohol?
Yes Q  
No □
b) In the 12 months prior to the date of interest have you engaged in any sexual activity with a man while 
feeling the effects of drugs?
Yes □  -  specify druos „ I I
No Q  ---------------------------------------------
QUESTION 9
a) The next questions are about your use of alcohol and drugs. In the 12 months prior to the date of interest, 
on average, how often did you drink any kind of alcoholic drink?
Never □
Monthly or less □
2-4 times a month □
2-3 times a week Q  
4 or more times a week [^ j
b) How many drinks containing alcohol do you have on a typical day when you are drinking? A "drink" is equiva­
lent to: half pint (285ml) of ordinary strength beer or lager; 1 small glass (125ml) of wine; 1 glass (50ml) of forti­
fied wine, eg. Sherry; 1 single measure (25ml) spirits.
1-2 □
3-4 □
5-6 □
7-8 □
10 or more □
c) How often do you have six or more drinks on one occasion?
Never □
Less than monthly □
Monthly □
Weekly □
Daily or almost daily □
6
GO TO QUESTION 10 (page 8)
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QUESTION 9 (Continued)
d) How often during the last year have you found that you were not able to stop drinking once you had started?
Never □
Less than monthly □
Monthly [~~j|
Weekly 
Daily or almost daily Q
e) How often during the last year have you failed to do what was normally expected from you because of drinking?
Never □
Less than monthly □
Monthly Q  
Weekly |
Daily or almost daily Q
f) How often in the last year have you needed a first drink in the morning to get yourself going after a heavy
drinking session?
Never □
Less than monthly □
Monthly [~~^ j 
Weekly [~~j]
Daily or almost daily Q
g) How often during the last year have you had a feeling of guilt or remorse after drinking?
Never □
Less than monthly □
Monthly [~7|
Weekly Q  
Daily or almost daily Q
h) How often during the last year have you been unable to remember what happened the night before because
you had been drinking?
Never □
Less than monthly □
Monthly □
Weekly □
Daily or almost daily □
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QUESTION 9 (Continued)
i) Have you or someone else been injured as a result of your drinking?
No Q
Yes, but not in the last year □
Yes, during the last year J^]
j) Has a relative or friend or a doctor or other health worker been concerned about your drinking or suggested 
you cut down?
No □
Yes, but not in the last year □  
Yes, during the last year
QUESTION 10
In the 12 months prior to ths date of interest have you used any drugs for recreational purposes?
Yes Q  
No Q GO TO QUESTION 16 (page 11)
8
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QUESTION 11
In the 12 months prior to the date of interest have you used:
a) Marijuana or hashish?
c) Crack cocaine?
e) Methamphetamines, also known as 
speed, crystal or crank?
g) Ecstasy, also known as MDMA, or 
other forms of MDA (eg High Fives)?
k) Ketamine or K?
Yes Q
NoC
b) Poppers or inhalants like amyl, butyl or Yes 
isopropyl nitrite?
No Q
Yes Q  
No Q
d) Cocaine, not including crack yes I
cocaine? '—
No Q
Yes 
NO □
f) Other amphetamines or “uppers"? Yes
No Q
Yes Q  
NO □
h) Psychedelics/ Hallucinogens, such Yes I
as LSD? L““
No Q
i) Downers including barbituates, Yes [ j
sleeping tablets such as valium and
rohypnol? No J^]
j) Heroin, methadone, other opiates, or Yes [ I
painkillers such as codeine or tra­
madol? No □
Yes □  
NO Q
I) Gamma Hydroxybutyrate or GBH? Yes Q
No Q
number of times
number of times
number of times
number of times
number of times
number of times
number of times
number of times
number of times
.flumtor Qf times
number of times
number of times
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QUESTION 12
In the 12 months prior to the date of interest have you taken recreational drugs:
Orally Yes Q  number of times 
No □
Nasally Yes (~~| number of times 
No □
By injection Yes [ [ ]  number of times 
No □
By other means Yes Q  number of times 
No Q
which drugs?.
which drugs?.
which drugs?,
which drugs?,
How was it taken?
QUESTION 13 _______
In the 12 months prior to the date of interest have you shared recreational drug implements:
oraiiy Yes | _ |  number of times „  
NO Q
which drugs?.
Kiaeaiiy Ya« Q  number of times ,
(eg bullets) .— .
No Q
which drugs?.
Py injos'tinn yas | | number oltimes ,
(eg needles) ,__.
No □
which druas?.
By other means Yes | | number Qf time? ». 
NO Q
which druas?.
With what implement?
10
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QUESTION 14
a) Have you ever injected any recreational drugs?
Yes □  
No □
Date ot last infection
GO TO QUESTION 16
b) Have you ever shared a needle with another person when you shot up drugs?
Yes □  Date ot last shared needle ^  
No Q  . GO TO QUESTION 16
QUESTION 15
Have you ever been concerned about your use of recreational drugs?
Yes Q  
No Q
QUESTION 16
During the 12 months prior to the date of interest, has anyone given you money or drugs in exchange 
for sex?
Yes Q  
NO □
How many dWterent people?
11
222
QUESTION 17
a) Do you have any tattoos?
Yes □  
No Q
Year of first tattoo Number of tattoos
b) Have you ever had a transfusion of blood or blood products?
Yes □  • Year of first transfusion 
NO Q
c) Have you had or have body piercings?
Yes □  -  Year of first piercing 
NO Q
Number of transfusions
Number of piercings
QUESTION 18
In the past year, other than an HIV test, have you been checked for a sexually-transmitted disease?
Yes Q  
No Q
QUESTION 19
There are many diseases you can get from having sex. Some common sexually transmitted diseases, 
besides the AIDS virus, are syphilis, gonorrhea, anal or genital warts, crabs, genital herpes, 
non-specific urethritis (NSU) and others. Has a doctor, nurse or other health care worker ever told you that 
you have a sexually-transmitted disease?
Yes Q  
No Q GO TO QUESTION 21 (page 14)
12
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QUESTION 20
Which sexually transmitted diseases have you previously had?
Genital Herpes Yes
No Q
Syphilis Yes Q  
No
Gonorrhea Yes
No Q
Non-specific urethritis (NSU) Yes
No [2
Genital Warts Yes 
No j
Hepatitis B Yes
N O  Q
Hepatitis A Yes
No □
Year of first diagnosis
Year of first diagnosis
Year o< first diagnosis
Year ol first diagnosis
Year ot first diagnosis
Year ot first diagnosis
Year of first diagnosis
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QUESTION 21
The following statements relate to your knowledge of hepatitis C. Please tick one box next to each statement to 
indicate how strongly you agree or disagree with the statement.
Strongly Agree Agree
a)Hepatitis C is an important health problem. j~ ]  Q
Disagree Strongly Disagree Don't Know □ □ □
Strongly Agree Agree
b) Someone with hepatitis C can feel fine. □  □
Disagree Strongly Disagree Don’t Know □ □ □
Strongly Agree Agree
c) Hepatitis C can be transmitted sexually. j ~ j  Q
Disagree Strongly Disagree Don’t Know
Q  C3 0
Strongly Agree Agree
d) Hepatitis C can make HIV worse. □  □
Disagree Strongly Disagree Don’t Know
O D D
Strongly Agree Agree
e) HIV can make Hepatitis C worse. |~~^ |
Disagree Strongly Disagree Don't Know □ □ □
Strongly Agree Agree
f) There is treatment available for hepatitis C. □  □
Disagree Strongly Disagree Don't Know □ □ □
Strongly Agree Agree
g) There is a vaccine available for hepatitis C. □  □
Disagree Strongly Disagree Don’t Know □ □ □
Q trnnnh/ Anraa  AnrMt
h) Most patients with hepatitis C have chronic   .   .
(persistent) infection. [_J j_ J
Disagree Strongly Disagree Don’t Know □ □ □
Strongly Agree Agree
i) Hepatitis C can cause the liver to stop working. □  □
Disagree Strongly Disagree Don't Know
C3 O O
j) Alcohol should not be drunk if you have liver .— . 
problems. LJ
Strongly Agree Agree□ Disagree Strongly Disagree Don't Know □ □ □
14
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Thank you for participating and answering these questions.
If there is anything that you would like to add, or comments that you would like to make, 
please write them below.
Now put the questionnaire in the envelope provided, and hand it to the interviewer.
Thank you
15
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